WO2016205259A1 - Methods of diagnosing and treating wounds - Google Patents
Methods of diagnosing and treating wounds Download PDFInfo
- Publication number
- WO2016205259A1 WO2016205259A1 PCT/US2016/037455 US2016037455W WO2016205259A1 WO 2016205259 A1 WO2016205259 A1 WO 2016205259A1 US 2016037455 W US2016037455 W US 2016037455W WO 2016205259 A1 WO2016205259 A1 WO 2016205259A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- wound
- igf
- akt
- pharmaceutical composition
- Prior art date
Links
- 208000027418 Wounds and injury Diseases 0.000 title claims abstract description 175
- 206010052428 Wound Diseases 0.000 title claims abstract description 173
- 238000000034 method Methods 0.000 title claims abstract description 101
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 333
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 314
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 87
- 230000014509 gene expression Effects 0.000 claims abstract description 61
- 230000004913 activation Effects 0.000 claims abstract description 48
- 238000006366 phosphorylation reaction Methods 0.000 claims abstract description 34
- 230000026731 phosphorylation Effects 0.000 claims abstract description 33
- 239000005557 antagonist Substances 0.000 claims abstract description 24
- 239000000556 agonist Substances 0.000 claims abstract description 18
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 4
- 208000008960 Diabetic foot Diseases 0.000 claims description 87
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims description 80
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims description 80
- 108091008611 Protein Kinase B Proteins 0.000 claims description 79
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 74
- -1 HIF Proteins 0.000 claims description 68
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims description 64
- 230000029663 wound healing Effects 0.000 claims description 48
- 206010028980 Neoplasm Diseases 0.000 claims description 47
- 206010012601 diabetes mellitus Diseases 0.000 claims description 44
- 230000011664 signaling Effects 0.000 claims description 43
- 230000019491 signal transduction Effects 0.000 claims description 41
- 102000004877 Insulin Human genes 0.000 claims description 38
- 108090001061 Insulin Proteins 0.000 claims description 38
- 229940125396 insulin Drugs 0.000 claims description 38
- 201000011510 cancer Diseases 0.000 claims description 31
- 210000001519 tissue Anatomy 0.000 claims description 29
- 102000015735 Beta-catenin Human genes 0.000 claims description 28
- 108060000903 Beta-catenin Proteins 0.000 claims description 28
- 108090000566 Caspase-9 Proteins 0.000 claims description 24
- 238000002560 therapeutic procedure Methods 0.000 claims description 24
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 19
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims description 19
- 101100325747 Mus musculus Bak1 gene Proteins 0.000 claims description 19
- 108700039689 bcl-2 Homologous Antagonist-Killer Proteins 0.000 claims description 19
- 102000055574 bcl-2 Homologous Antagonist-Killer Human genes 0.000 claims description 19
- 108090000397 Caspase 3 Proteins 0.000 claims description 18
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims description 18
- 241000282414 Homo sapiens Species 0.000 claims description 17
- 210000002510 keratinocyte Anatomy 0.000 claims description 17
- 230000001771 impaired effect Effects 0.000 claims description 16
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims description 15
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 claims description 15
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims description 15
- 208000025865 Ulcer Diseases 0.000 claims description 15
- 239000003937 drug carrier Substances 0.000 claims description 13
- 230000001413 cellular effect Effects 0.000 claims description 11
- 238000004891 communication Methods 0.000 claims description 11
- 239000003112 inhibitor Substances 0.000 claims description 11
- 231100000397 ulcer Toxicity 0.000 claims description 11
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 claims description 10
- 229950006137 dexfosfoserine Drugs 0.000 claims description 10
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 208000024827 Alzheimer disease Diseases 0.000 claims description 8
- FBCSDEQVNNRGEQ-DKWTVANSSA-N [P].OC[C@H](N)C(O)=O Chemical compound [P].OC[C@H](N)C(O)=O FBCSDEQVNNRGEQ-DKWTVANSSA-N 0.000 claims description 8
- 206010056340 Diabetic ulcer Diseases 0.000 claims description 7
- 206010040943 Skin Ulcer Diseases 0.000 claims description 7
- 208000014674 injury Diseases 0.000 claims description 7
- 238000004393 prognosis Methods 0.000 claims description 7
- 238000001356 surgical procedure Methods 0.000 claims description 7
- 102000001267 GSK3 Human genes 0.000 claims description 6
- 108060006662 GSK3 Proteins 0.000 claims description 6
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 claims description 6
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 6
- 208000002847 Surgical Wound Diseases 0.000 claims description 6
- 238000005259 measurement Methods 0.000 claims description 6
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 claims description 6
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 claims description 6
- 206010011985 Decubitus ulcer Diseases 0.000 claims description 5
- 201000004624 Dermatitis Diseases 0.000 claims description 5
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 5
- 208000028990 Skin injury Diseases 0.000 claims description 5
- 208000000558 Varicose Ulcer Diseases 0.000 claims description 5
- 230000005855 radiation Effects 0.000 claims description 5
- 150000003431 steroids Chemical class 0.000 claims description 5
- 230000008733 trauma Effects 0.000 claims description 5
- 108010034782 Ribosomal Protein S6 Kinases Proteins 0.000 claims description 4
- 102000009738 Ribosomal Protein S6 Kinases Human genes 0.000 claims description 4
- 101150001535 SRC gene Proteins 0.000 claims description 4
- 239000012190 activator Substances 0.000 claims description 4
- 238000004364 calculation method Methods 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims description 3
- 239000006166 lysate Substances 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 2
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims 11
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims 11
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 10
- 102100029855 Caspase-3 Human genes 0.000 claims 5
- 102000004039 Caspase-9 Human genes 0.000 claims 5
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 claims 5
- 240000006365 Vitis vinifera Species 0.000 claims 2
- 101150002416 Igf2 gene Chemical group 0.000 claims 1
- 239000000090 biomarker Substances 0.000 abstract description 3
- 235000018102 proteins Nutrition 0.000 description 203
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 56
- 238000001994 activation Methods 0.000 description 44
- 230000000694 effects Effects 0.000 description 43
- 230000037361 pathway Effects 0.000 description 41
- 108091007960 PI3Ks Proteins 0.000 description 38
- 239000003795 chemical substances by application Substances 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 35
- 230000035876 healing Effects 0.000 description 35
- 108010028501 Hypoxia-Inducible Factor 1 Proteins 0.000 description 30
- 102000016878 Hypoxia-Inducible Factor 1 Human genes 0.000 description 30
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 25
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 24
- 230000001965 increasing effect Effects 0.000 description 24
- 235000002639 sodium chloride Nutrition 0.000 description 24
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 23
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 23
- 239000003612 morphinomimetic agent Substances 0.000 description 23
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 22
- 101710184277 Insulin-like growth factor 1 receptor Proteins 0.000 description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
- 230000006870 function Effects 0.000 description 21
- 230000004155 insulin signaling pathway Effects 0.000 description 21
- 102100026550 Caspase-9 Human genes 0.000 description 20
- 230000006907 apoptotic process Effects 0.000 description 18
- 239000003814 drug Substances 0.000 description 18
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 18
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 18
- 102000005962 receptors Human genes 0.000 description 18
- 108020003175 receptors Proteins 0.000 description 18
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 17
- 235000019441 ethanol Nutrition 0.000 description 16
- 210000003491 skin Anatomy 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 108091000080 Phosphotransferase Proteins 0.000 description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- 229920002472 Starch Polymers 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 102000020233 phosphotransferase Human genes 0.000 description 15
- 230000008569 process Effects 0.000 description 15
- 235000019698 starch Nutrition 0.000 description 15
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 230000004083 survival effect Effects 0.000 description 14
- 239000001993 wax Substances 0.000 description 14
- 102000003952 Caspase 3 Human genes 0.000 description 13
- 235000003599 food sweetener Nutrition 0.000 description 13
- 239000000546 pharmaceutical excipient Substances 0.000 description 13
- 150000003839 salts Chemical class 0.000 description 13
- 108091006024 signal transducing proteins Proteins 0.000 description 13
- 102000034285 signal transducing proteins Human genes 0.000 description 13
- 239000003765 sweetening agent Substances 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 230000001684 chronic effect Effects 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 230000001105 regulatory effect Effects 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 11
- 239000013543 active substance Substances 0.000 description 11
- 235000010980 cellulose Nutrition 0.000 description 11
- 229920002678 cellulose Polymers 0.000 description 11
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 11
- 229960000240 hydrocodone Drugs 0.000 description 11
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 11
- 238000007726 management method Methods 0.000 description 11
- 230000001404 mediated effect Effects 0.000 description 11
- 229960003910 promethazine Drugs 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 239000003381 stabilizer Substances 0.000 description 11
- 239000008107 starch Substances 0.000 description 11
- 229940032147 starch Drugs 0.000 description 11
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 11
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 229910019142 PO4 Inorganic materials 0.000 description 10
- 102100035100 Transcription factor p65 Human genes 0.000 description 10
- 239000001913 cellulose Substances 0.000 description 10
- 235000011187 glycerol Nutrition 0.000 description 10
- 239000003446 ligand Substances 0.000 description 10
- 235000021317 phosphate Nutrition 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 108010057466 NF-kappa B Proteins 0.000 description 9
- 102000003945 NF-kappa B Human genes 0.000 description 9
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 9
- 230000033115 angiogenesis Effects 0.000 description 9
- 238000001804 debridement Methods 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 239000008297 liquid dosage form Substances 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 229960002085 oxycodone Drugs 0.000 description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 9
- 239000010452 phosphate Substances 0.000 description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- ZSZXYWFCIKKZBT-IVYVYLGESA-N 1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5-trisphosphate) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)O[C@@H]1[C@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O ZSZXYWFCIKKZBT-IVYVYLGESA-N 0.000 description 8
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 8
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 8
- 108010081589 Becaplermin Proteins 0.000 description 8
- 102000011727 Caspases Human genes 0.000 description 8
- 108010076667 Caspases Proteins 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 8
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 8
- 230000004075 alteration Effects 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 229940125717 barbiturate Drugs 0.000 description 8
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000006172 buffering agent Substances 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 239000003102 growth factor Substances 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- 229960001375 lactose Drugs 0.000 description 8
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 230000000699 topical effect Effects 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 7
- 102100032305 Bcl-2 homologous antagonist/killer Human genes 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 102000003746 Insulin Receptor Human genes 0.000 description 7
- 108010001127 Insulin Receptor Proteins 0.000 description 7
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 7
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 7
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 7
- 210000000988 bone and bone Anatomy 0.000 description 7
- 230000010261 cell growth Effects 0.000 description 7
- 239000003086 colorant Substances 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 229960004756 ethanol Drugs 0.000 description 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000015654 memory Effects 0.000 description 7
- 229940121367 non-opioid analgesics Drugs 0.000 description 7
- 229960005489 paracetamol Drugs 0.000 description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 230000009758 senescence Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 239000002562 thickening agent Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 239000004166 Lanolin Substances 0.000 description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 102000001253 Protein Kinase Human genes 0.000 description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 102000040945 Transcription factor Human genes 0.000 description 6
- 108091023040 Transcription factor Proteins 0.000 description 6
- 102100040247 Tumor necrosis factor Human genes 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 229940041181 antineoplastic drug Drugs 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 230000005779 cell damage Effects 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 210000002683 foot Anatomy 0.000 description 6
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 6
- 235000019388 lanolin Nutrition 0.000 description 6
- 229940039717 lanolin Drugs 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000004481 post-translational protein modification Effects 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- HKWJHKSHEWVOSS-OMDJCSNQSA-N 1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4-bisphosphate) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H]1O HKWJHKSHEWVOSS-OMDJCSNQSA-N 0.000 description 5
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 5
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- 241000416162 Astragalus gummifer Species 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000004376 Sucralose Substances 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 229920001615 Tragacanth Polymers 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 239000000619 acesulfame-K Substances 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 239000002269 analeptic agent Substances 0.000 description 5
- 239000002111 antiemetic agent Substances 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 239000004359 castor oil Substances 0.000 description 5
- 235000019438 castor oil Nutrition 0.000 description 5
- 230000033077 cellular process Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000002405 diagnostic procedure Methods 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 5
- 229920000609 methyl cellulose Polymers 0.000 description 5
- 235000010981 methylcellulose Nutrition 0.000 description 5
- 239000001923 methylcellulose Substances 0.000 description 5
- 229960002900 methylcellulose Drugs 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 229960004063 propylene glycol Drugs 0.000 description 5
- 235000013772 propylene glycol Nutrition 0.000 description 5
- 108060006633 protein kinase Proteins 0.000 description 5
- 229940116157 regranex Drugs 0.000 description 5
- 235000019204 saccharin Nutrition 0.000 description 5
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 5
- 229940081974 saccharin Drugs 0.000 description 5
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 229960002920 sorbitol Drugs 0.000 description 5
- 235000010356 sorbitol Nutrition 0.000 description 5
- 235000019408 sucralose Nutrition 0.000 description 5
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 229960004793 sucrose Drugs 0.000 description 5
- 239000002511 suppository base Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 235000010487 tragacanth Nutrition 0.000 description 5
- 229940116362 tragacanth Drugs 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 235000002374 tyrosine Nutrition 0.000 description 5
- 230000037314 wound repair Effects 0.000 description 5
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- XTKLTGBKIDQGQL-UHFFFAOYSA-N 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-morpholin-4-ylbenzimidazole-4-carboxylic acid Chemical compound CC1=NC2=C(C(O)=O)C=C(N3CCOCC3)C=C2N1CC1=CC=CC(C(F)(F)F)=C1C XTKLTGBKIDQGQL-UHFFFAOYSA-N 0.000 description 4
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 4
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- 200000000007 Arterial disease Diseases 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 4
- NIQCNGHVCWTJSM-UHFFFAOYSA-N Dimethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(=O)OC NIQCNGHVCWTJSM-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 206010051814 Eschar Diseases 0.000 description 4
- 229930091371 Fructose Natural products 0.000 description 4
- 239000005715 Fructose Substances 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 4
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 4
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 4
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 4
- 240000007472 Leucaena leucocephala Species 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 4
- 239000004264 Petrolatum Substances 0.000 description 4
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 4
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 4
- 101710113459 RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000003474 anti-emetic effect Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000003143 atherosclerotic effect Effects 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 229960000686 benzalkonium chloride Drugs 0.000 description 4
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- 229960001631 carbomer Drugs 0.000 description 4
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 4
- 230000005754 cellular signaling Effects 0.000 description 4
- 229940082500 cetostearyl alcohol Drugs 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 229940107161 cholesterol Drugs 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
- 230000007783 downstream signaling Effects 0.000 description 4
- 230000001804 emulsifying effect Effects 0.000 description 4
- 231100000333 eschar Toxicity 0.000 description 4
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 4
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 229940014259 gelatin Drugs 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 239000000416 hydrocolloid Substances 0.000 description 4
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 4
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 235000013980 iron oxide Nutrition 0.000 description 4
- 229960004592 isopropanol Drugs 0.000 description 4
- 229960000448 lactic acid Drugs 0.000 description 4
- 229960003511 macrogol Drugs 0.000 description 4
- 239000000391 magnesium silicate Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 235000010446 mineral oil Nutrition 0.000 description 4
- 229940042472 mineral oil Drugs 0.000 description 4
- 150000004682 monohydrates Chemical class 0.000 description 4
- 239000007922 nasal spray Substances 0.000 description 4
- 230000001338 necrotic effect Effects 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 4
- 229940066842 petrolatum Drugs 0.000 description 4
- 235000019271 petrolatum Nutrition 0.000 description 4
- 229960003742 phenol Drugs 0.000 description 4
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 4
- 229940067107 phenylethyl alcohol Drugs 0.000 description 4
- 229940069328 povidone Drugs 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000007781 signaling event Effects 0.000 description 4
- 229960002930 sirolimus Drugs 0.000 description 4
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 4
- 235000010234 sodium benzoate Nutrition 0.000 description 4
- 239000004299 sodium benzoate Substances 0.000 description 4
- 239000001488 sodium phosphate Substances 0.000 description 4
- 229910000162 sodium phosphate Inorganic materials 0.000 description 4
- 229960003339 sodium phosphate Drugs 0.000 description 4
- 235000011008 sodium phosphates Nutrition 0.000 description 4
- 229920003109 sodium starch glycolate Polymers 0.000 description 4
- 239000008109 sodium starch glycolate Substances 0.000 description 4
- 229940079832 sodium starch glycolate Drugs 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000009469 supplementation Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 4
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 4
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 239000000196 tragacanth Substances 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 230000036269 ulceration Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 3
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 3
- 102100030907 Aryl hydrocarbon receptor nuclear translocator Human genes 0.000 description 3
- 108010011485 Aspartame Proteins 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 description 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- 229920002907 Guar gum Polymers 0.000 description 3
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 3
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 3
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 3
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 description 3
- 102100022708 Insulin-like growth factor-binding protein 3 Human genes 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 239000004384 Neotame Substances 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 101150000187 PTGS2 gene Proteins 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 3
- 102100040990 Platelet-derived growth factor subunit B Human genes 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 3
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 3
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 3
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 3
- 108091005682 Receptor kinases Proteins 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 229960005164 acesulfame Drugs 0.000 description 3
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 3
- 235000010358 acesulfame potassium Nutrition 0.000 description 3
- 229960004998 acesulfame potassium Drugs 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 238000012387 aerosolization Methods 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 239000000783 alginic acid Substances 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- 150000004781 alginic acids Chemical class 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000000605 aspartame Substances 0.000 description 3
- 235000010357 aspartame Nutrition 0.000 description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 3
- 229960003438 aspartame Drugs 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- HYNPZTKLUNHGPM-KKERQHFVSA-N becaplermin Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]6CCCN6C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]7CCCN7C(=O)[C@H](Cc8c[nH]c9c8cccc9)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)N HYNPZTKLUNHGPM-KKERQHFVSA-N 0.000 description 3
- 229960004787 becaplermin Drugs 0.000 description 3
- 239000000440 bentonite Substances 0.000 description 3
- 229910000278 bentonite Inorganic materials 0.000 description 3
- 229940092782 bentonite Drugs 0.000 description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 3
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 3
- 229960001950 benzethonium chloride Drugs 0.000 description 3
- 229960002903 benzyl benzoate Drugs 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 235000010410 calcium alginate Nutrition 0.000 description 3
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 3
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000009087 cell motility Effects 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 229960004926 chlorobutanol Drugs 0.000 description 3
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 3
- 239000008119 colloidal silica Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 229930003836 cresol Natural products 0.000 description 3
- 229960001681 croscarmellose sodium Drugs 0.000 description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 229940050410 gluconate Drugs 0.000 description 3
- 230000004153 glucose metabolism Effects 0.000 description 3
- 150000002334 glycols Chemical class 0.000 description 3
- 235000010417 guar gum Nutrition 0.000 description 3
- 239000000665 guar gum Substances 0.000 description 3
- 229960002154 guar gum Drugs 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 3
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 229960003445 idelalisib Drugs 0.000 description 3
- YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 229940001447 lactate Drugs 0.000 description 3
- 229940099367 lanolin alcohols Drugs 0.000 description 3
- 235000005772 leucine Nutrition 0.000 description 3
- 229960003136 leucine Drugs 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 235000010449 maltitol Nutrition 0.000 description 3
- 239000000845 maltitol Substances 0.000 description 3
- 229940035436 maltitol Drugs 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- AJDUTMFFZHIJEM-UHFFFAOYSA-N n-(9,10-dioxoanthracen-1-yl)-4-[4-[[4-[4-[(9,10-dioxoanthracen-1-yl)carbamoyl]phenyl]phenyl]diazenyl]phenyl]benzamide Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2NC(=O)C(C=C1)=CC=C1C(C=C1)=CC=C1N=NC(C=C1)=CC=C1C(C=C1)=CC=C1C(=O)NC1=CC=CC2=C1C(=O)C1=CC=CC=C1C2=O AJDUTMFFZHIJEM-UHFFFAOYSA-N 0.000 description 3
- 239000007923 nasal drop Substances 0.000 description 3
- 229940097496 nasal spray Drugs 0.000 description 3
- 235000019412 neotame Nutrition 0.000 description 3
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 description 3
- 108010070257 neotame Proteins 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 235000010987 pectin Nutrition 0.000 description 3
- 239000001814 pectin Substances 0.000 description 3
- 229960000292 pectin Drugs 0.000 description 3
- 229920001277 pectin Polymers 0.000 description 3
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 3
- 229920001451 polypropylene glycol Polymers 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 229940068984 polyvinyl alcohol Drugs 0.000 description 3
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 3
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 3
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 229940005550 sodium alginate Drugs 0.000 description 3
- 235000010413 sodium alginate Nutrition 0.000 description 3
- 239000000661 sodium alginate Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000010199 sorbic acid Nutrition 0.000 description 3
- 239000004334 sorbic acid Substances 0.000 description 3
- 229940075582 sorbic acid Drugs 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 3
- 229940033663 thimerosal Drugs 0.000 description 3
- 239000004408 titanium dioxide Substances 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 229940074410 trehalose Drugs 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 150000003668 tyrosines Chemical class 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- 239000001043 yellow dye Substances 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 2
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 2
- NUFKRGBSZPCGQB-FLBSXDLDSA-N (3s)-3-amino-4-oxo-4-[[(2r)-1-oxo-1-[(2,2,4,4-tetramethylthietan-3-yl)amino]propan-2-yl]amino]butanoic acid;pentahydrate Chemical compound O.O.O.O.O.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C NUFKRGBSZPCGQB-FLBSXDLDSA-N 0.000 description 2
- CRDNMYFJWFXOCH-YPKPFQOOSA-N (3z)-3-(3-oxo-1h-indol-2-ylidene)-1h-indol-2-one Chemical compound N/1C2=CC=CC=C2C(=O)C\1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-YPKPFQOOSA-N 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 2
- NPNPZTNLOVBDOC-UHFFFAOYSA-N 1,1-difluoroethane Chemical compound CC(F)F NPNPZTNLOVBDOC-UHFFFAOYSA-N 0.000 description 2
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 2
- DTOUUUZOYKYHEP-UHFFFAOYSA-N 1,3-bis(2-ethylhexyl)-5-methyl-1,3-diazinan-5-amine Chemical compound CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1 DTOUUUZOYKYHEP-UHFFFAOYSA-N 0.000 description 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- LRMSQVBRUNSOJL-UHFFFAOYSA-N 2,2,3,3,3-pentafluoropropanoic acid Chemical compound OC(=O)C(F)(F)C(F)(F)F LRMSQVBRUNSOJL-UHFFFAOYSA-N 0.000 description 2
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- RGHYDLZMTYDBDT-UHFFFAOYSA-N 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone Chemical compound O=C1N(CC)C2=NC(N)=NC(C)=C2C=C1C=1C=CNN=1 RGHYDLZMTYDBDT-UHFFFAOYSA-N 0.000 description 2
- ATEBGNALLCMSGS-UHFFFAOYSA-N 2-chloro-1,1-difluoroethane Chemical compound FC(F)CCl ATEBGNALLCMSGS-UHFFFAOYSA-N 0.000 description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 2
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 2
- 102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 2
- NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 description 2
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- GYLDXIAOMVERTK-UHFFFAOYSA-N 5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine Chemical compound C12=C(N)N=CN=C2N(C(C)C)N=C1C1=CC=C(OC(N)=N2)C2=C1 GYLDXIAOMVERTK-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 230000007730 Akt signaling Effects 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 239000004377 Alitame Substances 0.000 description 2
- 235000019489 Almond oil Nutrition 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 108010049386 Aryl Hydrocarbon Receptor Nuclear Translocator Proteins 0.000 description 2
- 102100027839 Aryl hydrocarbon receptor nuclear translocator 2 Human genes 0.000 description 2
- 206010003658 Atrial Fibrillation Diseases 0.000 description 2
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 2
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 2
- 108091007914 CDKs Proteins 0.000 description 2
- 101150071146 COX2 gene Proteins 0.000 description 2
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- 102000016362 Catenins Human genes 0.000 description 2
- 108010067316 Catenins Proteins 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- 235000013913 Ceratonia Nutrition 0.000 description 2
- 241001060815 Ceratonia Species 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
- 241000206576 Chondrus Species 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 2
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 2
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 2
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 2
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- 102100030497 Cytochrome c Human genes 0.000 description 2
- 108010075031 Cytochromes c Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 2
- 239000004287 Dehydroacetic acid Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 2
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 2
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 102100030011 Endoribonuclease Human genes 0.000 description 2
- 101710199605 Endoribonuclease Proteins 0.000 description 2
- 102100036448 Endothelial PAS domain-containing protein 1 Human genes 0.000 description 2
- 102000010911 Enzyme Precursors Human genes 0.000 description 2
- 108010062466 Enzyme Precursors Proteins 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- YIKYNHJUKRTCJL-UHFFFAOYSA-N Ethyl maltol Chemical compound CCC=1OC=CC(=O)C=1O YIKYNHJUKRTCJL-UHFFFAOYSA-N 0.000 description 2
- 239000001329 FEMA 3811 Substances 0.000 description 2
- 108091008794 FGF receptors Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 206010061159 Foot deformity Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 2
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 2
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 2
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 2
- 108050009527 Hypoxia-inducible factor-1 alpha Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 239000005639 Lauric acid Substances 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 108010034057 Mechanistic Target of Rapamycin Complex 2 Proteins 0.000 description 2
- 102000009308 Mechanistic Target of Rapamycin Complex 2 Human genes 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 101150097381 Mtor gene Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 206010031252 Osteomyelitis Diseases 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- 108010089430 Phosphoproteins Proteins 0.000 description 2
- 102000007982 Phosphoproteins Human genes 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 229920000148 Polycarbophil calcium Polymers 0.000 description 2
- 229920001100 Polydextrose Polymers 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 229920000153 Povidone-iodine Polymers 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- PQCXVIPXISBFPN-UHFFFAOYSA-N SB 415286 Chemical compound C1=C(Cl)C(O)=CC=C1NC1=C(C=2C(=CC=CC=2)[N+]([O-])=O)C(=O)NC1=O PQCXVIPXISBFPN-UHFFFAOYSA-N 0.000 description 2
- 235000019485 Safflower oil Nutrition 0.000 description 2
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 2
- 229920001800 Shellac Polymers 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- ZIJKGAXBCRWEOL-SAXBRCJISA-N Sucrose octaacetate Chemical compound CC(=O)O[C@H]1[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@@]1(COC(C)=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1 ZIJKGAXBCRWEOL-SAXBRCJISA-N 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 229920002253 Tannate Polymers 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 239000005844 Thymol Substances 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 2
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 102000012249 Voltage-Dependent Anion Channel 2 Human genes 0.000 description 2
- 108010022109 Voltage-Dependent Anion Channel 2 Proteins 0.000 description 2
- 102100023038 WD and tetratricopeptide repeats protein 1 Human genes 0.000 description 2
- 229920002494 Zein Polymers 0.000 description 2
- 239000001344 [(2S,3S,4R,5R)-4-acetyloxy-2,5-bis(acetyloxymethyl)-2-[(2R,3R,4S,5R,6R)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxyoxolan-3-yl] acetate Substances 0.000 description 2
- QBGKPEROWUKSBK-QPPIDDCLSA-N [(4s,5r)-2-(4-tert-butyl-2-ethoxyphenyl)-4,5-bis(4-chlorophenyl)-4,5-dimethylimidazol-1-yl]-[4-(3-methylsulfonylpropyl)piperazin-1-yl]methanone Chemical compound CCOC1=CC(C(C)(C)C)=CC=C1C(N([C@]1(C)C=2C=CC(Cl)=CC=2)C(=O)N2CCN(CCCS(C)(=O)=O)CC2)=N[C@@]1(C)C1=CC=C(Cl)C=C1 QBGKPEROWUKSBK-QPPIDDCLSA-N 0.000 description 2
- RQQIRMLGKSPXSE-WIPMOJCBSA-N [1-acetyloxy-2-[[(2s,3r,5s,6s)-2,6-dihydroxy-3,4,5-triphosphonooxycyclohexyl]oxy-hydroxyphosphoryl]oxyethyl] acetate Chemical compound CC(=O)OC(OC(C)=O)COP(O)(=O)OC1[C@H](O)[C@H](OP(O)(O)=O)C(OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O RQQIRMLGKSPXSE-WIPMOJCBSA-N 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 2
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 2
- 229940081735 acetylcellulose Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000001361 adipic acid Substances 0.000 description 2
- 235000011037 adipic acid Nutrition 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 229940023476 agar Drugs 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 229920003232 aliphatic polyester Polymers 0.000 description 2
- 235000019409 alitame Nutrition 0.000 description 2
- 108010009985 alitame Proteins 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000008168 almond oil Substances 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- OLUKILHGKRVDCT-UHFFFAOYSA-N alsterpaullone Chemical compound C1C(=O)NC2=CC=CC=C2C2=C1C1=CC([N+](=O)[O-])=CC=C1N2 OLUKILHGKRVDCT-UHFFFAOYSA-N 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000011126 aluminium potassium sulphate Nutrition 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 235000010407 ammonium alginate Nutrition 0.000 description 2
- 239000000728 ammonium alginate Substances 0.000 description 2
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 229930014669 anthocyanidin Natural products 0.000 description 2
- 235000008758 anthocyanidins Nutrition 0.000 description 2
- 235000010208 anthocyanin Nutrition 0.000 description 2
- 239000004410 anthocyanin Substances 0.000 description 2
- 229930002877 anthocyanin Natural products 0.000 description 2
- 150000004636 anthocyanins Chemical class 0.000 description 2
- 230000006909 anti-apoptosis Effects 0.000 description 2
- 229940127218 antiplatelet drug Drugs 0.000 description 2
- 238000013176 antiplatelet therapy Methods 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 229960000892 attapulgite Drugs 0.000 description 2
- 230000002358 autolytic effect Effects 0.000 description 2
- 230000004900 autophagic degradation Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 229960004365 benzoic acid Drugs 0.000 description 2
- YYMVPVZYUYQSJE-UHFFFAOYSA-N benzyl-[2-(2,6-dimethylanilino)-2-oxoethyl]-diethylazanium;benzoate;hydrate Chemical compound O.[O-]C(=O)C1=CC=CC=C1.C=1C=CC=CC=1C[N+](CC)(CC)CC(=O)NC1=C(C)C=CC=C1C YYMVPVZYUYQSJE-UHFFFAOYSA-N 0.000 description 2
- 235000013734 beta-carotene Nutrition 0.000 description 2
- 239000011648 beta-carotene Substances 0.000 description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 229960002747 betacarotene Drugs 0.000 description 2
- 239000001045 blue dye Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 229960002645 boric acid Drugs 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- 229960003168 bronopol Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229950003628 buparlisib Drugs 0.000 description 2
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 229940067596 butylparaben Drugs 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 2
- 235000011092 calcium acetate Nutrition 0.000 description 2
- 239000001639 calcium acetate Substances 0.000 description 2
- 229960005147 calcium acetate Drugs 0.000 description 2
- 239000000648 calcium alginate Substances 0.000 description 2
- 229960002681 calcium alginate Drugs 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 229960002713 calcium chloride Drugs 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
- 239000000920 calcium hydroxide Substances 0.000 description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
- 229940095643 calcium hydroxide Drugs 0.000 description 2
- 235000011116 calcium hydroxide Nutrition 0.000 description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 2
- 239000001527 calcium lactate Substances 0.000 description 2
- 229960002401 calcium lactate Drugs 0.000 description 2
- 235000011086 calcium lactate Nutrition 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 235000011132 calcium sulphate Nutrition 0.000 description 2
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 2
- 230000009400 cancer invasion Effects 0.000 description 2
- 239000000828 canola oil Substances 0.000 description 2
- 235000019519 canola oil Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- QRYRORQUOLYVBU-VBKZILBWSA-N carnosic acid Chemical compound CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 229960001777 castor oil Drugs 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 230000006364 cellular survival Effects 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 229940043431 ceratonia Drugs 0.000 description 2
- 229960002798 cetrimide Drugs 0.000 description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 2
- NFCRBQADEGXVDL-UHFFFAOYSA-M cetylpyridinium chloride monohydrate Chemical compound O.[Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NFCRBQADEGXVDL-UHFFFAOYSA-M 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940045110 chitosan Drugs 0.000 description 2
- 229960003260 chlorhexidine Drugs 0.000 description 2
- 229960002242 chlorocresol Drugs 0.000 description 2
- 229930002875 chlorophyll Natural products 0.000 description 2
- 235000019804 chlorophyll Nutrition 0.000 description 2
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 2
- 229960005443 chloroxylenol Drugs 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 229960004588 cilostazol Drugs 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 229960002303 citric acid monohydrate Drugs 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 229920001531 copovidone Polymers 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 2
- 229940086555 cyclomethicone Drugs 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000019258 dehydroacetic acid Nutrition 0.000 description 2
- 229940061632 dehydroacetic acid Drugs 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 229960001610 denatonium benzoate Drugs 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- 229940077445 dimethyl ether Drugs 0.000 description 2
- FBSAITBEAPNWJG-UHFFFAOYSA-N dimethyl phthalate Natural products CC(=O)OC1=CC=CC=C1OC(C)=O FBSAITBEAPNWJG-UHFFFAOYSA-N 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 2
- 229940113088 dimethylacetamide Drugs 0.000 description 2
- 229960001826 dimethylphthalate Drugs 0.000 description 2
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 2
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 2
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 2
- IDAGXRIGDWCIET-SDFKWCIISA-L disodium;(2s,3s,4s,5r)-2,3,4,5-tetrahydroxyhexanedioate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IDAGXRIGDWCIET-SDFKWCIISA-L 0.000 description 2
- 229960000878 docusate sodium Drugs 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- BXKDSDJJOVIHMX-UHFFFAOYSA-N edrophonium chloride Chemical compound [Cl-].CC[N+](C)(C)C1=CC=CC(O)=C1 BXKDSDJJOVIHMX-UHFFFAOYSA-N 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 235000010350 erythorbic acid Nutrition 0.000 description 2
- 239000004318 erythorbic acid Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229940093499 ethyl acetate Drugs 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 229960004667 ethyl cellulose Drugs 0.000 description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 2
- 229940116333 ethyl lactate Drugs 0.000 description 2
- 229940093503 ethyl maltol Drugs 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 2
- 229940073505 ethyl vanillin Drugs 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 102000054078 gamma Catenin Human genes 0.000 description 2
- 108010084448 gamma Catenin Proteins 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 229940049654 glyceryl behenate Drugs 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 2
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 2
- 239000001087 glyceryl triacetate Substances 0.000 description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 229940116364 hard fat Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 2
- 229910000271 hectorite Inorganic materials 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- UKACHOXRXFQJFN-UHFFFAOYSA-N heptafluoropropane Chemical compound FC(F)C(F)(F)C(F)(F)F UKACHOXRXFQJFN-UHFFFAOYSA-N 0.000 description 2
- 229960004867 hexetidine Drugs 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000002169 hydrotherapy Methods 0.000 description 2
- 230000037417 hyperactivation Effects 0.000 description 2
- 238000002639 hyperbaric oxygen therapy Methods 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 2
- 229940113174 imidurea Drugs 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002664 inhalation therapy Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 229940026239 isoascorbic acid Drugs 0.000 description 2
- 239000000905 isomalt Substances 0.000 description 2
- 235000010439 isomalt Nutrition 0.000 description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 229940074928 isopropyl myristate Drugs 0.000 description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 2
- 229940075495 isopropyl palmitate Drugs 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 229960000829 kaolin Drugs 0.000 description 2
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 239000000832 lactitol Substances 0.000 description 2
- 235000010448 lactitol Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 2
- 229960003451 lactitol Drugs 0.000 description 2
- 238000000370 laser capture micro-dissection Methods 0.000 description 2
- 229940033355 lauric acid Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 229960001708 magnesium carbonate Drugs 0.000 description 2
- 235000014380 magnesium carbonate Nutrition 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- 229960000869 magnesium oxide Drugs 0.000 description 2
- 235000012245 magnesium oxide Nutrition 0.000 description 2
- 235000019792 magnesium silicate Nutrition 0.000 description 2
- 229910052919 magnesium silicate Inorganic materials 0.000 description 2
- 235000019793 magnesium trisilicate Nutrition 0.000 description 2
- 229940099273 magnesium trisilicate Drugs 0.000 description 2
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 229940098895 maleic acid Drugs 0.000 description 2
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 229940099690 malic acid Drugs 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 229940043353 maltol Drugs 0.000 description 2
- 229960002160 maltose Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 229960003194 meglumine Drugs 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- WVJKHCGMRZGIJH-UHFFFAOYSA-N methanetriamine Chemical compound NC(N)N WVJKHCGMRZGIJH-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 235000006109 methionine Nutrition 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 210000003632 microfilament Anatomy 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 2
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 2
- 235000013923 monosodium glutamate Nutrition 0.000 description 2
- 239000004223 monosodium glutamate Substances 0.000 description 2
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 2
- 229940043348 myristyl alcohol Drugs 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- ITVGXXMINPYUHD-CUVHLRMHSA-N neohesperidin dihydrochalcone Chemical compound C1=C(O)C(OC)=CC=C1CCC(=O)C(C(=C1)O)=C(O)C=C1O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ITVGXXMINPYUHD-CUVHLRMHSA-N 0.000 description 2
- 229940089953 neohesperidin dihydrochalcone Drugs 0.000 description 2
- 235000010434 neohesperidine DC Nutrition 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000001272 nitrous oxide Substances 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- OIPZNTLJVJGRCI-UHFFFAOYSA-M octadecanoyloxyaluminum;dihydrate Chemical compound O.O.CCCCCCCCCCCCCCCCCC(=O)O[Al] OIPZNTLJVJGRCI-UHFFFAOYSA-M 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000000014 opioid analgesic Substances 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 235000013348 organic food Nutrition 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 2
- 229910052625 palygorskite Inorganic materials 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 229960003330 pentetic acid Drugs 0.000 description 2
- 229960001476 pentoxifylline Drugs 0.000 description 2
- SZFPYBIJACMNJV-UHFFFAOYSA-N perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 229940096826 phenylmercuric acetate Drugs 0.000 description 2
- VUXSPDNLYQTOSY-UHFFFAOYSA-N phenylmercuric borate Chemical compound OB(O)O[Hg]C1=CC=CC=C1 VUXSPDNLYQTOSY-UHFFFAOYSA-N 0.000 description 2
- 229960000247 phenylmercuric borate Drugs 0.000 description 2
- 229940067631 phospholipid Drugs 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229960004838 phosphoric acid Drugs 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical group 0.000 description 2
- 230000000865 phosphorylative effect Effects 0.000 description 2
- LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
- 229960000540 polacrilin potassium Drugs 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229950005134 polycarbophil Drugs 0.000 description 2
- 235000013856 polydextrose Nutrition 0.000 description 2
- 239000001259 polydextrose Substances 0.000 description 2
- 229940035035 polydextrose Drugs 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 235000010408 potassium alginate Nutrition 0.000 description 2
- 239000000737 potassium alginate Substances 0.000 description 2
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 2
- 229940050271 potassium alum Drugs 0.000 description 2
- GNHOJBNSNUXZQA-UHFFFAOYSA-J potassium aluminium sulfate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GNHOJBNSNUXZQA-UHFFFAOYSA-J 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 235000010235 potassium benzoate Nutrition 0.000 description 2
- 239000004300 potassium benzoate Substances 0.000 description 2
- 229940103091 potassium benzoate Drugs 0.000 description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 description 2
- 239000011736 potassium bicarbonate Substances 0.000 description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
- 229940094025 potassium bicarbonate Drugs 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 229960002816 potassium chloride Drugs 0.000 description 2
- 239000001508 potassium citrate Substances 0.000 description 2
- 229960002635 potassium citrate Drugs 0.000 description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 2
- 235000011082 potassium citrates Nutrition 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 229940093932 potassium hydroxide Drugs 0.000 description 2
- 235000011118 potassium hydroxide Nutrition 0.000 description 2
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 2
- 229940043349 potassium metabisulfite Drugs 0.000 description 2
- 235000010263 potassium metabisulphite Nutrition 0.000 description 2
- 235000010241 potassium sorbate Nutrition 0.000 description 2
- 239000004302 potassium sorbate Substances 0.000 description 2
- 229940069338 potassium sorbate Drugs 0.000 description 2
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 2
- 229960001621 povidone-iodine Drugs 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000861 pro-apoptotic effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 235000010388 propyl gallate Nutrition 0.000 description 2
- 239000000473 propyl gallate Substances 0.000 description 2
- 229940075579 propyl gallate Drugs 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229940032159 propylene carbonate Drugs 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 229960005359 propylparaben sodium Drugs 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000250 revascularization Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 2
- 229940085605 saccharin sodium Drugs 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- 229950009216 sapanisertib Drugs 0.000 description 2
- 229910000275 saponite Inorganic materials 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000004208 shellac Substances 0.000 description 2
- 229940113147 shellac Drugs 0.000 description 2
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 2
- 235000013874 shellac Nutrition 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 2
- 229940083037 simethicone Drugs 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000010378 sodium ascorbate Nutrition 0.000 description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 2
- 229960005055 sodium ascorbate Drugs 0.000 description 2
- 229960000999 sodium citrate dihydrate Drugs 0.000 description 2
- 229960001462 sodium cyclamate Drugs 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- 239000001540 sodium lactate Substances 0.000 description 2
- 235000011088 sodium lactate Nutrition 0.000 description 2
- 229940005581 sodium lactate Drugs 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 229940001584 sodium metabisulfite Drugs 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 2
- 235000010334 sodium propionate Nutrition 0.000 description 2
- 239000004324 sodium propionate Substances 0.000 description 2
- 229960003212 sodium propionate Drugs 0.000 description 2
- 229960004025 sodium salicylate Drugs 0.000 description 2
- 229940001482 sodium sulfite Drugs 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 229940001474 sodium thiosulfate Drugs 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- IXMINYBUNCWGER-UHFFFAOYSA-M sodium;4-propoxycarbonylphenolate Chemical compound [Na+].CCCOC(=O)C1=CC=C([O-])C=C1 IXMINYBUNCWGER-UHFFFAOYSA-M 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 229940013883 sucrose octaacetate Drugs 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 2
- 235000010436 thaumatin Nutrition 0.000 description 2
- 239000000892 thaumatin Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 229960000790 thymol Drugs 0.000 description 2
- 230000008467 tissue growth Effects 0.000 description 2
- 229960005196 titanium dioxide Drugs 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 239000003860 topical agent Substances 0.000 description 2
- SLGRAIAQIAUZAQ-UHFFFAOYSA-N toxoflavin Chemical compound CN1N=CN=C2C1=NC(=O)N(C)C2=O SLGRAIAQIAUZAQ-UHFFFAOYSA-N 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 102000027257 transmembrane receptors Human genes 0.000 description 2
- 108091008578 transmembrane receptors Proteins 0.000 description 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 2
- 229960002622 triacetin Drugs 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229940093609 tricaprylin Drugs 0.000 description 2
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 2
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 2
- 229940117972 triolein Drugs 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 2
- 235000012141 vanillin Nutrition 0.000 description 2
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000005019 zein Substances 0.000 description 2
- 229940093612 zein Drugs 0.000 description 2
- 239000004246 zinc acetate Substances 0.000 description 2
- 229960000314 zinc acetate Drugs 0.000 description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 2
- 229940057977 zinc stearate Drugs 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 2
- YXEWPGYLMHXLPS-UHFFFAOYSA-N (2,5-dioxopyrrol-1-yl)methyl propanoate Chemical compound CCC(=O)OCN1C(=O)C=CC1=O YXEWPGYLMHXLPS-UHFFFAOYSA-N 0.000 description 1
- GRZXWCHAXNAUHY-NSISKUIASA-N (2S)-2-(4-chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]-1-piperazinyl]-3-(propan-2-ylamino)-1-propanone Chemical compound C1([C@H](C(=O)N2CCN(CC2)C=2C=3[C@H](C)C[C@@H](O)C=3N=CN=2)CNC(C)C)=CC=C(Cl)C=C1 GRZXWCHAXNAUHY-NSISKUIASA-N 0.000 description 1
- STUWGJZDJHPWGZ-LBPRGKRZSA-N (2S)-N1-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-2-thiazolyl]pyrrolidine-1,2-dicarboxamide Chemical compound S1C(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C(C)N=C1NC(=O)N1CCC[C@H]1C(N)=O STUWGJZDJHPWGZ-LBPRGKRZSA-N 0.000 description 1
- UXFNAATUJSSAHF-SZWANQOLSA-N (2r)-2-[(2e,7e,9e)-13-(furan-3-yl)-2,6,10-trimethyltrideca-2,7,9-trienyl]-3-hydroxy-4-methyl-2h-furan-5-one Chemical compound C1=COC=C1CCCC(/C)=C/C=C/C(C)CC\C=C(/C)C[C@H]1OC(=O)C(C)=C1O UXFNAATUJSSAHF-SZWANQOLSA-N 0.000 description 1
- DKXNBNKWCZZMJT-JVCRWLNRSA-N (2r,3r,4r,5r)-2,3,5,6-tetrahydroxy-4-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanal Chemical compound O=C[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DKXNBNKWCZZMJT-JVCRWLNRSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- YOVVNQKCSKSHKT-HNNXBMFYSA-N (2s)-1-[4-[[2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]-2-hydroxypropan-1-one Chemical compound C1CN(C(=O)[C@@H](O)C)CCN1CC1=C(C)C2=NC(C=3C=NC(N)=NC=3)=NC(N3CCOCC3)=C2S1 YOVVNQKCSKSHKT-HNNXBMFYSA-N 0.000 description 1
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 1
- NUKCQDDVORQLDB-OLILMLBXSA-N (3s)-4-[(1r)-1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-7-iodo-1-[3-(4-methylpiperazin-1-yl)propyl]-3h-1,4-benzodiazepine-2,5-dione Chemical compound C1([C@@H]2N(C(C3=CC(I)=CC=C3N(CCCN3CCN(C)CC3)C2=O)=O)[C@H](C)C=2C(=CC(Cl)=CC=2)N)=CC=C(Cl)C=C1 NUKCQDDVORQLDB-OLILMLBXSA-N 0.000 description 1
- JLHWBVQBEGDSEZ-LFOOZZFTSA-N (4s)-5-[[(2s)-1-[(2s)-2-[(2s)-2-[[(2s)-1-[(2s)-2-[(2s)-2-[[(2s)-5-amino-1-[[(2s)-1-[(2s)-2-carbamoylpyrrolidin-1-yl]-1-oxo-3-phosphonooxypropan-2-yl]amino]-1,5-dioxopentan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]carbamoyl]p Chemical compound CCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)N[C@@H](C)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](COP(O)(O)=O)C(=O)N2[C@@H](CCC2)C(N)=O)CCC1 JLHWBVQBEGDSEZ-LFOOZZFTSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Polymers FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- CEGSUKYESLWKJP-UHFFFAOYSA-N 1-n-[2-(1h-indol-3-yl)ethyl]-4-n-pyridin-4-ylbenzene-1,4-diamine Chemical compound C=1NC2=CC=CC=C2C=1CCNC(C=C1)=CC=C1NC1=CC=NC=C1 CEGSUKYESLWKJP-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 102100025007 14-3-3 protein epsilon Human genes 0.000 description 1
- RFBVBRVVOPAAFS-UHFFFAOYSA-N 2,2-bis(hydroxymethyl)-1-azabicyclo[2.2.2]octan-3-one Chemical compound C1CC2CCN1C(CO)(CO)C2=O RFBVBRVVOPAAFS-UHFFFAOYSA-N 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- BGBNULCRKBVAKL-UHFFFAOYSA-N 2-(hydroxymethyl)-2-(methoxymethyl)-1-azabicyclo[2.2.2]octan-3-one Chemical compound C1CC2CCN1C(COC)(CO)C2=O BGBNULCRKBVAKL-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
- UAXHPOBBKRWJGA-ZDUSSCGKSA-N 2-[2-[(2s)-2-methyl-2,3-dihydroindol-1-yl]-2-oxoethyl]-6-morpholin-4-yl-1h-pyrimidin-4-one Chemical compound C([C@@H]1C)C2=CC=CC=C2N1C(=O)CC(NC(=O)C=1)=NC=1N1CCOCC1 UAXHPOBBKRWJGA-ZDUSSCGKSA-N 0.000 description 1
- QINPEPAQOBZPOF-UHFFFAOYSA-N 2-amino-n-[3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-2-methylpropanamide Chemical compound COC1=CC=C(Cl)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C(C)(C)N)C=CC=2)=C1 QINPEPAQOBZPOF-UHFFFAOYSA-N 0.000 description 1
- BEUQXVWXFDOSAQ-UHFFFAOYSA-N 2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide Chemical compound CC(C)N1N=C(C)N=C1C1=CN(CCOC=2C3=CC=C(C=2)C2=CN(N=C2)C(C)(C)C(N)=O)C3=N1 BEUQXVWXFDOSAQ-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical class CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- VQMWCYHBHMGBDP-UHFFFAOYSA-N 2h-1,2-benzodiazepine-3,4-dione Chemical class N1C(=O)C(=O)C=C2C=CC=CC2=N1 VQMWCYHBHMGBDP-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
- JUSFANSTBFGBAF-IRXDYDNUSA-N 3-[2,4-bis[(3s)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(C=2N=C3N=C(N=C(C3=CC=2)N2[C@H](COCC2)C)N2[C@H](COCC2)C)=C1 JUSFANSTBFGBAF-IRXDYDNUSA-N 0.000 description 1
- HNFMVVHMKGFCMB-UHFFFAOYSA-N 3-[3-[4-(1-aminocyclobutyl)phenyl]-5-phenylimidazo[4,5-b]pyridin-2-yl]pyridin-2-amine Chemical compound NC1=NC=CC=C1C1=NC2=CC=C(C=3C=CC=CC=3)N=C2N1C1=CC=C(C2(N)CCC2)C=C1 HNFMVVHMKGFCMB-UHFFFAOYSA-N 0.000 description 1
- VPVLEBIVXZSOMQ-UHFFFAOYSA-N 3-[[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol Chemical compound NC1=CC=CC(C=2NC3=NC=NC(OC=4C=C(O)C=CC=4)=C3C=2)=C1 VPVLEBIVXZSOMQ-UHFFFAOYSA-N 0.000 description 1
- CFHMRJUTHATPLW-UHFFFAOYSA-N 3-anilinopyrrole-2,5-dione Chemical class O=C1NC(=O)C(NC=2C=CC=CC=2)=C1 CFHMRJUTHATPLW-UHFFFAOYSA-N 0.000 description 1
- YJQYHFMKGAVKDP-UHFFFAOYSA-N 3-butanoyl-1,8-dihydroxy-2-methylphenanthrene-9,10-dione Chemical compound C12=CC=CC(O)=C2C(=O)C(=O)C2=C1C=C(C(=O)CCC)C(C)=C2O YJQYHFMKGAVKDP-UHFFFAOYSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- JDUBGYFRJFOXQC-KRWDZBQOSA-N 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide Chemical compound C1([C@H](CCO)NC(=O)C2(CCN(CC2)C=2C=3C=CNC=3N=CN=2)N)=CC=C(Cl)C=C1 JDUBGYFRJFOXQC-KRWDZBQOSA-N 0.000 description 1
- 102100033714 40S ribosomal protein S6 Human genes 0.000 description 1
- VERUFXOALATMPS-UHFFFAOYSA-N 5,5-diamino-2-(2-phenylethenyl)cyclohex-3-ene-1,1-disulfonic acid Chemical compound C1=CC(N)(N)CC(S(O)(=O)=O)(S(O)(=O)=O)C1C=CC1=CC=CC=C1 VERUFXOALATMPS-UHFFFAOYSA-N 0.000 description 1
- GKFPPCXIBHQRQT-UHFFFAOYSA-N 6-(2-carboxy-4,5-dihydroxy-6-methoxyoxan-3-yl)oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(OC)C(C(O)=O)O1 GKFPPCXIBHQRQT-UHFFFAOYSA-N 0.000 description 1
- DDLZLOKCJHBUHD-WAVHTBQISA-N 6-bromoindirubin-3'-oxime Chemical compound O=C/1NC2=CC(Br)=CC=C2C\1=C\1/C(=N/O)/C2=CC=CC=C2N/1 DDLZLOKCJHBUHD-WAVHTBQISA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- PRIGRJPRGZCFAS-UHFFFAOYSA-N 6-phenyl[5h]pyrrolo[2,3-b]pyrazine Chemical compound N1C2=NC=CN=C2C(CCCC)=C1C1=CC=C(O)C=C1 PRIGRJPRGZCFAS-UHFFFAOYSA-N 0.000 description 1
- 229960005531 AMG 319 Drugs 0.000 description 1
- 108700001666 APC Genes Proteins 0.000 description 1
- 108091005508 Acid proteases Proteins 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 102000008102 Ankyrins Human genes 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- 108010001781 Apligraf Proteins 0.000 description 1
- 108010089941 Apoptosomes Proteins 0.000 description 1
- 102100033648 Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 3 Human genes 0.000 description 1
- 206010062542 Arterial insufficiency Diseases 0.000 description 1
- 101710084072 Aryl hydrocarbon receptor nuclear translocator 2 Proteins 0.000 description 1
- 102100037211 Aryl hydrocarbon receptor nuclear translocator-like protein 1 Human genes 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000010264 Axin Signaling Complex Human genes 0.000 description 1
- 108010077596 Axin Signaling Complex Proteins 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 206010006585 Bunion Diseases 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- UFKLYTOEMRFKAD-SHTZXODSSA-N C1C[C@@H](OC)CC[C@@H]1N1C2=NC(C=3C=NC(=CC=3)C(C)(C)O)=CN=C2NCC1=O Chemical compound C1C[C@@H](OC)CC[C@@H]1N1C2=NC(C=3C=NC(=CC=3)C(C)(C)O)=CN=C2NCC1=O UFKLYTOEMRFKAD-SHTZXODSSA-N 0.000 description 1
- 102100025752 CASP8 and FADD-like apoptosis regulator Human genes 0.000 description 1
- 101710100501 CASP8 and FADD-like apoptosis regulator Proteins 0.000 description 1
- 229940126074 CDK kinase inhibitor Drugs 0.000 description 1
- 101150041972 CDKN2A gene Proteins 0.000 description 1
- 101150070189 CIN3 gene Proteins 0.000 description 1
- 108010069682 CSK Tyrosine-Protein Kinase Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 101000690445 Caenorhabditis elegans Aryl hydrocarbon receptor nuclear translocator homolog Proteins 0.000 description 1
- 101001059929 Caenorhabditis elegans Forkhead box protein O Proteins 0.000 description 1
- 101100496968 Caenorhabditis elegans ctc-1 gene Proteins 0.000 description 1
- 101100450705 Caenorhabditis elegans hif-1 gene Proteins 0.000 description 1
- 101100205088 Caenorhabditis elegans iars-1 gene Proteins 0.000 description 1
- 101100458634 Caenorhabditis elegans mtx-2 gene Proteins 0.000 description 1
- 101100484538 Caenorhabditis elegans vav-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 102100033620 Calponin-1 Human genes 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 101150100916 Casp3 gene Proteins 0.000 description 1
- 102000004041 Caspase 7 Human genes 0.000 description 1
- 108090000567 Caspase 7 Proteins 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 102100028914 Catenin beta-1 Human genes 0.000 description 1
- 101710174494 Catenin beta-1 Proteins 0.000 description 1
- 101150066912 Cbl gene Proteins 0.000 description 1
- 101150015280 Cel gene Proteins 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- CRDNMYFJWFXOCH-BUHFOSPRSA-N Couroupitine B Natural products N\1C2=CC=CC=C2C(=O)C/1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-BUHFOSPRSA-N 0.000 description 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 1
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 101001058087 Dictyostelium discoideum Endonuclease 4 homolog Proteins 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 102100031918 E3 ubiquitin-protein ligase NEDD4 Human genes 0.000 description 1
- 102100032036 EH domain-containing protein 1 Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 229920003163 Eudragit® NE 30 D Polymers 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 102000053334 GRB10 Adaptor Human genes 0.000 description 1
- 108700031835 GRB10 Adaptor Proteins 0.000 description 1
- 229940126656 GS-4224 Drugs 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 108010001483 Glycogen Synthase Proteins 0.000 description 1
- 102100022975 Glycogen synthase kinase-3 alpha Human genes 0.000 description 1
- 101150090959 Grb10 gene Proteins 0.000 description 1
- 102100033067 Growth factor receptor-bound protein 2 Human genes 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 101150019946 Gsk3b gene Proteins 0.000 description 1
- 208000000013 Hammer Toe Syndrome Diseases 0.000 description 1
- 241000193159 Hathewaya histolytica Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101000760079 Homo sapiens 14-3-3 protein epsilon Proteins 0.000 description 1
- 101000733571 Homo sapiens Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 3 Proteins 0.000 description 1
- 101000793115 Homo sapiens Aryl hydrocarbon receptor nuclear translocator Proteins 0.000 description 1
- 101000768838 Homo sapiens Aryl hydrocarbon receptor nuclear translocator 2 Proteins 0.000 description 1
- 101000740484 Homo sapiens Aryl hydrocarbon receptor nuclear translocator-like protein 1 Proteins 0.000 description 1
- 101000798320 Homo sapiens Bcl-2 homologous antagonist/killer Proteins 0.000 description 1
- 101100382566 Homo sapiens CASP9 gene Proteins 0.000 description 1
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
- 101000983523 Homo sapiens Caspase-9 Proteins 0.000 description 1
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 description 1
- 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 description 1
- 101000636713 Homo sapiens E3 ubiquitin-protein ligase NEDD4 Proteins 0.000 description 1
- 101000921221 Homo sapiens EH domain-containing protein 1 Proteins 0.000 description 1
- 101000851937 Homo sapiens Endothelial PAS domain-containing protein 1 Proteins 0.000 description 1
- 101000903717 Homo sapiens Glycogen synthase kinase-3 alpha Proteins 0.000 description 1
- 101000871017 Homo sapiens Growth factor receptor-bound protein 2 Proteins 0.000 description 1
- 101001077604 Homo sapiens Insulin receptor substrate 1 Proteins 0.000 description 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 1
- 101000961071 Homo sapiens NF-kappa-B inhibitor alpha Proteins 0.000 description 1
- 101001128158 Homo sapiens Nanos homolog 2 Proteins 0.000 description 1
- 101001124991 Homo sapiens Nitric oxide synthase, inducible Proteins 0.000 description 1
- 101001098116 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit gamma Proteins 0.000 description 1
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 1
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 101001130509 Homo sapiens Ras GTPase-activating protein 1 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000927774 Homo sapiens Rho guanine nucleotide exchange factor 12 Proteins 0.000 description 1
- 101000864057 Homo sapiens Serine/threonine-protein kinase SMG1 Proteins 0.000 description 1
- 101000623857 Homo sapiens Serine/threonine-protein kinase mTOR Proteins 0.000 description 1
- 101000577874 Homo sapiens Stromelysin-2 Proteins 0.000 description 1
- 101000687808 Homo sapiens Suppressor of cytokine signaling 2 Proteins 0.000 description 1
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
- 101000795659 Homo sapiens Tuberin Proteins 0.000 description 1
- 101001087416 Homo sapiens Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 1
- 208000002682 Hyperkalemia Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 108010021699 I-kappa B Proteins Proteins 0.000 description 1
- 102000008379 I-kappa B Proteins Human genes 0.000 description 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 1
- 102000038455 IGF Type 1 Receptor Human genes 0.000 description 1
- 101150088952 IGF1 gene Proteins 0.000 description 1
- 101150030450 IRS1 gene Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010021518 Impaired gastric emptying Diseases 0.000 description 1
- 206010021519 Impaired healing Diseases 0.000 description 1
- 108010034219 Insulin Receptor Substrate Proteins Proteins 0.000 description 1
- 101710201824 Insulin receptor substrate 1 Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- 101710149643 Integrin alpha-IIb Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- CZQHHVNHHHRRDU-UHFFFAOYSA-N LY294002 Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1C1=CC=CC=C1 CZQHHVNHHHRRDU-UHFFFAOYSA-N 0.000 description 1
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 1
- 229920002884 Laureth 4 Polymers 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 208000005230 Leg Ulcer Diseases 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025282 Lymphoedema Diseases 0.000 description 1
- 101150105382 MET gene Proteins 0.000 description 1
- 229940124640 MK-2206 Drugs 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 229920003094 Methocel™ K4M Polymers 0.000 description 1
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 1
- 101100087591 Mus musculus Rictor gene Proteins 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- AFJRDFWMXUECEW-LBPRGKRZSA-N N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methyl-3-pyrazolyl)-2-thiophenecarboxamide Chemical compound CN1N=CC(Cl)=C1C1=C(Cl)SC(C(=O)N[C@H](CN)CC=2C=C(F)C=CC=2)=C1 AFJRDFWMXUECEW-LBPRGKRZSA-N 0.000 description 1
- WOWJIWFCOPZFGV-UHFFFAOYSA-N N-[(4-acetamidoanilino)-sulfanylidenemethyl]-4-tert-butylbenzamide Chemical compound C1=CC(NC(=O)C)=CC=C1NC(=S)NC(=O)C1=CC=C(C(C)(C)C)C=C1 WOWJIWFCOPZFGV-UHFFFAOYSA-N 0.000 description 1
- IFOHRIXRQPOHQZ-UHFFFAOYSA-N N-[(4-chlorophenyl)-(2-methyl-1H-indol-3-yl)methyl]-2-pyridinamine Chemical compound CC=1NC2=CC=CC=C2C=1C(C=1C=CC(Cl)=CC=1)NC1=CC=CC=N1 IFOHRIXRQPOHQZ-UHFFFAOYSA-N 0.000 description 1
- VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 1
- 108010063250 N-myristoyl-glycyl-lysyl-glutamyl-alanyl-prolyl-prolyl-alanyl-prolyl-prolyl-glutaminyl-phosphoseryl-proline Proteins 0.000 description 1
- 102100039337 NF-kappa-B inhibitor alpha Human genes 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 101100221647 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cox-1 gene Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 206010031112 Oropharyngeal squamous cell carcinoma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 239000012828 PI3K inhibitor Substances 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 101150073900 PTEN gene Proteins 0.000 description 1
- 230000007732 PTEN-Akt signaling Effects 0.000 description 1
- 101150062589 PTGS1 gene Proteins 0.000 description 1
- QIUASFSNWYMDFS-NILGECQDSA-N PX-866 Chemical compound CC(=O)O[C@@H]1C[C@]2(C)C(=O)CC[C@H]2C2=C1[C@@]1(C)[C@@H](COC)OC(=O)\C(=C\N(CC=C)CC=C)C1=C(O)C2=O QIUASFSNWYMDFS-NILGECQDSA-N 0.000 description 1
- ZCEPTSRBSLJCSK-UHFFFAOYSA-N Palinurin Natural products CC(CCC=C(/C)C1OC(=O)C(=C1O)C)C=CC=C(/C)CCCc2cocc2 ZCEPTSRBSLJCSK-UHFFFAOYSA-N 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 1
- 102100032543 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Human genes 0.000 description 1
- 101710132081 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Proteins 0.000 description 1
- 102100037553 Phosphatidylinositol 3-kinase regulatory subunit gamma Human genes 0.000 description 1
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 229920001991 Proanthocyanidin Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 101710180313 Protease 3 Proteins 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 1
- 101150020518 RHEB gene Proteins 0.000 description 1
- 102100031426 Ras GTPase-activating protein 1 Human genes 0.000 description 1
- 102000046951 Ras Homolog Enriched in Brain Human genes 0.000 description 1
- 108700019578 Ras Homolog Enriched in Brain Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 108050002653 Retinoblastoma protein Proteins 0.000 description 1
- 102100033193 Rho guanine nucleotide exchange factor 12 Human genes 0.000 description 1
- 108090000221 Ribosomal protein S6 Proteins 0.000 description 1
- 230000006295 S-nitrosylation Effects 0.000 description 1
- 102100022340 SHC-transforming protein 1 Human genes 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 102100029938 Serine/threonine-protein kinase SMG1 Human genes 0.000 description 1
- 101150043341 Socs3 gene Proteins 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 102100028848 Stromelysin-2 Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 101000930762 Sulfolobus acidocaldarius (strain ATCC 33909 / DSM 639 / JCM 8929 / NBRC 15157 / NCIMB 11770) Signal recognition particle receptor FtsY Proteins 0.000 description 1
- 108700027337 Suppressor of Cytokine Signaling 3 Proteins 0.000 description 1
- 102100024784 Suppressor of cytokine signaling 2 Human genes 0.000 description 1
- 102100024283 Suppressor of cytokine signaling 3 Human genes 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102000002154 T-Lymphoma Invasion and Metastasis-inducing Protein 1 Human genes 0.000 description 1
- 108010001288 T-Lymphoma Invasion and Metastasis-inducing Protein 1 Proteins 0.000 description 1
- JDSJDASOXWCHPN-UHFFFAOYSA-N TDZD-8 Chemical compound O=C1N(C)SC(=O)N1CC1=CC=CC=C1 JDSJDASOXWCHPN-UHFFFAOYSA-N 0.000 description 1
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 101710173511 Tensin homolog Proteins 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108010040625 Transforming Protein 1 Src Homology 2 Domain-Containing Proteins 0.000 description 1
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 108030003004 Triphosphatases Proteins 0.000 description 1
- 102100031638 Tuberin Human genes 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 102100031167 Tyrosine-protein kinase CSK Human genes 0.000 description 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 description 1
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 102000004962 Voltage-dependent anion channels Human genes 0.000 description 1
- 108090001129 Voltage-dependent anion channels Proteins 0.000 description 1
- 230000004156 Wnt signaling pathway Effects 0.000 description 1
- KLGQSVMIPOVQAX-UHFFFAOYSA-N XAV939 Chemical compound N=1C=2CCSCC=2C(O)=NC=1C1=CC=C(C(F)(F)F)C=C1 KLGQSVMIPOVQAX-UHFFFAOYSA-N 0.000 description 1
- HGVNLRPZOWWDKD-UHFFFAOYSA-N ZSTK-474 Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCOCC1 HGVNLRPZOWWDKD-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- KZENBFUSKMWCJF-UHFFFAOYSA-N [5-[5-[5-(hydroxymethyl)-2-thiophenyl]-2-furanyl]-2-thiophenyl]methanol Chemical compound S1C(CO)=CC=C1C1=CC=C(C=2SC(CO)=CC=2)O1 KZENBFUSKMWCJF-UHFFFAOYSA-N 0.000 description 1
- OTROUIPMYQVNGX-QRPNPIFTSA-N [P].N[C@@H](CC1=CC=C(C=C1)O)C(=O)O Chemical compound [P].N[C@@H](CC1=CC=C(C=C1)O)C(=O)O OTROUIPMYQVNGX-QRPNPIFTSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- KQNKJJBFUFKYFX-UHFFFAOYSA-N acetic acid;trihydrate Chemical compound O.O.O.CC(O)=O KQNKJJBFUFKYFX-UHFFFAOYSA-N 0.000 description 1
- 229940022682 acetone Drugs 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- YAJCHEVQCOHZDC-QMMNLEPNSA-N actrapid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@H](C)CC)[C@H](C)CC)[C@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C(N)=O)C1=CNC=N1 YAJCHEVQCOHZDC-QMMNLEPNSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 210000002867 adherens junction Anatomy 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229950010482 alpelisib Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- 229940009868 aluminum magnesium silicate Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 1
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229960001040 ammonium chloride Drugs 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 229950003153 amsonate Drugs 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003540 anti-differentiation Effects 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 230000005756 apoptotic signaling Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- OISFUZRUIGGTSD-LJTMIZJLSA-N azane;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound N.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO OISFUZRUIGGTSD-LJTMIZJLSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229960005364 bacitracin zinc Drugs 0.000 description 1
- 238000001266 bandaging Methods 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 229910052790 beryllium Inorganic materials 0.000 description 1
- ATBAMAFKBVZNFJ-UHFFFAOYSA-N beryllium atom Chemical compound [Be] ATBAMAFKBVZNFJ-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229940064804 betadine Drugs 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000000091 biomarker candidate Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000020827 calorie restriction Nutrition 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 150000005323 carbonate salts Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- MGQSIUXWCFOENX-UHFFFAOYSA-N cazpaullone Chemical compound C12=NC=CC=C2NC(=O)CC2=C1NC1=CC=C(C#N)C=C21 MGQSIUXWCFOENX-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 230000010094 cellular senescence Effects 0.000 description 1
- 230000004715 cellular signal transduction Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- JWFLIMIGORGZMQ-UHFFFAOYSA-N cercosporin Natural products COC1=C(CC(C)O)c2c3c(CC(C)O)c(OC)c(O)c4C(=O)C=C5OCOc6cc(O)c(C1=O)c2c6c5c34 JWFLIMIGORGZMQ-UHFFFAOYSA-N 0.000 description 1
- 201000006612 cervical squamous cell carcinoma Diseases 0.000 description 1
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
- CEZCCHQBSQPRMU-UHFFFAOYSA-L chembl174821 Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1N=NC1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-UHFFFAOYSA-L 0.000 description 1
- 239000013000 chemical inhibitor Substances 0.000 description 1
- 230000014564 chemokine production Effects 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 230000008711 chromosomal rearrangement Effects 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- SRJYZPCBWDVSGO-UHFFFAOYSA-N cladochrome E Natural products COC1=CC(O)=C(C(C(OC)=C(CC(C)OC(=O)OC=2C=CC(O)=CC=2)C2=3)=O)C2=C1C1=C(OC)C=C(O)C(C(C=2OC)=O)=C1C=3C=2CC(C)OC(=O)C1=CC=CC=C1 SRJYZPCBWDVSGO-UHFFFAOYSA-N 0.000 description 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- FDEODCTUSIWGLK-RSAXXLAASA-N clopidogrel sulfate Chemical compound [H+].OS([O-])(=O)=O.C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl FDEODCTUSIWGLK-RSAXXLAASA-N 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- PZBCKZWLPGJMAO-UHFFFAOYSA-N copanlisib Chemical compound C1=CC=2C3=NCCN3C(NC(=O)C=3C=NC(N)=NC=3)=NC=2C(OC)=C1OCCCN1CCOCC1 PZBCKZWLPGJMAO-UHFFFAOYSA-N 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940013361 cresol Drugs 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 229950006418 dactolisib Drugs 0.000 description 1
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- CRVGKGJPQYZRPT-UHFFFAOYSA-N diethylamino acetate Chemical compound CCN(CC)OC(C)=O CRVGKGJPQYZRPT-UHFFFAOYSA-N 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- LQJVOKWHGUAUHK-UHFFFAOYSA-L disodium 5-amino-4-hydroxy-3-phenyldiazenylnaphthalene-2,7-disulfonate Chemical compound [Na+].[Na+].OC1=C2C(N)=CC(S([O-])(=O)=O)=CC2=CC(S([O-])(=O)=O)=C1N=NC1=CC=CC=C1 LQJVOKWHGUAUHK-UHFFFAOYSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- RAGZEDHHTPQLAI-UHFFFAOYSA-L disodium;2',4',5',7'-tetraiodo-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C([O-])C(I)=C1OC1=C(I)C([O-])=C(I)C=C21 RAGZEDHHTPQLAI-UHFFFAOYSA-L 0.000 description 1
- IVKWXPBUMQZFCW-UHFFFAOYSA-L disodium;2-(2,4,5,7-tetraiodo-3-oxido-6-oxoxanthen-9-yl)benzoate;hydrate Chemical compound O.[Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IVKWXPBUMQZFCW-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000017793 embryonic organ development Effects 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 108010018033 endothelial PAS domain-containing protein 1 Proteins 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 235000012732 erythrosine Nutrition 0.000 description 1
- 229940011411 erythrosine Drugs 0.000 description 1
- 239000004174 erythrosine Substances 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000008622 extracellular signaling Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229960005191 ferric oxide Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- NWKFECICNXDNOQ-UHFFFAOYSA-N flavylium Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=[O+]1 NWKFECICNXDNOQ-UHFFFAOYSA-N 0.000 description 1
- 239000000989 food dye Substances 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000001288 gastroparesis Diseases 0.000 description 1
- 229950008209 gedatolisib Drugs 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000008359 glycogelatin Substances 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 235000019534 high fructose corn syrup Nutrition 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229960002163 hydrogen peroxide Drugs 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 208000021156 intermittent vascular claudication Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- CRDNMYFJWFXOCH-UHFFFAOYSA-N isoindigotin Natural products N1C2=CC=CC=C2C(=O)C1=C1C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-UHFFFAOYSA-N 0.000 description 1
- QQUXFYAWXPMDOE-UHFFFAOYSA-N kenpaullone Chemical compound C1C(=O)NC2=CC=CC=C2C2=C1C1=CC(Br)=CC=C1N2 QQUXFYAWXPMDOE-UHFFFAOYSA-N 0.000 description 1
- 230000029774 keratinocyte migration Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-M lactobionate Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-M 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 235000011475 lollipops Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000002502 lymphedema Diseases 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229960002366 magnesium silicate Drugs 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- FUCSLKWLLSEMDQ-MKYGIPPKSA-N manzamine A Chemical compound C1C\C=C/CCCCN2CC[C@H]3C(C=4C=5NC6=CC=CC=C6C=5C=CN=4)=C[C@]1(O)[C@@H]1N4CCCC\C=C/[C@H]4C[C@@]13C2 FUCSLKWLLSEMDQ-MKYGIPPKSA-N 0.000 description 1
- FUCSLKWLLSEMDQ-UHFFFAOYSA-N manzamine A hydrochloride Natural products C1CC=CCCCCN2CCC3C(C=4C=5NC6=CC=CC=C6C=5C=CN=4)=CC1(O)C1N4CCCCC=CC4CC13C2 FUCSLKWLLSEMDQ-UHFFFAOYSA-N 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 229940120309 medicated tape Drugs 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229930188764 meridianine Natural products 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- RKKFQJXGAQWHBZ-LICLKQGHSA-N methyl 2-[2-chloro-6-ethoxy-4-[(e)-(3-methyl-5-oxo-1-phenylpyrazol-4-ylidene)methyl]phenoxy]acetate Chemical compound ClC1=C(OCC(=O)OC)C(OCC)=CC(\C=C/2C(N(N=C\2C)C=2C=CC=CC=2)=O)=C1 RKKFQJXGAQWHBZ-LICLKQGHSA-N 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- YAEMHJKFIIIULI-UHFFFAOYSA-N n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea Chemical compound C1=CC(OC)=CC=C1CNC(=O)NC1=NC=C([N+]([O-])=O)S1 YAEMHJKFIIIULI-UHFFFAOYSA-N 0.000 description 1
- KWRYMZHCQIOOEB-LBPRGKRZSA-N n-[(1s)-1-(7-fluoro-2-pyridin-2-ylquinolin-3-yl)ethyl]-7h-purin-6-amine Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=C(F)C=C2N=C1C1=CC=CC=N1 KWRYMZHCQIOOEB-LBPRGKRZSA-N 0.000 description 1
- AXTAPYRUEKNRBA-JTQLQIEISA-N n-[(2s)-1-amino-3-(3,4-difluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methylpyrazol-3-yl)furan-2-carboxamide Chemical compound CN1N=CC(Cl)=C1C1=C(Cl)OC(C(=O)N[C@H](CN)CC=2C=C(F)C(F)=CC=2)=C1 AXTAPYRUEKNRBA-JTQLQIEISA-N 0.000 description 1
- XDHBUMNIQRLHGO-UKTHLTGXSA-N n-[(e)-1-pyridin-2-ylethylideneamino]azetidine-1-carbothioamide Chemical compound C=1C=CC=NC=1C(/C)=N/NC(=S)N1CCC1 XDHBUMNIQRLHGO-UKTHLTGXSA-N 0.000 description 1
- NIHSNFSFDGHHRG-SDNWHVSQSA-N n-[2-[(e)-2-(4-methoxyphenyl)ethenyl]quinazolin-4-yl]-n',n'-dimethylpropane-1,3-diamine Chemical compound C1=CC(OC)=CC=C1\C=C\C1=NC(NCCCN(C)C)=C(C=CC=C2)C2=N1 NIHSNFSFDGHHRG-SDNWHVSQSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 229940098247 neosporin ointment Drugs 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000101 novel biomarker Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 208000022698 oropharynx squamous cell carcinoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 108700042657 p16 Genes Proteins 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000008756 pathogenetic mechanism Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 229950010632 perifosine Drugs 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229930004090 phosphatidylinositide Natural products 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
- 150000003906 phosphoinositides Chemical class 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229950004941 pictilisib Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229940020573 plavix Drugs 0.000 description 1
- 229940095638 pletal Drugs 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- JHDGRHBHQOGVBZ-UHFFFAOYSA-N potassium;7h-purin-6-amine;sodium Chemical compound [Na].[K].NC1=NC=NC2=C1NC=N2 JHDGRHBHQOGVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 229940051201 quinoline yellow Drugs 0.000 description 1
- 235000012752 quinoline yellow Nutrition 0.000 description 1
- FZUOVNMHEAPVBW-UHFFFAOYSA-L quinoline yellow ws Chemical compound [Na+].[Na+].O=C1C2=CC=CC=C2C(=O)C1C1=NC2=C(S([O-])(=O)=O)C=C(S(=O)(=O)[O-])C=C2C=C1 FZUOVNMHEAPVBW-UHFFFAOYSA-L 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000033300 receptor internalization Effects 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000007261 regionalization Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 230000020874 response to hypoxia Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- BLGWHBSBBJNKJO-UHFFFAOYSA-N serabelisib Chemical compound C=1C=C2OC(N)=NC2=CC=1C(=CN12)C=CC1=NC=C2C(=O)N1CCOCC1 BLGWHBSBBJNKJO-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 229940099261 silvadene Drugs 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 229960003600 silver sulfadiazine Drugs 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000025175 skeletal muscle hypertrophy Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 229940083608 sodium hydroxide Drugs 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 229940100515 sorbitan Drugs 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000006354 stress signaling Effects 0.000 description 1
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
- 235000010965 sucrose esters of fatty acids Nutrition 0.000 description 1
- 239000001959 sucrose esters of fatty acids Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008054 sulfonate salts Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- KUNICNFETYAKKO-UHFFFAOYSA-N sulfuric acid;pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O KUNICNFETYAKKO-UHFFFAOYSA-N 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000004654 survival pathway Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 229950001269 taselisib Drugs 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- BVJSXSQRIUSRCO-UHFFFAOYSA-N tenovin-6 Chemical compound C1=CC(NC(=O)CCCCN(C)C)=CC=C1NC(=S)NC(=O)C1=CC=C(C(C)(C)C)C=C1 BVJSXSQRIUSRCO-UHFFFAOYSA-N 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- OTLUUQOHVRZSKD-UHFFFAOYSA-N tricantin Natural products CC(CCC=C(/C)C1OC(=O)C(=O)C1=O)C=CC=C(/C)CCCc2cocc2 OTLUUQOHVRZSKD-UHFFFAOYSA-N 0.000 description 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 210000004231 tunica media Anatomy 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000009424 underpinning Methods 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 229940117960 vanillin Drugs 0.000 description 1
- 210000001125 vasa nervorum Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960000834 vinyl ether Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 1
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 1
- UCRLQOPRDMGYOA-DFTDUNEMSA-L zinc;(4r)-4-[[(2s)-2-[[(4r)-2-[(1s,2s)-1-amino-2-methylbutyl]-4,5-dihydro-1,3-thiazole-4-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[(2s,3s)-1-[[(3s,6r,9s,12r,15s,18r,21s)-3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-[(2s)-butan-2-yl]-6-(carbox Chemical compound [Zn+2].C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC([O-])=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@H](CC([O-])=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 UCRLQOPRDMGYOA-DFTDUNEMSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
Definitions
- the present disclosure provides for a method, comprising: measuring an individual level of an expression or activation of two or more proteins (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 proteins) in a sample from the wound.
- the present disclosure provides for a method, comprising: measuring an individual level of an expression or activation of a first protein and a second protein in a sample from the wound, wherein the first protein and the second protein are individually selected from the group consisting of: IGF-1R, PI3 Kinase, Akt, insulin, mTOR, HIF, PTEN, IGFRBP-3, c-MET, GSK-3 , COX-2, iNOS, NFKB/p65, ⁇ - ⁇ , p53, pl6INK4a, ⁇ -Catenin, Bak, Caspase 3, Caspase 9, or any combination thereof; and calculating a ratio of the first protein to the second protein.
- the determination is implemented at least in part by a computer. In some embodiments, the determination is implemented at least in part by a computer processor. In some embodiments, the computer process is a computer microprocessor. In some embodiments, the method further comprises evaluating the wound visually, e.g., by comparing an image (e.g., digital or paper) of the wound with an earlier image of the same wound. In some embodiments, the method further comprises communicating a result with a communication medium. In some embodiments, the communication medium is a document. In some embodiments, the communication medium is a computer file, an email, a fax, or a paper document. In some embodiments, the ratio is calculated with values generated from a comparison of the measured levels and corresponding reference standards.
- the activation is phosphorylation.
- the measured levels are normalized fluorescence intensity (NFI) per mg protein.
- the values are normalized expression values.
- the subject has or is suspected of having diabetes, Alzheimer's disease, a cancer, or any combination thereof.
- the subject is a human.
- the wound will not heal when the ratio is > 1.2, > 1.3, > 1.4, or > 1.5.
- the method further comprises treating the subject, e.g., administering to the subject a pharmaceutical composition that comprises an antagonist of a first protein, an agonist of a second protein, or a combination thereof, wherein the first protein or the second protein are individually selected from the group consisting of: IGF-IR, PI3 Kinase, Akt, insulin, mTOR, HIF, PTEN, IGFRBP-3, c-MET, GSK-3 , COX-2, iNOS, NFKB/p65, ⁇ - ⁇ , p53, pl6INK4a, ⁇ -Catenin, Bak, Caspase 3, Caspase 9, and any combination thereof.
- a pharmaceutical composition that comprises an antagonist of a first protein, an agonist of a second protein, or a combination thereof, wherein the first protein or the second protein are individually selected from the group consisting of: IGF-IR, PI3 Kinase, Akt, insulin, mTOR, HIF, PTEN, IGFRBP-3, c-
- a pharmaceutical composition disclosed herein comprises the agonist and the antagonist, which are administered simultaneously, or sequentially.
- a pharmaceutical composition disclosed herein further comprises a pharmaceutically acceptable carrier.
- the pharmaceutically acceptable carrier comprises water.
- the second protein is IGF-IR.
- the second protein is Akt.
- the first protein is PI3 Kinase and the second protein is IGF-IR.
- the first protein is PI3 Kinase and the second protein is insulin.
- the first protein is PI3 Kinase and the second protein is Akt.
- the first protein or the second protein is Akt that is Aktl. In some embodiments, the first protein or the second protein is IGF-IR that is IGF-lR . In some embodiments, the first protein or the second protein is IGF-IR that is p-IGF-lR Yl 135-1150 (phospho-tyrosine 1135-1150). In some embodiments, the first protein or the second protein is HIF that is HIF-la. In some embodiments, the first protein or the second protein is mTOR that is p-mTOR S2448 (phospho-serine 2448). In some embodiments, the first protein or the second protein is PTEN that is p-PTEN S380 (phosphor-serine 380).
- the subject has or is suspected of having diabetes, Alzheimer's disease, a cancer, or any combination thereof.
- the subject is a human.
- the wound is a diabetic ulcer, a pressure ulcer, a venous stasis ulcer, a radiation ulcer, a skin injury, an unhealed surgical wound, a wound from a surgical procedure, a wound from a peripheral vascular disease, a wound from a complication of trauma, a wound in a cancer patient, a wound in a patient receiving a steroid therapy, a wound from an inflammatory skin disease, a chronically impaired cutaneous wound, or any combination thereof.
- the wound is a diabetic foot ulcer.
- the present disclosure provides for a method of treating a wound in a subject in need thereof, comprising treating the subject with a pharmaceutical composition that comprises an antagonist of a first protein, an agonist of a second protein, or a combination thereof, wherein the first protein or the second protein are individually selected from the group consisting of: IGF-IR, PI3 Kinase, Akt, insulin, mTOR, HIF, PTEN, IGFRBP-3, c-MET, GSK- 3 ⁇ , COX-2, iNOS, NFKB/p65, ⁇ - ⁇ , p53, pl6INK4a, ⁇ -Catenin, Bak, Caspase 3, Caspase 9, and any combination thereof.
- a pharmaceutical composition that comprises an antagonist of a first protein, an agonist of a second protein, or a combination thereof, wherein the first protein or the second protein are individually selected from the group consisting of: IGF-IR, PI3 Kinase, Akt, insulin, mTOR, HIF, PTEN,
- the first protein or the second protein is IGF-IR that is IGF-lRp. In some embodiments, the first protein or the second protein is IGF-lRp that is p-IGF-lR Yl 135- 1150 (phospho-tyrosine 1135-1150). In some embodiments, the first protein or the second protein is HIF that is HIF-la. In some embodiments, the first protein or the second protein is mTOR that is p-mTOR S2448 (phospho-serine 2448). In some embodiments, the first protein or the second protein is PTEN that is p-PTEN S380 (phosphor-serine 380).
- the subject has or is suspected of having diabetes, Alzheimer's disease, a cancer, or any combination thereof.
- the subject is a human.
- the wound is a diabetic ulcer, a pressure ulcer, a venous stasis ulcer, a radiation ulcer, a skin injury, an unhealed surgical wound, a wound from a surgical procedure, a wound from a peripheral vascular disease, a wound from a complication of trauma, a wound in a cancer patient, a wound in a patient receiving a steroid therapy, a wound from an inflammatory skin disease, a chronically impaired cutaneous wound, or any combination thereof.
- the wound is a diabetic foot ulcer.
- the present disclosure provides for a pharmaceutical composition that comprises an antagonist of a first protein, an agonist of a second protein, or a combination thereof, wherein the first protein or the second protein are individually selected from the group consisting of: IGF-IR, PI3 Kinase, Akt, insulin, mTOR, HIF, PTEN, IGFRBP-3, c-MET, GSK- 3 ⁇ , COX-2, iNOS, NFKB/p65, ⁇ - ⁇ , p53, pl6INK4a, ⁇ -Catenin, Bak, Caspase 3, Caspase 9, and any combination thereof.
- the second protein is IGF-IR.
- the second protein is Akt.
- the first protein is PI3 Kinase and the second protein is IGF-IR. In some embodiments, the first protein is PI3 Kinase and the second protein is insulin. In some embodiments, the first protein is PI3 Kinase and the second protein is Akt. In some embodiments, the first protein or the second protein is Akt that is Aktl. In some embodiments, the first protein or the second protein is IGF-IR that is IGF-lRp. In some embodiments, the first protein or the second protein is IGF-lRp that is p-IGF-lR Yl 135-1150 (phospho-tyrosine 1135-1150). In some embodiments, the first protein or the second protein is HIF that is HIF-la.
- the first protein or the second protein is mTOR that is p-mTOR S2448 (phospho-serine 2448). In some embodiments, the first protein or the second protein is PTEN that is p-PTEN S380 (phosphor-serine 380). In some embodiments, a pharmaceutical composition disclosed herein further comprises a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutically acceptable carrier comprises water.
- the present disclosure provides for a method of making a pharmaceutical composition disclosed herein.
- the present disclosure provides for a kit that comprises reagents for measuring a total amount or a phosphorylation level of two or more proteins selected from the group consisting of: IGF-IR, PI3 Kinase, Akt, insulin, mTOR, HIF, PTEN, IGFRBP-3, c-MET, GSK-3 COX-2, iNOS, NFKB/p65, ⁇ - ⁇ , p53, pl6INK4a, ⁇ -Catenin, Bak, Caspase 3, and Caspase 9.
- the kit is employed to predict a likelihood of wound healing in a subject.
- the kit predicts the prognosis of a wound in a subject.
- one of the proteins is PI3 Kinase, IGF-IR, or Akt.
- the proteins are PI3 Kinase and IGF-1R.
- the proteins are PI3 Kinase and insulin.
- the proteins are PI3 Kinase and Akt.
- the first protein or the second protein is Akt that is Aktl.
- the first protein or the second protein is IGF-1R that is IGF-1R ⁇ $.
- the first protein or the second protein is IGF- ⁇ that is p-IGF- ⁇ Yl 135-1150 (phospho-tyrosine 1135-1150).
- the first protein or the second protein is HIF that is HIF- ⁇ . In some embodiments, the first protein or the second protein is mTOR that is p-mTOR S2448 (phospho- serine 2448). In some embodiments, the first protein or the second protein is PTEN that is p- PTEN S380 (phosphor-serine 380). In some embodiments, the subject has or is suspected of having diabetes, Alzheimer's disease, a cancer, or any combination thereof. In some
- the subject is a human.
- the wound is a diabetic ulcer, a pressure ulcer, a venous stasis ulcer, a radiation ulcer, a skin injury, an unhealed surgical wound, a wound from a surgical procedure, a wound from a peripheral vascular disease, a wound from a complication of trauma, a wound in a cancer patient, a wound in a patient receiving a steroid therapy, a wound from an inflammatory skin disease, a chronically impaired cutaneous wound, or any combination thereof.
- the kit further compries an instruction manual.
- a first protein disclosed herein is not identical to a second protein disclosed herein.
- Figure 1 is a diagram showing DFU (diabetic foot ulcer) proteomic signaling study pathway nodes including HIF-1 and downstream gene expression related to wound repair.
- ISP Ratio is defined as the ratio between PI3K and IGF-1R.
- Apoptosis Pathways Bak - BCL2-antagonist/killer 1, Caspase 3 - cysteine-aspartic protease 3, and Caspase 9 - cysteine-aspartic protease 9.
- Figure 4 is a set of box-plots showing significantly increased levels of downstream proteins compared to levels of IGF-1R in Healed and Unhealed DFU keratinocytes. Boxplots showing the calculated ratios for the Level of Each Analyte / Level of IGF-1R demonstrate that the Unhealed patients have significantly (p ⁇ 0.05) elevated ratios of POKinase, mTOR, Cox2, p53, Bak and Caspase 9 than Healed patients. Not only is the center higher for unhealed patients, but the quantitative independent two-sample t-test analysis suggests that the 2 population means differ beyond random variation.
- Figure 5 is a scheme showing the dynamic Akt switch between DFU and Normal tissues and the ratios calculated for significantly modulated analytes (box-plots). Increased levels of PI3 kinase-induced activation of Akt promote angiogenesis and apoptosis through various downstream effectors.
- Figure 6 is a diagram showing the ratio of PI3K to IGF-1R can distinguish Normal, Healing, and Nonhealing DFU. This distinction can be used in order to predict healing or not in DFU Subjects.
- Figure 8 shows a computer system 801 that is programmed or configured to implement or regulate a communication with results related to a prognosis of a wound.
- the biomarkers disclosed herein can serve as diagnostic markers that predict healing versus nonhealing DFU.
- the signaling pathways in which these proteins reside and function are points of therapeutic intervention, wherein combinations of therapies targeting these interrelated pathway signaling proteins is identified.
- the patterns of protein expression and activation are useful in guiding treatment decisions on an individual, per-patient basis.
- the present disclosure provides a comprehensive assessment of protein signaling cascades related to proliferation, migration, inflammation, and apoptosis/senescence in diabetic wounds.
- a protein disclosed herein can mean the entire protein or a fragment thereof.
- An agonist disclosed herein can include a partial agonist.
- An antagonist disclosed herein can include a partial antagonist.
- An agonist or an antagonist can be purified or isolated.
- a ratio (e.g., a ratio of a first protein to a second protein) is calculated with normalized values or quantitated values in weight (e.g., ng, ⁇ g, mg), moles (e.g, nmol, ⁇ , mmol).
- subject can refer to a mammal (e.g. , a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee or baboon).
- a mammal e.g. , a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee or baboon.
- the subject is a human subject, male or female.
- the subject is an adult, a senior, or a child.
- a subject disclosed herein may have one or more of the following conditions: HTN, Lymphedema Rt.
- treatment can refer to cure or ameliorate a condition or disorder including a disease.
- an effectiveness of a cancer treatment may be an assessment of the anti-cancer drug to reduce tumor or cancer cell invasiveness, to kill cancer or tumor cells, to eliminate a cancer or tumor in a subject, to reduce a size of a tumor, to weaken or make more susceptible to apoptosis a cancer cell or tumor cell, to reduce or prevent metastasis, or others, or combinations thereof.
- an effectiveness of an anti-cancer drug or an anti-tumor drug may be an assessment of the anti-cancer drug or the anti-tumor drug to reduce tumor or cancer cell invasiveness, to kill cancer or tumor cells, or to eliminate a cancer or tumor in a subject.
- An effectiveness of a drug may also include an assessment of the severity and number of side effects or conditions brought on by consuming the drug. The assessment or determination may be performed using methods as described herein.
- An "effective amount" when used in connection with a pharmaceutical composition disclosed herein can be an amount sufficient to produce a therapeutic result in a subject in need thereof.
- prognosis generally refers to a prediction of the likely outcome of a subject's current standing or a predication of a future outcome.
- a prognosis may include a judgment or an opinion of a medical professional of a subject's current standing or future standing. Diagnostic methods or assays may be utilized to make a prognosis.
- a diagnostic method may include performing a tissue biopsy, a cell cytology, an endoscopy, a diagnostic imaging, a blood test, a genetic screening or analysis or any combination thereof.
- Wound a breakdown in the protective function of the skin; the loss of continuity of epithelium, with or without loss of underlying connective tissue (i.e. muscle, bone, nerves) following injury to the skin or underlying tissues/ organs caused by surgery, a blow, a cut, chemicals, heat/ cold, friction/ shear force, pressure or as a result of disease, such as leg ulcers or carcinomas.
- connective tissue i.e. muscle, bone, nerves
- Nonhealing Wound a non-healing or chronic wound is defined as a wound that does not improve after four weeks or does not heal in eight weeks. These include: diabetic foot ulcers, venous-related ulcerations, non-healing surgical wounds, pressure ulcers, wounds related to metabolic disease, wounds that repeatedly break down.
- Wound the process of returning to health; the restoration of structure and function of injured or diseased tissues.
- the healing processes include blood clotting, tissue mending, scarring, and bone healing.
- Wound healing is a complex and dynamic process of replacing devitalized and missing cellular structures and tissue layers.
- the human adult wound healing process can be divided into 4-phases: the hemostasis phase, the inflammatory phase, the proliferation phase, and the remodeling phase.
- DFU - Diabetic Foot Ulcer is a serious complication of diabetes which aggravates the patient's condition whilst also having significant socioeconomic impact.
- the aim of the present review is to summarize the causes and pathogenetic mechanisms leading to diabetic foot, and to focus on the management of this important health issue.
- Increasing physicians' awareness and hence their ability to identify the "foot at risk,” along with guidance on how to treat each individual's DFU with proper foot care and therapeutics, may prevent diabetic foot ulceration and thus reduce the risk of amputation.
- Wound Healing Diagnostic (WHD)- a diagnostic test that can be administered to a subject with a wound that measures certain biological parameters and can distinguish between wounds that will heal and those that will not heal.
- WTD Wound Therapy Diagnostic
- Phosphorylation the addition of phosphate to an organic compound, such as a protein, through the action of a phosphotransferase (phosphorylase) or kinase, that results in increased or decreased functions, such as signal transduction, of the protein.
- phosphotransferase phosphorylase
- kinase kinase
- Signal Transduction occurs when an extracellular signaling molecule, or ligand, activates a specific receptor located on the cell surface, such as a receptor kinase, or inside the cell. Phosphorylation, or other post-translational modifications like methylation or acetylation,), receptor triggers a biochemical chain of events inside the cell, eventually eliciting a response. Depending on the cell, the response may alter the cell's metabolism, shape, gene expression, or ability to divide.
- the signal can be amplified at any step, as signaling involves the interaction of multiple proteins in a step-wise fashion of activation. Thus, one signaling molecule can generate a response involving hundreds to millions of molecules.
- IGF1R The insulin-like growth factor (IGF-1) and its signaling through insulin receptor (IR) or mainly through IGF-1 receptor (IGF-IR) is highly implicated in tumor transformation and survival of malignant cell, but is only partially involved in normal cell growth. This is in part due to the interactions with oncogenes. IGF-IR is mainly involved in regulation of cell proliferation, anti-apoptosis, differentiation and cell motility, whereas IR is mostly of impact for control of glucose uptake and metabolism. Ligand-receptor binding results in phosphorylation of tyrosine residues in the IGF-IR tyrosine kinase domain.
- the activation loop of IGF-IR activation loop (a-loop) is not phosphorylated and several tyrosine residues (1131, 1135 and 1136) block the active site.
- the three tyrosines of the activation loop are trans-phosphorylated by IGF-lR's dimeric subunit partner.
- proteins associated with and participate in the functional signaling of IGF-IR any of which may have altered structure or function and, and have the potential to reduce signaling through IGF-IR.
- IGF-IR insulin receptor substrate family of proteins [such as Insulin receptor substrate 1 (IRS-1 ), She (Src homology 2 domain containing) transforming protein 1 ] and some others.
- IGF-IR insulin receptor substrate family of proteins
- IGF-1R is ubiquitously expressed in tissues, playing a role in tissue growth stimulated by insulin, which liberates IGF-1 to activate the IGF-1R.
- IGF -I and bFGF regulate transcriptional activity of the IGF-IR gene negatively and positively, respectively.
- bFGF increases IGF-IR gene promoter activity by 2-fold and IGF-I decreases transcriptional activity by 50%.
- IGF-IR is not an absolute requirement for normal growth.
- IGF-IR is crucial for anchorage independent growth, a property of malignant cells, where anchorage dependency can be acquired when the number of IGF-IRs at the cell surface is increased.
- IGF- IR has a critical role in anchorage independent growth in prostate cancer and anchorage independent growth in wounds.
- Insulin-like growth factor 1- beta) - a protein found on the surface of human cells. It is a transmembrane receptor that is activated by a hormone called insulin-like growth factor 1 (IGF-1) and by a related hormone called IGF-2. It belongs to the large class of tyrosine kinase receptors and it mediates the effects of IGF-1, which is a polypeptide protein hormone similar in molecular structure to insulin.
- IGF-1 insulin-like growth factor 1
- IGF- IR activation by phosphorylation for example on tyrosines 1135-1150, the earliest major autophosphorylation sites necessary for kinase activation) plays an important role in growth and continues to have anabolic effects in adults - meaning that it can induce hypertrophy of skeletal muscle and other target tissues.
- c-MET- a protein that in humans is encoded by the MET gene (MET proto-oncogene, receptor tyrosine kinase), which earlier in the discovery process had also been called MNNG HOS transforming gene.
- the protein possesses tyrosine kinase activity.
- the primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor.
- MET is a single pass tyrosine kinase receptor essential for embryonic development, organogenesis and wound healing.
- p53 - a specific protein with a mass of 53 kilo Daltons that is produced by a tumor- suppressor gene. Like other tumor-suppressor genes, the p53 gene normally controls cell growth. If p53 is physically lost or functionally inactivated, cells can grow without restraint. Many human tumors have mutations in the gene coding for the p53 protein
- pl6INK4a also known as cyclin-dependent kinase inhibitor 2A, multiple tumor suppressor 1 and as several other synonyms, is a tumor suppressor protein, that in humans is encoded by the CDKN2A gene, pi 6 plays an important role in cell cycle regulation by decelerating cells progression from Gl phase to S phase, and therefore acts as a tumor suppressor that is implicated in the prevention of cancers, notably melanoma, oropharyngeal squamous cell carcinoma, cervical cancer, and esophageal cancer. pl6 can be used to improve the histological diagnostic accuracy of CIN3.
- the CDK 2A gene is frequently mutated or deleted in a wide variety of tumors.
- pl6 is an inhibitor of cyclin dependent kinases such as CDK4 and CDK6. These latter kinases phosphorylate retinoblastoma protein (pRB) which eventually results in progression from Gl phase to S phase, pi 6 was originally found in an "open reading frame" of 148 amino acids encoding a protein of molecular weight 15,845 comprising four ankyrin repeats. pl6Ink4a is named after its molecular weight and its role in inhibiting CDK4.
- pRB retinoblastoma protein
- ⁇ -Catenin - a dual function protein, regulating the coordination of cell-cell adhesion and gene transcription.
- the CTNNBl protein is encoded by the CTNNBl gene
- ⁇ -catenin is a subunit of the cadherin protein complex and acts as an intracellular signal transducer in the Wnt signaling pathway. It is a member of the catenin protein family and homologous to ⁇ - catenin, also known as plakoglobin.
- Beta-catenin is widely expressed in many tissues. In cardiac muscle, beta-catenin localizes to adherens junctions in intercalated disc structures, which are critical for electrical and mechanical coupling between adjacent cardiomyocyte.
- ⁇ -catenin Mutations and overexpression of ⁇ -catenin are associated with many cancers, including hepatocellular carcinoma, colorectal carcinoma, lung cancer, malignant breast tumors, ovarian and endometrial cancer. Alterations in the localization and expression levels of beta-catenin have been associated with various forms of heart disease, including dilated cardiomyopathy, ⁇ -catenin is regulated and destroyed by the beta-catenin destruction complex, and in particular by the adenomatous polyposis coli (APC) protein, encoded by the tumor-suppressing APC gene.
- APC adenomatous polyposis coli
- BAK - this protein functions as a pro-apoptotic regulator involved in a wide variety of cellular activities. In healthy mammalian cells, BAK localizes primarily to the MOM
- BAK is believed to induce the opening of the mitochondrial voltage-dependent anion channel, leading to release of cytochrome c from the mitochondria.
- BAK itself forms an oligomeric pore, MAC, in the MOM, through which pro-apoptotic factors leak in a process called MOM permeabilization.
- Caspase 3 - is a caspase protein that interacts with caspase-8 and caspase-9. It is encoded by the CASP3 gene. CASP3 orthologs have been identified in numerous mammals for which complete genome data are available. Unique orthologs are also present in birds, lizards, lissamphibians, and teleosts. The CASP3 protein is a member of the cysteine-aspartic acid protease (caspase) family. Sequential activation of caspases plays a central role in the execution- phase of cell apoptosis.
- Caspases exist as inactive proenzymes that undergo proteolytic processing at conserved aspartic residues to produce two subunits, large and small, that dimerize to form the active enzyme. This protein cleaves and activates caspases 6 and 7; and the protein itself is processed and activated by caspases 8, 9, and 10. It is the predominant caspase involved in the cleavage of amyloid-beta 4A precursor protein, which is associated with neuronal death in Alzheimer's disease. Alternative splicing of this gene results in two transcript variants that encode the same protein
- Caspase 9 - is an initiator caspase, encoded by the CASP9 gene.
- CASP9 orthologs have been identified in all mammals for which complete genome data are available.
- the aspartic acid specific protease caspase-9 has been linked to the mitochondrial death pathway. It is activated during programmed cell death (apoptosis). Induction of stress signaling pathways JNK/SAPK causes release of cytochrome c from mitochondria and activation of apaf-1 (apoptosome), which in turn cleaves the pro-enzyme of caspase-9 into the active form.
- Once initiated caspase-9 goes on to cleave procaspase-3 & procaspase-7, which cleave several cellular targets, including poly ADP ribose polymerase.
- a “subject,” as used herein, includes any animal, e.g. , an animal that has diabetes, an Alzheimer's disease, or a cancer. Suitable subjects include laboratory animals (such as mouse, rat, rabbit, or guinea pig), farm animals, and domestic animals or pets (such as a cat or dog). Non-human primates and, preferably, humans (e.g., human patients), are included.
- a “phosphorylation state" of a protein refers to the degree of (total amount of) phosphorylation of the protein. This includes both the number of sites (e.g. suitable Ser, Thr or Tyr amino acid residues) of the protein that are phosphorylated, and the le vel of phosphorylation at any given acceptor site on the amino acid chain.
- the protein kinase enzymes fall into two broad classes, characterized with respect to substrate specificity: serine/threonine-specific and tyrosine-specific kinases. Phosphorylation of proteins is an important mechanism for communicating signals within a cell (signal transduction) to modulate cellular activity. Tyrosine kinases are divided into two main families: the
- RTKs Receptor tyrosine kinases
- RTKs are composed of: an extracellular domain, some of which may have a specific ligand binding domain; a transmembrane domain that spans the plasma membrane; and an intracellular kinase domain, which binds proteins based on recognition domains on their protein substrates.
- Ligand binding results in a series of structural rearrangements to the RTK, including activation of the kinase and substrate phosphorylation.
- RTK signaling in the absence of ligand may be modulated by spatial deregulation, controlled by receptor internalization or alterations to the lipid and actin filament composition of cellular membranes.
- Such aberrant, ligand-independent, non-regulated RTK signaling in cancer cells results in the hyper-activation of downstream signaling cascades leading to cancerous processes and such processes may occur in the keratinocytes in the epithelia of healing wounds.
- Ligand- dependent activation is also implicated as an aberrant cancer signaling processes wherein compensatory autocrine- or paracrine-based over expression of ligands can activate RTK signaling, especially as a resistance mechanism.
- the common output is increased phosphorylation of the RTK and downstream signaling.
- RTKs growth factor receptors, for example
- RTKs growth factor receptors, for example
- Receptors become activated, and dysregulation of receptor signaling has been correlated to the development and progression of wound healing and cancers in a wide range of tissues. Many of these receptors become phosphorylated at specific amino acid residues: tyrosine, threonine, and serine. Phosphorylation either activates the receptors intrinsic kinase activity or enhances binding of adaptor proteins that mediate downstream signaling. As tyrosine is a major phosphorylation, many of these receptors are known as Receptor Tyrosine Kinases (RTK).
- RTK Receptor Tyrosine Kinases
- RTK signaling There are several ways that pharmaceuticals can inhibit RTK signaling, including: blocking ligand binding (the antibody trastuzumab, for example), inhibiting dimer formation where dimer formation is required for activation of signaling (the antibody pertuzumab, for example), or by inhibiting the kinase activity of the RTK with small molecular weight inhibitors (lapatinib, for example) that can cross the cell membrane.
- Some of these receptors are activated by mutations/translocations/amplifi cations directly to the receptor itself, such as HER2, EGFR, c-MET, fibroblast growth factor receptor (FGFR), or insulin-like growth factor- 1 receptor (IGF- IR).
- genes coding for proteins that are members of signaling pathways may activate signaling distant and downstream from the receptor, such as in certain mutations/loss of heterozygosity to the tumor suppressor PTEN (phosphatase and tensin homolog) whose loss of function can activate the PBKinase (phosphoinositide-3
- kinase kinase
- Akt also known as PKB, Protein Kinase B
- signaling may be mediated by the spatial effects of monomer concentration or the sequestering of homo- or heterodimers due to alterations in lipid and actin filaments.
- the advent of molecularly targeted drugs has generated a number of therapies that specifically target RTKs or proteins in downstream pathways that the RTKs modulate and these therapies have found clinical utility in treating proliferative diseases like cancer.
- Atherosclerosis thickening of capillary basement membranes, arteriolar hyalinosis, and endothelial proliferation. Calcification and thickening of the arterial media are also noted with higher frequency in the diabetic population, although whether these factors have any impact on the circulatory status is unclear. Diabetics may develop atherosclerotic disease of large-sized and medium-sized arteries, and a common atherosclerotic disease of the infrapopliteal segments is particularly common and significant in the diabetic population. Underlying digital arterial disease, when compounded by an infected ulcer in close proximity, can result in complete loss of digital collaterals and precipitate gangrene.
- LDL low-density lipoprotein
- VLDL very-low-density lipoprotein
- the pathophysiology of peripheral neuropathy in diabetics is multifactorial and some of the contributing factors include: vascular disease occluding the vasa nervorum; endothelial dysfunction; deficiency of myoinositol-altering myelin synthesis; diminishing sodium-potassium adenine triphosphatase (ATPase) activity; chronic hyperosmolarity, causing edema of nerve trunks; and effects of increased sorbitol and fructose.
- the resultant loss of sensation in the foot is repetitive stress; unnoticed injuries and fractures; structural foot deformity (such as
- the management of diabetic foot ulcers requires offloading the wound by using appropriate therapeutic footwear, daily saline or similar dressings to provide a moist wound environment, debridement when necessary, antibiotic therapy if osteomyelitis or cellulitis is present, optimal control of blood glucose, or evaluation and correction of peripheral arterial insufficiency.
- wound coverage by cultured human cells or heterogeneic dressings/grafts, application of recombinant growth factors and hyperbaric oxygen treatments may also be beneficial.
- topical wound management is to provide a moist, but not wet, wound bed.
- moist sodium chloride dressings or isotonic sodium chloride gels e.g., Normlgel®, IntraSite® gel
- a hydroactive paste e.g., DuoDERM®
- Optimal wound coverage requires wet-to-damp dressings, to support autolytic debridement, absorb exudate, and to protect the surrounding healthy tissues.
- a polyvinyl film dressing e.g., OpSite, Tegaderm
- Wound coverage may also be based upon other approaches:
- Hydrocolloid dressings such as DuoDERM® or IntraSite® Hydrocolloid, are impermeable to oxygen, moisture, and bacteria; maintain a moist environment; and support autolytic debridement. They are a good choice for relatively desiccated wounds;
- Absorptive dressings such as calcium alginates (e.g., Kaltostat®,
- Curasorb® are highly absorptive and are appropriate for exudative wounds. Alginates are available in a rope form, which is useful for packing deep wounds;
- Impregnated gauze dressings e.g., Mesalt®
- hydrofiber dressings e.g., Aquacel®, Aquacel-Ag®
- Antiplatelet therapy with aspirin or clopidogrel may be warranted in some cases for the prevention of the complications of atherosclerosis.
- Antiplatelet agents inhibit platelet function by blocking cyclooxygenase and subsequent platelet aggregation.
- the present disclosure describes the WHD as a panel of ratios of protein expression between IGF-1R and PI3K (PI3K/IGF-1R) and/or mTOR (mTOR/IGF-lR) and/or COX-2 (COX-2/IGF-1R) and/or p53 (p53/IGF-lR) and/or Bak (Bak/IGF-IR) and/or Caspase-9
- a WTD as a panel of signaling protein expression ratios that characterize the mediating processes of normal or impaired wound healing that would be used to identify pharmaceutical therapies to optimize signaling protein expression relationships associated with DFU wound closure or normal tissue signaling.
- the present disclosure provides several important cellular processes associated with normal healing for the DFU subjects which include angiogenesis (HIF- ⁇ , iNOS and VEGFR) and intrinsic cell death/apoptosis (Bak and Caspase-9) signaling proteins.
- angiogenesis HIF- ⁇ , iNOS and VEGFR
- intrinsic cell death/apoptosis Bak and Caspase-9 signaling proteins.
- the cellular processes associated with impaired DFU subject healing include survival (NFkB, GSK-3P and ⁇ -Catenin) and senescence (p53 and pl6INK4a) signaling proteins.
- Bak Bak and/or Caspase-9 (Caspase-9/Akt) and/or VEGFR1 (VEGFR 1 /Akt) and/or iNOS
- iNOS/Akt HIF- ⁇
- HIF-la/Akt HIF-la/Akt
- GSK-3P GSK-3p/Akt
- ⁇ -Catenin ⁇ -Catenin
- Akt NFkB and/or NFkB (NFkB/Akt) and/or p53 (p53/Akt) and/or pl6INK4a (P16INK4a/Akt).
- the present disclosure provides information for the development of pharmaceutical wound healing therapies based on the abnormal signaling protein ratios obtained from the unhealed subject's wound being evaluated.
- the example is given of a non-healing DFU subject demonstrating WTD ratio values below normal subject values for iNOS/Akt, HIF- ⁇ /Akt and VEGFR/Akt (angiogenesis panel) and with WTD ratio values abnormally elevated for NFkB/Akt (survival panel).
- Therapeutic evaluations and considerations for these groupings of abnormal values would prioritize the signaling protein pathway relationships for therapy to achieve the broadest impact for protein expression modulation through supplementation, or inhibition, of pharmaceuticals selected for topical therapy.
- nitric oxide (NO) for the correction of deficient iNOS protein ratio expression nitric oxide (NO) pharmaceutical wound supplementation by the use of an NO donor compound for wound healing would provide direct enhancement of wound NO bioactivity - and iNOS protein expression - that enhances wound epithelialization (keratinocyte migration), angiogenesis (keratinocyte VEGF activation), collagen deposition and wound remodeling ). NO plays a primary role in the control of VEGF-synthesis and in cell adaptations with upregulated activity. HIF-1 a
- iNOS prolyl hydroxylase
- NO not only modulates the HIF-1 response but also functions as a HIF-1 inducer during sustained formation.
- Levels of wound fluid NO metabolites have also been determined to accurately predict the wound healing trajectory of chronic wounds and may individually provide diagnostic information for wound healing to support the need for iNOS supplementation.
- iNOS supplementation of the example wound would not only improve the protein expression of iNOS but also the protein expression of VEGF and HIF- ⁇ , possibly promoting the necessary corrective influence of the angiogenesis signaling proteins to optimize wound recovery.
- NF-kB transcription factor nuclear factor-kappa B
- TNF-a tumor necrosis factor-a
- NFkB is a mediator of induced p53-directed programmed cell death/apoptosis by a RAF/MAPK pathway, bypassing TNF-a regulated NFkB activation, signaling the repression of p53-mediated cell death following NFkB inhibition.
- the reduction of NFkB protein expression promotes improved recovery of wound healing, reduces dysregulated inflammatory cytokine and chemokine production (SASP), facilitates improved insulin pathway signaling, and/or modulate excessive p53-mediated cell death.
- SASP dysregulated inflammatory cytokine and chemokine production
- the topical application (or other use) of a pharmaceutical combination of an acceptable NO (iNOS) donor with an acceptable inhibitor of NFkB protein expression can provide appropriate therapy for the correction of impaired healing of the example wound based on protein expression profiles provided from RPPA tissue analysis.
- the WTD may provide clinical information useful in the selection of currently available therapies to improve wound healing as well as for the development of unique or novel pharmaceutical therapies for impaired DFU wound subjects who are evaluated by the use of RPPA tissue analysis.
- the paradigm for wound healing is divided into four overlapping stages: hemostasis, inflammation, proliferation and remodeling. This process requires a complex coordination of key molecular, cellular and physiologic events by facilitative signaling between hematopoietic, immunologic, and resident skin cells.
- increased expression of the tumor suppressor transcription factor p53 and ischemia-induced apoptosis may result in senescence and the inhibition of signaling pathways driving inflammation or cell survival.
- Other proteins identified in healing models like the hypoxia-inducible factor-1 (HIF-1) and HIF-1 a proteins (which modulate angiogenesis, cell proliferation, and wound healing, as well as cancer invasion/metastasis) may be altered in the diabetic environment, contributing to impaired wound healing.
- HIF-1 hypoxia-inducible factor-1
- HIF-1 a proteins which modulate angiogenesis, cell proliferation, and wound healing, as well as cancer invasion/metastasis
- proteomics is defined as the large-scale study of proteins, including their structure, function, and, for those in signal transduction pathways, their activation status. Comparative analyses are made difficult because the proteome differs from cell to cell, the patterns change dynamically over time, and there are many proteins that contain polymorphisms, splice variants, and different levels and types of posttranslational modifications. Attempts at the proteomic characterization of diseased tissues have for the most part relied on technologies that assess a single protein (immunohistochemistry, ELISA, Western Blot analysis, for example) and the newer technologies related to Mass Spectroscopy following an initial parsing based upon two-dimensional gel electrophoresis.
- the Reverse Phase Protein micro- Array is a highly sensitive, high- throughput, functional proteomic technology that offers many of the advantages needed. It extends beyond the power of immunoblotting by providing a quantitative measure on the differential expression of total proteins and their activation, which is usually the phosphorylated species. Total proteins and their corresponding phosphoproteins, across multiple proteins that are involved in signaling cascades, can be assessed across multiple patient samples, simultaneously, providing a 'snap- shot' of the activation state/functionality of entire pathways. With RPPA, all samples are spotted at the same time, making this method ideally suited for the retrospective analysis of a large number of specimens, in a manner that is analogous to genomic-dot blots.
- RPPA analysis uses 20,000 cells to generate quantitative data across multiple. From a lysate of 20,000 cells, multiple, identical nitrocellulose slides are printed and each slide is interrogated with a single highly specific antibody that recognizes either the total protein or a modified protein in the multiplexed samples (over 300 individual samples per array). Thus, samples prepared from 20,000 cells are sufficient to analyze many different protein targets. This enables the simultaneous analysis of a much larger number of proteins from each sample and makes this technique suitable for the analysis of cell populations present in low numbers.
- the present disclosure is related to the area of wound healing in diabetes. In some embodiments, it is related to the novel use of RPPA proteomic analysis of chronic wound tissues from subjects with diabetes for the documentation of the prediction and mechanisms of healing using the ratios of selected sites of proteomic phosphorylation and cellular signaling from prepared chronic wound specimens.
- impaired neuropathic-diabetic foot ulcer (DFU) wound healing may be predicted by determination of keratinocyte PI3K (phosphatidyl inositol -3- kinase)/IGF-lR
- RPPA reverse phase microarray
- LCD laser-capture microdissection
- DFU wound keratinocyte signaling activity was significantly (p ⁇ 0.05) elevated for: 1) the proinflammatory transcription factor, NF- kB; 2) the tumor suppressor transcription factor, P53; 3) the senescence biomarker, P16INK4a; 4) the cellular survival and growth transduction pathway proteins: PI3K, AKT (protein kinase B), ⁇ -catenin, glycogen synthase kinase-3 (GSK-3 ), and C- Met; and 5) the P53-directed apoptosis cleavage protein Caspase-3.
- PI3K- AKT/mTOR (mammalian target of rapamycin) is the maj or signaling pathway activated by insulin and insulin-like growth factors- 1 and 2 (IGF-1 and IGF-2) through IGF-IR. IGF-IR stimulation activates AKT signaling transduction pathways leading to hypoxia-inducible factor-1 (HIF- 1) expression. Increased HIF-1 expression promotes cell proliferation/survival and is documented as a critical factor for diabetic wound healing.
- phosphatase tensilon homolog PTEN
- P/I-ratio values ⁇ SEM of: 0.7 ( ⁇ 0.01) for control study subjects, 1.0 ( ⁇ 0.06) for healed-DFU study subj ects, and 1.3 ( ⁇ 0.03) for unhealed- DFU study subjects.
- a P/I-ratio provides a novel quantitative gauge of IGF-IR initiated AKT/mTOR signal transduction activity predictive for DFU healing and/or HIF-1 -mediated cellular processes.
- increasing P/I- ratio values is inversely proportional to decreasing AKT/mTOR signal transduction activity associated with impaired DFU wound repair.
- P53-directed dysfunctional regulation of IGF-IR, PI3K, and AKT/mTOR are important factors associated with impaired DFU wound healing.
- the present disclosure provides a method for predicting whether or not a wound in a diabetic patient will heal, comprising the steps of:
- the present disclosure also provides a method of treating a wound in a diabetic patient identified by the method described above as having a wound that will not heal, comprising the steps of:
- the antagonist is an antagonist of PBKinase complex, Akt, mTOR, 4E.BP1, Ribosomal Protein S6 Kinase, HIF- ⁇ , PTEN, POKinase, IGFRPB3, Src, GSK3 , ⁇ -catenin, or any protein that is a member of the insulin signaling or PBKinase signaling pathways of proteins, or any combination thereof.
- the agonist is an agonist of insulin, insulin-like growth factor 1 (IGF-1), IGF-2, PTEN, PBKinase, mTOR, 4E.BP1, Ribosomal Protein S6 Kinase, HIF-la, PTEN, IGFRPB3, Src, GSK3 , ⁇ -catenin, any protein that is a member of the insulin signaling or PBKinase signaling pathways of proteins, or any combination thereof.
- IGF-1 insulin-like growth factor 1
- IGF-2 insulin-like growth factor 1
- PTEN insulin-like growth factor 1
- PBKinase mTOR
- 4E.BP1 Ribosomal Protein S6 Kinase
- HIF-la HIF-la
- PTEN IGFRPB3
- Src Ribosomal Protein S6 Kinase
- GSK3 ⁇ -catenin
- ⁇ -catenin any protein that is a member of the insulin signaling or PBKina
- DFU diabetic foot ulcer
- proteomic RPPA methodology used to quantify the level of signaling proteins and the activation states (e.g., phosphorylation sites) in the insulin signaling pathway (ISP), which is exemplified in a comparative clinical study of chronic DFU
- keratinocytes and non-diabetic (control) plantar skin specimens See Figure 1). Patterns of proteomic pathway and nodal analysis for this study were selected to investigate the following as factors correlating to wound outcomes in DFU study subjects: 1) Senescence- related pl6INK4a antagonism of NF-kB expression and apoptosis (Bak, Caspase-3, and Caspase-9); 2) Expression of insulin signaling pathway (ISP) nodes: IGF-1R, PI3K, GSK-3 , ⁇ -Catenin, AKT and mTOR; 3) NF-kB-regulated angiogenesis factors - TNF-a, NF-kB, VEGF, NOS2 and COX2; and 3) Correlations of P53, NF-kB, P16INK4a and ISP nodal expression and signal transduction to DFU subject wound study outcomes ( Figure 1). During the data analysis of the clinical study it was determined that the clinical status of DFU subject wound healing
- P/I ratio values may contribute to the expression of mTOR, a downstream insulin-signaling pathway, influencing HIF-1 expression and, perhaps, patterns of wound repair signaling in DFU subjects.
- This proteomic expression ratio determination may function as a quantitative measure of ISP signal transduction for AKT/mTOR pathways predictive for DFU wound healing and, perhaps, increased production of the hypoxia-inducible factor-1 (HIF-1) protein as part of the cellular injury response for wound keratinocytes ( Figure 1).
- HIF-1 hypoxia-inducible factor-1
- IGF-1R mediates a cellular signaling response to PI3K where, in turn, phosphatidylinositol (3,4)- bisphosphate (PIP2) is converted to phosphatidylinositol (3,4,5)-trisphosphate (PIP3).
- PIP3 activity is sufficient, activation of the AKT/mTOR pathways is initiated to downstream pathways and transcription factors.
- critical levels of IGF-1/PI3K mediate signaling of the AKT/mTOR pathways for the increased expression of the hypoxia-inducible factor-1 (HIF-1) protein.
- HIF-1 hypoxia-inducible factor-1
- HIF-1 protein production stimulates tumor cell invasion and metastasis. It is suggested that the effect of growth factor (IGF-1) signaling initiation and increased ISP signal transduction (via AKT/mTOR) is an increase in the rate at which the HIF-1 protein is produced. This would suggest that below a threshold of ISP signal transduction, required by AKT/mTOR pathways, that HIF-1 protein production would be insufficient to elevate HIF-1 stimulated gene expression to the levels required for unimpaired wound healing to proceed or for effective promotion of the cellular injury response.
- IGF-1-1 growth factor
- Impaired diabetes wound healing is associated with attenuation of HIF-1 production.
- IGFBP-3 insulin-like growth factor binding protein-3
- PTEN phosphatase and tensilon homolog
- an overall increased level of PIP2 phosphorylation and increased site activation for PI3K now reflects the presence of "inhibited" PIP3 redirected by
- PTEN Increased PI3K expression in diabetes, as documented in our clinical DFU study, now provided a quantitative gauge of the impact of PTEN inhibition on insulin signaling pathway transduction. In the DFU environment, increasing PTEN inhibition as related to the diversion of PIP3 signal initiation at PI3K was determined by comparison of DFU study subject
- antagonists include Beryllium, Lithium,
- [3,4-b] pyridine 4 Bisindole maleimides (e.g., Ro 31-8220, GF 109203x), Indirubins (6- bromoindirubin-3'-oxime, aka BIO), Paullones (alsterpaullone), Psuedosubstrate peptide,
- a pharmaceutical composition disclosed herein comprises one or more excipients, carriers, or additives.
- excipients, carriers, or additives can include antioxidant agents, binders, coating materials, colorant agents, diluents, disintegrants, dispersants, emulsifying agents, flavoring agents, glidants, lubricants, pH modifying agents (e.g. , buffering agents), plasticizers, preservative agents, solubilizing agents, stabilizers or stabilizing agents, surfactants, sweetening agents, thickening agents, or pharmaceutically inert materials.
- excipients can comprise nontoxic auxiliary substances.
- Exemplary antioxidants can include flavonoids, anthocyanidins, anthocyanins, proanthocyanidins, or combinations thereof.
- one or more antioxidants can be included in the liquid dosage form.
- antioxidants help provide long term stability to liquid compositions, e.g. , at ambient conditions for at least about one month, at least about 3 months, at least about 24 months, or longer, depending on the type and concentration of antioxidant used and depending on other components of the storage microenvironment, such as pH, buffering agent, etc.
- Exemplary coating materials include hydroxypropyl methyl cellulose 2910, aminoalkyl methacrylate copolymer E, polyvinylacetal diethylaminoacetate, macrogol 6000, titanium oxide, or combinations thereof.
- Exemplary plasticizers include triethyl citrate, triacetin, macrogol 6000, or combinations thereof.
- a colorant agent when included in the liquid dosage form, can be provided in an amount sufficient to provide the pharmaceutical compositions with a more aesthetic and/or distinctive appearance.
- exemplary diluents include cellulose and cellulose derivatives such as microcrystalline cellulose; starches such as dry starch, hydrolyzed starch, and starch derivatives such as corn starch; cyclodextrin; sugars such as powdered sugar and sugar alcohols such as lactose; D- mannitol; inorganic diluents such as aluminum hydroxide gel, precipitated calcium carbonate, carbonate, magnesium aluminometasilicate, dibasic calcium phosphate; and sodium chloride, silicon dioxide, titanium dioxide, titanium oxide, dicalcium phosphate dihydrate, calcium sulfate, alumina, kaolin, talc, or combinations thereof.
- Diluents also terms “fillers”, can increase the bulk of a tablet so that a practical size is provided for compression.
- Exemplary disintegrants include starches, alginic acid, crosslinked polymers such as, e.g. , crosslinked polyvinylpyrrolidone, croscarmellose sodium, potassium or sodium starch glycolate, clays, celluloses, starches, gums, or combinations thereof. Disintegrants can facilitate tablet disintegration after administration, or following contact with dissolution fluid, or as measured in an in vitro dissolution study.
- crosslinked polymers such as, e.g. , crosslinked polyvinylpyrrolidone, croscarmellose sodium, potassium or sodium starch glycolate, clays, celluloses, starches, gums, or combinations thereof.
- Disintegrants can facilitate tablet disintegration after administration, or following contact with dissolution fluid, or as measured in an in vitro dissolution study.
- Exemplary emulsifying agents include gelatin, egg yolk, casein, cholesterol, acacia, tragacanth, chondrus, pectin, methyl cellulose, carbomer, cetostearyl alcohol, cetyl alcohol, or combinations thereof.
- Emulsifying agents can be included in the liquid dosage form in an amount sufficient to facilitate more uniform dispersion of one or more active ingredients or other pharmaceutically acceptable excipient that is not generally soluble in the liquid.
- Exemplary glidants include silicon dioxide, talc, dried aluminum hydroxide gel, magnesium silicate, or combinations thereof.
- Exemplary lubricants include magnesium stearate, calcium stearate, stearic acid, glyceryl behenate, polyethylene glycol, talc, or combinations thereof. Lubricants can also facilitate tablet manufacture.
- preservative agents include sodium benzoate, paraoxybenzoic acid esters, methyl, ethyl, butyl, and propyl parabens, chlorobutanol, benzyl alcohol, phenylethylalcohol, dehydroacetic acid, sorbic acid, benzalkonium chloride (BKC), benzethonium chloride, phenol, phenylmercuric nitrate, thimerosal, or combinations thereof.
- Preservative agents can be included in the liquid dosage form.
- the preservative agents can be in an amount sufficient to extend the shelf-life or storage stability, or both, of the liquid dosage form.
- solubilizing agents include an alcohol, e.g. , 95% ethyl alcohol, a glycol, glycerin, D-mannitol, trehalose, benzyl benzoate, trisaminomethane, cholesterol,
- exemplary alcohols can include ethanol, isopropanol, t-butanol, phenol, cresol, a benzyl alcohol, or any combination thereof.
- exemplary glycols include C2-20 alkenes functionalized with a glycol, including propylene glycol, polypropylene glycol, polyethylene glycol, etc., or any combination thereof.
- Solubilizing agents can be included in the liquid dosage form, e.g. , in an amount sufficient to facilitate greater or more rapid dissolution of one or more active ingredients or other excipients.
- a solubilizing agent can be included in an amount of about 1 volume percent to 20 volume percent (v/v), or about 4 volume percent to 15 volume percent (v/v), based on the total volume of the solution.
- Exemplary amounts of solubilizing agent include about 7 volume percent to 12 volume percent (v/v) based on the total volume of the solution.
- Exemplary stabilizing agents include one or more liquid excipients such as ethanol or glycerin; one or more glycols, such as polyethylene glycol, e.g. , PEG-400, propylene glycol, or polypropylene glycol; a cellulose-based component, such as hydroxypropyl
- Exemplary surfactants include sucrose esters of fatty acids, polyoxyl stearate, polyoxyethylene hydrogenated castor oil, polyoxyethylene polyoxypropylene glycol, sorbitan sesquioleate, sorbitan trioleate, sorbitan monostearate, sorbitan monopalmitate, sorbitan monolaurate, polysorbate, glyceryl monostearate, sodium lauryl sulfate, lauromacrogol, or combinations thereof.
- Surfactants can also be anionic, cationic, amphoteric, or nonionic.
- a viscous sweetener such as one or more of a sorbitol solution, a syrup (sucrose solution), or high-fructose corn syrup can increase viscosity and retard sedimentation.
- the sweetening agent can include an acesulfame-containing, sucralose-containing, or saccharin- containing component.
- the sweetening agent can include glycerin, saccharin, liquid sugar (sucrose solution), or any combination thereof.
- a sweetening agent can be present in an amount sufficient to minimize or mask any off-flavors in the taste of the active agents (e.g. , opioid analgesic, non-opioid analgesic, antiemetic, laxative, barbiturate, etc), and also to minimize or mask any other off-flavor components included in the pharmaceutical composition.
- a sweetening agent is present in an amount of about 0.1 volume percent to 85 volume percent (v/v), based on the total volume of the solution. In one example, the sweetening agent is present in an amount of about 5 volume percent to 70 volume percent (v/v), based on the total volume of the solution.
- Exemplary amounts of glycerin can include about 2 volume percent to 18 volume percent (v/v), or about 5 volume percent to 10 volume percent (v/v).
- Exemplary amounts of liquid sugar can include about 40 volume percent to 75 volume percent (v/v), or about 60 volume percent to 70 volume percent (v/v), based on the total volume of the solution.
- Exemplary thickening agents include acacia, alginic acid bentonite, carbomer, carboxymethylcellulose calcium or sodium, cetostearyl alcohol, methyl cellulose, ethylcellulose, glycerin, gelatin guar gum, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose ("HPMC"), any other suitable cellulose-based component, maltodextrin, polyvinyl alcohol, povidone, propylene carbonate, propylene glycol alginate, sodium alginate, sodium starch glycolate, starch tragacanth, and xanthan gum, or combinations thereof.
- a thickening agent or viscosity-enhancing agent can improve the mouth- feel of the liquid oral dosage form and/or to help coat the lining of the gastrointestinal tract.
- a thickening agent is present in an amount of about 0.1 volume percent to 20 volume percent (v/v), based on the total volume of the solution.
- glycerin can be present in an amount of about 1 volume percent to 10 volume percent (v/v), based on the total volume of the solution.
- Exemplary amounts of thickening agent can include from about 1 volume percent to 12 volume percent (v/v), or at an amount of about 4 volume percent to 10 volume percent (v/v), based on the total volume of the solution.
- An exemplary amount can include about 6 to 10 volume percent (v/v).
- an excipient includes cellulose ethers such as hydroxypropyl methylcellulose (e.g., Methocel K4M) or silicified microcrystalline cellulose; polyvinylacetate- based excipients such as, e.g. , Kollidon SR, and polymers and copolymers based on
- an excipient includes acesulfame potassium, glacial acetic acid, acetone, acetyltributyl citrate, acetyltriethyl citrate, adipic acid, albumin, aliphatic polyester, alitame, almond oil, alpha tocopherol, aluminum monostearate, aluminum oxide, aluminum phosphate adjuvant, ammonia, ammonium alginate, ammonium chloride, anthocyanidin, anthocyanin, ascorbic acid, ascorbyl palmitate, aspartame, attapulgite, bentonite, benzalkonium chloride, benzethonium chloride, benzoic acid, benzyl alcohol, benzyl benzoate, boric acid, bronopol, butylated hydroxyanisole, butylated hydroxytoluene, butylene glycol, butylparaben, calcium acetate, calcium alginate, calcium chloride, calcium hydrox
- carboxymethylcellulose calcium carboxymethylcellulose sodium, carrageenan, casein, castor oil, podere cellulose, cellulose acetate, cellulose acetate phthalate, ceratonia, ceresin, cetostearyl alcohol, cetrimide, cetyl alcohol, cetylpyridinium chloride, chitosan, chlorhexidine,
- polyoxyethylene alkyl ether polyoxyethylene sorbitan fatty acid ester, polyoxyethylene stearate, polyoxylglyceride, polyvinyl acetate phthalate, potassium alginate, potassium alum, potassium benzoate, potassium bicarbonate, potassium chloride, potassium citrate, potassium hydroxide, potassium metabisulfite, potassium sorbate,
- proanthocyanidin propionic acid, propyl gallate, propylene carbonate, propylene glycol, propylene glycol alginate, propylparaben, propylparaben sodium, pyrrolidone, raffinose, saccharin, saccharin sodium, safflower oil, saponite, sesame oil, shellac, simethicone, sodium acetate, sodium ascorbate, sodium benzoate, sodium bicarbonate, sodium borate, sodium carbonate, sodium citrate dihydrate, sodium cyclamate, sodium formaldehyde sulfoxylate, sodium hyaluronate, sodium lactate, sodium metabisulfite, sodium phosphate (dibasic), sodium phosphate (monobasic), sodium propionate, sodium sulfite, sodium thiosulfate, sorbic acid, sorbitan fatty acid ester, soybean oil, stearyl alcohol, sucralose, sucrose octaa
- phenylethylalcohol dehydroacetic acid, ethyl alcohol, trisaminomethane, sodium salicylate, ethanol, isopropanol, t-butanol, polypropylene glycol, hydroxymethylcellulose, acesulfame, sodium saccharate, glycyrrhizin dipotassium, acesulfame K, or ethylcellulose.
- excipients include acacia, acesulfame potassium, acetic acid (glacial), acetone, acetyltributyl citrate, acetyltriethyl citrate, adipic acid, agar, albumin, alcohol, alginic acid, aliphatic polyesters, alitame, almond oil, alpha tocopherol, aluminum hydroxide adjuvant, aluminum monostearate, aluminum oxide, aluminum phosphate adjuvant, ammonia solution, ammonium alginate, ammonium chloride, ascorbic acid, ascorbyl palmitate, aspartame, attapulgite, bentonite, benzalkonium chloride, benzethonium chloride, benzoic acid, benzyl alcohol, benzyl benzoate, boric acid, bronopol, butylated hydroxyanisole, butylated
- HFC heptafluoropropane
- HC hydrocarbons
- hydrochloric acid hydrophobic colloidal silica
- hydroxyethyl cellulose hydroxyethylmethyl cellulose
- hydroxypropyl betadex hydroxypropyl cellulose
- hydroxypropyl cellulose low-substituted
- hydroxypropyl starch hypromellose, hypromellose acetate succinate
- hypromellose phthalate imidurea, inulin, iron oxides, isomalt, isopropyl alcohol, isopropyl myristate, isopropyl palmitate, kaolin, lactic acid, lactitol, lactose (anhydrous), lactose (inhalation), lactose (monohydrate), lactose (monohydrate and corn starch), lactose (monohydrate and microcrystalline cellulose), lactose (monohydrate and povidone), lactose (
- phenoxyethanol phenylethyl alcohol, phenylmercuric acetate, phenylmercuric borate, phenylmercuric nitrate, phospholipids, phosphoric acid, polacrilin potassium, poloxamer, polycarbophil, polydextrose, poly (dl-lactic acid), polyethylene glycol, polyethylene oxide, polymethacrylates, poly(methyl vinylether/maleic anhydride), polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters,
- polyoxyethylene stearates polyoxyethylene stearates, polyoxylglycerides, polyvinyl acetate phthalate, polyvinyl alcohol, potassium alginate, potassium alum, potassium benzoate, potassium bicarbonate, potassium chloride, potassium citrate, potassium hydroxide, potassium metabi sulfite, potassium sorbate, povidone, propionic acid, propyl gallate, propylene carbonate, propylene glycol, propylene glycol alginate, propylparaben, propylparaben sodium, pyrrolidone, raffinose, saccharin, saccharin sodium, safflower oil, saponite, sesame oil, shellac, simethicone, sodium acetate, sodium alginate, sodium ascorbate, sodium benzoate, sodium bicarbonate, sodium borate, sodium carbonate, sodium chloride, sodium citrate dihydrate, sodium cyclamate, sodium formaldehyde sulfoxylate, sodium
- composition disclosed herein comprises a
- a pharmaceutically acceptable salt includes bitartrate, bitartrate hydrate, hydrochloride, p-toluenesulfonate, phosphate, sulfate, trifluoroacetate, bitartrato hemipentahydrate, pentafluoropropionate, hydrobromide, mucate, oleate, phosphate dibasic, phosphate monobasic, acetate trihydrate, bis(heptafuorobutyrate), bis(pentafluoropropionate), bis(pyridine carboxylate), bis(trifluoroacetate), chlorhydrate, sulfate pentahydrate, or combinations thereof.
- exemplary pharmaceutically acceptable salts include, e.g.
- water-soluble and water-insoluble salts such as the acetate, amsonate(4,4- diaminostilbene-2,2-disulfonate), benzenesulfonate, benzonate, bicarbonate, bisulfate, bitartrate, borate, butyrate, calcium edetate, camphorsulfonate, camsylate, carbonate, citrate, clavulariate, dihydrochloride, edetate, edisylate, estolate, esylate, flunarate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexafluorophosphate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate,
- active agents disclosed herein are formulated to be administered through oral dosage forms (e.g. , tablets, capsules, gels, lollipops), inhalations, nasal sprays, patches, absorbing gels, liquids, liquid tannates, suppositories, injections, I.V. drips, other delivery methods, or any combination thereof to treat subjects in need thereof.
- Administration can be performed in a variety of ways, including, but not limited to orally, subcutaneously, intravenously, intranasally, intraoptically, trans dermally, topically (e.g. , gels, salves, lotions, creams, etc.), intraperitoneally, intramuscularly, intrapulmonary (e.g. , AERx.RTM. inhalable technology commercially available from Aradigm, or Inhance, pulmonary delivery system commercially available from Inhale Therapeutics), vaginally, parenterally, rectally, or intraocularly.
- oral dosage forms e.g. , tablets, capsules,
- an agent described herein is administered by the nasal inhalation route using conventional nebulizers or by oxygen aerosolization to provide convenient pain relief with reduced adverse effects.
- the agents can be suspended or dissolved in a pharmacologically acceptable inhalation carrier.
- a pharmacologically acceptable inhalation carrier examples include distilled water, water/ethanol mixtures, and physiological saline solution.
- Conventional additives including sodium chloride, glucose, citric acid and the like can be employed in these dosage forms to stabilize or to provide isotonic media.
- the pharmaceutical compositions suitable for nasal inhalation by oxygen aerosolization administration comprise hydrocodone or oxycodone, acetaminophen, and promethazine.
- compositions suitable for nasal inhalation by oxygen aerosolization administration comprise hydrocodone or oxycodone, and promethazine.
- an antiemetic e.g. , promethazine
- an antiemetic can be administered separately, prior to, or during administration of the pharmaceutical compositions described herein (e.g. , those comprising hydrocodone and acetaminophen).
- an agent described herein can also be administered as a self- propelled dosage unit in an aerosol form suitable for inhalation therapy.
- suitable means for employing the aerosol inhalation therapy technique are described, for example, in U. S. Pat. No. 6,913,768 to Couch et al., a reference which is incorporated herein by reference in its entirety.
- the agent can be suspended in an inert propellant such as a mixture of
- the agents useful for a self-propelled dosage unit in aerosol form administration are hydrocodone or oxycodone, acetaminophen, and promethazine.
- the agents useful for a self-propelled dosage unit in aerosol form administration are hydrocodone or oxycodone, and promethazine.
- the dosage unit can further comprise an agent such as a bronchodilator (e.g. , albuterol).
- an agent described herein can also be administered as nasal spray/drop pharmaceutical compositions, which can conveniently and safely be applied to subjects in need thereof to effectively treat pain with reduced adverse effects.
- compositions can further comprise a water soluble polymer such as
- the components of a pharmaceutical composition for nasal spray or drop administration are hydrocodone or oxycodone agent, acetaminophen, and promethazine, or a pharmaceutically acceptable salt of any one of the foregoing, or any combination thereof.
- the components of a pharmaceutical composition for nasal spray or drop administration are hydrocodone or oxycodone agent, and promethazine, or a pharmaceutically acceptable salt of any one of the foregoing, or any combination thereof.
- a pharmaceutical composition described herein can also be administered topically to the skin of a subject in need thereof.
- the agents can be mixed with a pharmaceutically acceptable carrier or a base which is suitable for topical application to skin to form a dermatological pharmaceutical composition.
- suitable examples of carriers or bases include but not limited to: water, glycols, alcohols, lotions, creams, gels, emulsions, and sprays.
- a dermatological pharmaceutical composition comprising an analgesic agent can be integrated into a topical dressing, medicated tape, dermal patch absorbing gel and cleansing tissues.
- the dermatological pharmaceutical composition comprises hydrocodone or oxycodone, acetaminophen, and promethazine.
- the dermatological pharmaceutical composition comprises hydrocodone or oxycodone, and promethazine.
- the pharmaceutical compositions described herein can also be in liquid or liquid tannate form.
- the liquid formulations can comprise, for example, an agent in water-in- solution and/or suspension form; and a vehicle comprising polyethoxylated castor oil, alcohol and/or a polyoxyethylated sorbitan mono-oleate with or without flavoring.
- Each dosage form comprises an effective amount of an active agent and can comprise pharmaceutically inert agents, such as conventional excipients, vehicles, fillers, binders, disintegrants, pH adjusting substances, buffer, solvents, solubilizing agents, sweeteners, colorant agents and any other inactive agents that can be included in pharmaceutical dosage forms for oral administration. Examples of such vehicles and additives can be found in Remington's Pharmaceutical
- the pharmaceutical compositions described herein are administered in a suppository form, comprising an outer layer containing the pharmaceutical composition in a suppository base.
- the suppository base can, for example, be any conventional suppository base material such as glycogelatin, polyethylene glycol, fractionated palm kernel oil, or one or more natural, synthetic or semi synthetic hard fats such as cocoa butter.
- the suppository base can, for example, be any conventional suppository base material such as glycogelatin, polyethylene glycol, fractionated palm kernel oil, or one or more natural, synthetic or semi synthetic hard fats such as cocoa butter.
- concentrations and dosages e.g., a single unit dosage or multiple unit dosages
- concentrations and dosages can be varied as desired, as further described herein.
- the active agent in a pharmaceutical composition can generally be administered in dosages of 0.01 mg to 500 mg per kg body weight per day, e.g. about 20 mg/day for an average person. The dosage can be adjusted based on the mode of administration.
- dosage for one or a combination of agents can be from about 0.01 to 5mg, 1 to 10 mg, 5 to 20 mg, 10 to 50 mg,
- the computer system in communication with determining or recording a prognosis of a wound.
- the network 830 can be the Internet, an internet and/or extranet, or an intranet and/or extranet that is in communication with the Internet.
- the network 830 in some cases is a telecommunication and/or data network.
- the network 830 can include one or more computer servers, which can enable distributed computing, such as cloud computing.
- the network 830 in some cases with the aid of the computer system 801, can implement a peer-to-peer network, which may enable devices coupled to the computer system 801 to behave as a client or a server.
- the CPU 805 can execute a sequence of machine-readable instructions, which can be embodied in a program or software. The instructions may be stored in a memory location, such as the memory 810.
- the instructions can be directed to the CPU 805, which can subsequently program or otherwise configure the CPU 805 to implement methods of the present disclosure. Examples of operations performed by the CPU 805 can include fetch, decode, execute, and writeback.
- the CPU 805 can be part of a circuit, such as an integrated circuit. One or more other components of the system 801 can be included in the circuit. In some cases, the circuit is an application specific integrated circuit (ASIC).
- the storage unit 815 can store files, such as drivers, libraries and saved programs.
- the storage unit 815 can store user data, e.g., user preferences and user programs.
- the computer system 801 in some cases can include one or more additional data storage units that are external to the computer system 801, such as located on a remote server that is in communication with the computer system 801 through an intranet or the Internet.
- the computer system 801 can communicate with one or more remote computer systems through the network 830.
- the computer system 801 can communicate with a remote computer system of a user.
- Examples of remote computer systems include personal computers (e.g., portable PC), slate or tablet PC's (e.g., Apple® iPad, Samsung® Galaxy Tab), telephones, Smart phones (e.g., Apple® iPhone, Android-enabled device, Blackberry®), or personal digital assistants.
- the user can access the computer system 801 via the network 830.
- Storage type media can include any or all of the tangible memory of the computers, processors or the like, or associated modules thereof, such as various semiconductor memories, tape drives, disk drives and the like, which may provide non-transitory storage at any time for the software programming. All or portions of the software may at times be communicated through the Internet or various other telecommunication networks. Such communications, for example, may enable loading of the software from one computer or processor into another, for example, from a management server or host computer into the computer platform of an application server.
- another type of media that may bear the software elements includes optical, electrical and electromagnetic waves, such as used across physical interfaces between local devices, through wired and optical landline networks and over various air-links.
- a machine readable medium such as computer-executable code, may take many forms, including but not limited to, a tangible storage medium, a carrier wave medium or physical transmission medium.
- Non-volatile storage media include, for example, optical or magnetic disks, such as any of the storage devices in any computer(s) or the like, such as may be used to implement the databases, etc. shown in the drawings.
- Volatile storage media include dynamic memory, such as main memory of such a computer platform.
- Tangible transmission media include coaxial cables; copper wire and fiber optics, including the wires that comprise a bus within a computer system.
- Carrier-wave transmission media may take the form of electric or electromagnetic signals, or acoustic or light waves such as those generated during radio frequency (RF) and infrared (IR) data communications.
- RF radio frequency
- IR infrared
- Computer-readable media therefore include for example: a floppy disk, a flexible disk, hard disk, magnetic tape, any other magnetic medium, a CD-ROM, DVD or DVD-ROM, any other optical medium, punch cards paper tape, any other physical storage medium with patterns of holes, a RAM, a ROM, a PROM and EPROM, a FLASH-EPROM, any other memory chip or cartridge, a carrier wave transporting data or instructions, cables or links transporting such a carrier wave, or any other medium from which a computer may read programming code and/or data. Many of these forms of computer readable media may be involved in carrying one or more sequences of one or more instructions to a processor for execution.
- kits that comprises reagents for measuring a total amount or a phosphorylation level of two or more proteins disclosed herein, e.g., selected from the group consisting of IGF-1R, PI3 Kinase, Akt, insulin, mTOR, HIF, PTEN, IGFRBP-3, c-MET, GSK- 3 ⁇ , COX-2, iNOS, NFKB/p65, ⁇ - ⁇ , p53, pl6INK4a, ⁇ -Catenin, Bak, Caspase 3, and Caspase 9.
- reagents for measuring a total amount or a phosphorylation level of two or more proteins disclosed herein e.g., selected from the group consisting of IGF-1R, PI3 Kinase, Akt, insulin, mTOR, HIF, PTEN, IGFRBP-3, c-MET, GSK- 3 ⁇ , COX-2, iNOS, NFKB/p65, ⁇ - ⁇ , p53, pl6IN
- the reagents may include H202, Amp, PB, Avidin, Biotin, TPER reagent.
- Use of a kit may involve one or more of the following procedures:
- Cells of interest are isolated from a FFPE biopsy using LCM or macro-dissection.
- SDS strong denaturing
- Denatured proteins in the lysate are then arrayed on a nitrocellulose slide using a touch pin spotter (we use Aushon).
- the slide is then reacted with a biotin-labeled secondary antibody that recognizes the primary Ab (can bind to multiple primaries, so each slide is a specific primary Ab).
- Biotin is then reacted with a SA-labeling system (tyramide) to decorate the spot with fluorophores.
- SA-labeling system tyramide
- healers/nonhealers and a determination is made as to which signals are up and which are down, and does the pattern match nonhealers or healers. Depending on what analytes are up in the inhibition of survival or activation of senescence signaling pathway are then considered targets for a drug.
- the present disclosure provides a method for using a protein microarray to identify a combination of therapeutic agents for individualized treatment of a disease in a patient caused by a peculiar, abnormal network of interconnected cell signaling proteins that leads to an aberrant cellular response in the patient, comprising the steps of: a) measuring with the protein microarray activity states for a plurality of different signaling proteins extracted from diseased cells obtained from the patient; b) providing activity states of signaling proteins from reference cells corresponding to the signaling proteins extracted from the diseased cells obtained from the patient; c) detecting differences between the activity states of the individual signaling proteins from the diseased cells and the activity states of the corresponding individual signaling proteins from the reference cells, thereby providing a snapshot of the signaling proteins in the diseased cells that form an abnormal network of interconnected cell signaling proteins that leads to the aberrant cellular response in the patient; and/or d) reporting a combination of at least two different therapeutic agents for administration to the patient for the purpose of correcting the abnormal network by reducing the difference that was detected in
- every array has on-board calibrators (with known amounts of each specific analyte) that allow knowing how much of each protein is detected.
- Each protein signal on the assay is normalized to the amount of protein in each individual spot on the array.
- a value of Normalized Fluorescence Intensity (NFI) per mg protein is generated and compared to the linear range of the calibrators to calculate the amount of each protein per mg total protein in the test samples. This gives a semi-quantitative value used to calculate a ratio. For example, a value for an analyte HIF-1 alpha is divided by one that does not change (IGF-IR or Akt for example) to get the ratio.
- the ratio is high, e.g., >1, then there is an increased level of the HIF-la that correlates to healing or nonhealing.
- total proteins are measured to gauge the effect of transcription factors on gene expression.
- phosphoproteins are measured to see if actively signaling or not.
- expression or activation levels of proteins are first measured and then compared to their reference standards. Each comparison gives a value, which is used in the next step of determining a ratio to another protein.
- calibrators are generated, and a large population of patients is run to get a distribution, which allows to bin the patients on a per analyte basis from low to high. Then the unknown is compared to the distribution to place the patient on a per analyte basis somewhere in the population. Multiple analytes are evaluated, for example those in a signaling pathway (HER2 - Akt - mTOR ->4EBP1), to see if a pathway is on or not.
- DFU Diabetic Foot Ulcers
- PI3K-AKT/mTOR is the major signaling pathway activated by the hormone insulin and insulin-like growth factor-1 (IGF-1). IGF-1 cellular stimulation of AKT signaling has been demonstrated to induce the expression of hypoxia-inducible factor-1 (HIF-1) that may be critical to the initiation of angiogenesis and the healing of diabetic wounds.
- IGF-1 hypoxia-inducible factor-1
- DFU study subj ects had been taking medications for glycemic control prior to tissue specimen retrieval. These medications were not changed during the study observation period and are listed in Table 3- Diabetic Medications Taken During the Study. DFU study subjects listed by number with their pre-study medications for glycemic control. HEALED- indicates subjects with healed study DFU wounds at the completion of the twelve-week observation period. TIDM-indicates study subject with Type I DM; all other study subjects diagnosed with Type II DM. Significant differences were observed in multiple signaling proteins following non- parametric Whitney-Mann U-Test comparison of normal and DFU keratinocytes ( Figure 3).
- IGF-1 R a cell surface receptor involved in insulin and IGF-1 signaling
- PI3 Kinase and mTOR members of the Akt signaling pathway that facilitates cell cycle progression and inhibits apoptotic events
- p53 a regulator of cell cycle arrest, apoptosis, and senescence
- Caspase 9 indicative of intrinsic apoptosis
- Bak the pro-apoptotic protein that is increased in response to p53 and which is activated by Caspase 9
- COX-2 whose transcription and stabilization may be modulated by Akt and/or NfKB/p65 signaling, indicative of a pro-inflammatory state.
- c-Met was significantly increased in DFUs compared to normal.
- the observed increased levels of c-Met may be responsible for the observed increased PI3
- IGF-1R and IR receptors are known to form heterodimer pairs with c-Met, mediating transactivation of c-Met in the absence of its ligand, HGF
- DFU hepatocyte growth factor
- RPPA identified active signaling pathways in DFUs which may help identify points of therapeutic intervention to treat nonhealing DFUs (Figure 5). Observed differences between healing and nonhealing DFUs suggest an increased level of pro-apoptotic proteins and a potential role for c-Met/IGF-lR heterodimer signaling through the PI3Kinase/Akt pathway as an important driver in the nonhealing wound. In the absence of altered levels of IGF-1R or its activation by phosphorylation, a significant modulation of pathways related to increased
- PI3Kinase/AKT signaling coupled with increased inflammatory and apoptotic signaling occurs, perhaps in response to c-Met activation.
- the nonhealing DFU is a disease of dysregulated signal transduction potentially influenced by somatic mutations to many of the same genes as those involved in cancer. Altered signaling due to somatic mutations can interfere with mRNA transcription or protein function. These mutations change signaling efficiency, altering the control of transcription factors that modulate the intercellular levels of key proteins or the regulated patterns of post-translational modifications (PTM).
- PTM post-translational modifications
- An interesting observation in DFUs is the inactivating phosphorylation of PTEN (p-PTEN S380), resulting in increased PI3Kinase/Akt signaling which can trigger senescence in addition to survival ( Figure 7).
- a PI3Kinase/Akt imbalance can contribute to the prevention of healing in DFUs and can potentiate certain cancers. Many of the active signaling pathways observed in DFUs are evident in cancers, suggesting that drugs developed for one disease may have utility in treating the other. For example, the diabetes drug metformin, an activator of AMPK-directed inhibition of
- Akt/mTOR-mediated proliferation and Cyclin Dl synthesis reduces the incidence and progression of some cancers.
- metformin may be associated with larger ulcerations and inhibition of keratinocyte proliferation, but these DFUs do not progress to amputation.
- nonhealing DFUs can be treated using topical applications of anti-cancer therapies targeting proteins in these pathways or for the development of diagnostic tests to guide therapeutic decisions when treating DFUs.
- This example illustrates an assessment of the wound healing potential of DFU wound subjects A and B from a comparative analysis of the IGF-1R protein expression ratio of the subject ulcer following RPPA analysis in the Wound Healing Diagnostic (WHD).
- WTD Wound Healing Diagnostic
- each subject has completed the steps of having a small ( ⁇ 3mm diameter) punch biopsy of the wound marginal epidermis performed after wound debridement. This is followed by the step of immediately placing the epidermal wound margin biopsy tissue in formalin fixative solution. Following tissue fixation the specimen is dissected using macro-dissection or laser capture microdissection methods to adequately isolate the basal keratinocyte cells from the specimen for RPPA analysis.
- the WHD panel for healing assessment would include values of IGF-1R protein expression ratios with the following signaling proteins: PI3K (PI3K/IGF-1R) and/or mTOR (mTOR/IGF-lR) and/or COX-2(COX-2/IGF-lR) and/or Bak (Bak/IGF-IR) and/or p53 (p53/IGF-lR).
- Subject A's tissue specimen PI3K/IGF-1R ratio value was 0.9, while the Subject B tissue specimen PI3K/IGF-1R ratio value was 1.4.
- DFU study WHD ratios for this invention see Figure 7 it was determined that the values obtained from Subject A's DFU wound demonstrated that the PI3K/IGF-1R value was associated with wounds that experienced healing, while the PI3K/IGF-1R value determine for Subject B's DFU wound value was associated with wounds that did not heal.
- Subject B was expected to have a nonhealing DFU, a subsequent analysis was performed to identify potential points of therapeutic intervention based upon the ratio of a number of analytes to Akt.
- the analytes included: VEGFR1, iNOS, HIF-la, Bak, GSK-3b, Catenin b, NFkb p65, pl6INK4a, and p53 ( Figure 7).
- the levels of these protein analytes increased there is a decrease in the ratio, and those with significant differences would be considered points of therapeutic intervention.
- the ratio of pl6INK4a / Akt was found to be 1.4 and this ratio in Normal keratinocytes is 0.5.
- Temsirolimus (Pfizer), BEZ235 (Novartis), GDC-0980 (Genentech), PF-05212384 (Pfizer),
- SAR245409 (XL-765; Sanofi/Exelixis), BAY80-6946 (Bayer), Bupariisib (BKM120; Novartis),
- Additional antagonists include PKF118-310, CGP049090, PKF115-584, PKF222-815, PKF118-744, ICGOOl,
- Table 1 Patient Demographics and Clinical Information
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Disclosed are biomarkers, kits, and methods for diagnosing or treating wounds. In some aspects, the present disclosure provides for a method, comprising: measuring an individual level of an expression or activation of two or more proteins in a sample from the wound. In some aspects, the present disclosure provides for a method of treating a wound in a subject in need thereof, comprising treating the subject with a pharmaceutical composition that comprises an antagonist of a first protein, an agonist of a second protein, or a combination thereof. In some aspects, the present disclosure provides for a kit that comprises reagents for measuring a total amount or a phosphorylation level of two or more proteins.
Description
Methods of Diagnosing and Treating Wounds
Cr os s-Reference
This application claims the benefit of U. S. Provisional Application No. 62/175,394, filed on June 14, 2015, which is incorporated herein by reference in its entirety.
Incorporation by Reference
All publications, patents, and patent applications disclosed herein are incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. In the event of a conflict between a term disclosed herein and a term in an incorporated reference, the term herein controls.
Brief Summary
In some aspects, the present disclosure provides for a method, comprising: measuring an individual level of an expression or activation of two or more proteins (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 proteins) in a sample from the wound. In some embodiments, the present disclosure provides for a method, comprising: measuring an individual level of an expression or activation of a first protein and a second protein in a sample from the wound, wherein the first protein and the second protein are individually selected from the group consisting of: IGF-1R, PI3 Kinase, Akt, insulin, mTOR, HIF, PTEN, IGFRBP-3, c-MET, GSK-3 , COX-2, iNOS, NFKB/p65, ΙκΒ-α, p53, pl6INK4a, β-Catenin, Bak, Caspase 3, Caspase 9, or any combination thereof; and calculating a ratio of the first protein to the second protein. In some embodiments, the method is a method of determining a diagnosis of the wound in a subject. In some embodiments, the measurement is repeated for at least 1, 2, 3, 4, or 5 times, and when the method is repeated more than 1 time, the measurement may be conducted at different time points or at the same time point. In some embodiments, the measurement is repeated during a course of monitoring the wound. In some embodiments, the calculation is implemented at least in part by a computer. In some embodiments, the calculation is implemented at least in part by a computer processor. In some embodiments, the computer process is a computer microprocessor. In some embodiments, the method further comprises determining the diagnosis that a wound will not heal when the ratio is greater than 1, or that the wound will heal when the ratio is 1 or less. In some embodiments, the determination is implemented at least in part by a computer. In some embodiments, the determination is implemented at least in part by a computer processor. In some embodiments, the computer process is a computer microprocessor. In some embodiments, the method further comprises evaluating the wound visually, e.g., by comparing an image (e.g., digital or paper) of the wound with an earlier image of the same wound. In some embodiments, the method further comprises communicating a result with a communication medium. In some embodiments, the
communication medium is a document. In some embodiments, the communication medium is a computer file, an email, a fax, or a paper document. In some embodiments, the ratio is calculated with values generated from a comparison of the measured levels and corresponding reference standards. In some embodiments, the sample is a tissue from the wound. In some embodiments, the sample is from a marginal edge of the wound. In some embodiments, the sample comprises a keratinocyte isolated or purified from the wound. In some embodiments, the first protein and the second protein are individually measured from the keratinocyte or a cellular lysate thereof. In some embodiments, the method comprises measuring the expression of the first protein and the second protein individually. In some embodiments, the method comprises measuring the activation of the first protein and the second protein individually. In some embodiments, the measured level is determined by measuring a total amount of the first protein or the second protein individually. In some embodiments, the measured level is determined by measuring an amount of an activated form of the first protein or the second protein individually. In some embodiments, the activation is phosphorylation. In some embodiments, the measured levels are normalized fluorescence intensity (NFI) per mg protein. In some embodiments, the values are normalized expression values. In some embodiments, the subject has or is suspected of having diabetes, Alzheimer's disease, a cancer, or any combination thereof. In some embodiments, the subject is a human. In some embodiments, the wound will not heal when the ratio is > 1.2, > 1.3, > 1.4, or > 1.5. In some embodiments, the method further comprises treating the subject, e.g., administering to the subject a pharmaceutical composition that comprises an antagonist of a first protein, an agonist of a second protein, or a combination thereof, wherein the first protein or the second protein are individually selected from the group consisting of: IGF-IR, PI3 Kinase, Akt, insulin, mTOR, HIF, PTEN, IGFRBP-3, c-MET, GSK-3 , COX-2, iNOS, NFKB/p65, ΙκΒ-α, p53, pl6INK4a, β-Catenin, Bak, Caspase 3, Caspase 9, and any combination thereof. In some embodiments, a pharmaceutical composition disclosed herein comprises the agonist and the antagonist, which are administered simultaneously, or sequentially. In some embodiments, a pharmaceutical composition disclosed herein further comprises a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutically acceptable carrier comprises water. In some embodiments, the second protein is IGF-IR. In some embodiments, the second protein is Akt. In some embodiments, the first protein is PI3 Kinase and the second protein is IGF-IR. In some embodiments, the first protein is PI3 Kinase and the second protein is insulin. In some embodiments, the first protein is PI3 Kinase and the second protein is Akt. In some
embodiments, the first protein or the second protein is Akt that is Aktl. In some embodiments, the first protein or the second protein is IGF-IR that is IGF-lR . In some embodiments, the first protein or the second protein is IGF-IR that is p-IGF-lR Yl 135-1150 (phospho-tyrosine
1135-1150). In some embodiments, the first protein or the second protein is HIF that is HIF-la. In some embodiments, the first protein or the second protein is mTOR that is p-mTOR S2448 (phospho-serine 2448). In some embodiments, the first protein or the second protein is PTEN that is p-PTEN S380 (phosphor-serine 380). In some embodiments, the subject has or is suspected of having diabetes, Alzheimer's disease, a cancer, or any combination thereof. In some embodiments, the subject is a human. In some embodiments, the wound is a diabetic ulcer, a pressure ulcer, a venous stasis ulcer, a radiation ulcer, a skin injury, an unhealed surgical wound, a wound from a surgical procedure, a wound from a peripheral vascular disease, a wound from a complication of trauma, a wound in a cancer patient, a wound in a patient receiving a steroid therapy, a wound from an inflammatory skin disease, a chronically impaired cutaneous wound, or any combination thereof. In some embodiments, the wound is a diabetic foot ulcer.
In some aspects, the present disclosure provides for a method of treating a wound in a subject in need thereof, comprising treating the subject with a pharmaceutical composition that comprises an antagonist of a first protein, an agonist of a second protein, or a combination thereof, wherein the first protein or the second protein are individually selected from the group consisting of: IGF-IR, PI3 Kinase, Akt, insulin, mTOR, HIF, PTEN, IGFRBP-3, c-MET, GSK- 3β, COX-2, iNOS, NFKB/p65, ΙκΒ-α, p53, pl6INK4a, β-Catenin, Bak, Caspase 3, Caspase 9, and any combination thereof. In some embodiments, a pharmaceutical composition disclosed herein comprises the agonist and the antagonist, which are administered simultaneously, or sequentially. In some embodiments, a pharmaceutical composition disclosed herein further comprises a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutically acceptable carrier comprises water. In some embodiments, the second protein is IGF-IR. In some embodiments, the second protein is Akt. In some embodiments, the first protein is PI3 Kinase and the second protein is IGF-IR. In some embodiments, the first protein is PI3 Kinase and the second protein is insulin. In some embodiments, the first protein is PI3 Kinase and the second protein is Akt. In some embodiments, the first protein or the second protein is Akt that is Aktl . In some embodiments, the first protein or the second protein is IGF-IR that is IGF-lRp. In some embodiments, the first protein or the second protein is IGF-lRp that is p-IGF-lR Yl 135- 1150 (phospho-tyrosine 1135-1150). In some embodiments, the first protein or the second protein is HIF that is HIF-la. In some embodiments, the first protein or the second protein is mTOR that is p-mTOR S2448 (phospho-serine 2448). In some embodiments, the first protein or the second protein is PTEN that is p-PTEN S380 (phosphor-serine 380). In some embodiments, the subject has or is suspected of having diabetes, Alzheimer's disease, a cancer, or any combination thereof. In some embodiments, the subject is a human. In some embodiments, the
wound is a diabetic ulcer, a pressure ulcer, a venous stasis ulcer, a radiation ulcer, a skin injury, an unhealed surgical wound, a wound from a surgical procedure, a wound from a peripheral vascular disease, a wound from a complication of trauma, a wound in a cancer patient, a wound in a patient receiving a steroid therapy, a wound from an inflammatory skin disease, a chronically impaired cutaneous wound, or any combination thereof. In some embodiments, the wound is a diabetic foot ulcer.
In some aspects, the present disclosure provides for a pharmaceutical composition that comprises an antagonist of a first protein, an agonist of a second protein, or a combination thereof, wherein the first protein or the second protein are individually selected from the group consisting of: IGF-IR, PI3 Kinase, Akt, insulin, mTOR, HIF, PTEN, IGFRBP-3, c-MET, GSK- 3β, COX-2, iNOS, NFKB/p65, ΙκΒ-α, p53, pl6INK4a, β-Catenin, Bak, Caspase 3, Caspase 9, and any combination thereof. In some embodiments, the second protein is IGF-IR. In some embodiments, the second protein is Akt. In some embodiments, the first protein is PI3 Kinase and the second protein is IGF-IR. In some embodiments, the first protein is PI3 Kinase and the second protein is insulin. In some embodiments, the first protein is PI3 Kinase and the second protein is Akt. In some embodiments, the first protein or the second protein is Akt that is Aktl. In some embodiments, the first protein or the second protein is IGF-IR that is IGF-lRp. In some embodiments, the first protein or the second protein is IGF-lRp that is p-IGF-lR Yl 135-1150 (phospho-tyrosine 1135-1150). In some embodiments, the first protein or the second protein is HIF that is HIF-la. In some embodiments, the first protein or the second protein is mTOR that is p-mTOR S2448 (phospho-serine 2448). In some embodiments, the first protein or the second protein is PTEN that is p-PTEN S380 (phosphor-serine 380). In some embodiments, a pharmaceutical composition disclosed herein further comprises a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutically acceptable carrier comprises water.
In some aspects, the present disclosure provides for a method of making a pharmaceutical composition disclosed herein.
In some aspects, the present disclosure provides for a kit that comprises reagents for measuring a total amount or a phosphorylation level of two or more proteins selected from the group consisting of: IGF-IR, PI3 Kinase, Akt, insulin, mTOR, HIF, PTEN, IGFRBP-3, c-MET, GSK-3 COX-2, iNOS, NFKB/p65, ΙκΒ-α, p53, pl6INK4a, β-Catenin, Bak, Caspase 3, and Caspase 9. In some embodiments, the kit is employed to predict a likelihood of wound healing in a subject. In some embodiments, the kit predicts the prognosis of a wound in a subject. In some embodiments, one of the proteins is PI3 Kinase, IGF-IR, or Akt. In some embodiments, the
proteins are PI3 Kinase and IGF-1R. In some embodiments, the proteins are PI3 Kinase and insulin. In some embodiments, the proteins are PI3 Kinase and Akt. In some embodiments, the first protein or the second protein is Akt that is Aktl. In some embodiments, the first protein or the second protein is IGF-1R that is IGF-1R{$. In some embodiments, the first protein or the second protein is IGF-ΙΡνβ that is p-IGF-ΙΡνβ Yl 135-1150 (phospho-tyrosine 1135-1150). In some embodiments, the first protein or the second protein is HIF that is HIF-Ια. In some embodiments, the first protein or the second protein is mTOR that is p-mTOR S2448 (phospho- serine 2448). In some embodiments, the first protein or the second protein is PTEN that is p- PTEN S380 (phosphor-serine 380). In some embodiments, the subject has or is suspected of having diabetes, Alzheimer's disease, a cancer, or any combination thereof. In some
embodiments, the subject is a human. In some embodiments, the wound is a diabetic ulcer, a pressure ulcer, a venous stasis ulcer, a radiation ulcer, a skin injury, an unhealed surgical wound, a wound from a surgical procedure, a wound from a peripheral vascular disease, a wound from a complication of trauma, a wound in a cancer patient, a wound in a patient receiving a steroid therapy, a wound from an inflammatory skin disease, a chronically impaired cutaneous wound, or any combination thereof. In some embodiments, the kit further compries an instruction manual.
In some instances, a first protein disclosed herein is not identical to a second protein disclosed herein.
Brief Descriptions of the Drawings
Figure 1 is a diagram showing DFU (diabetic foot ulcer) proteomic signaling study pathway nodes including HIF-1 and downstream gene expression related to wound repair.
Pathway signaling map of the interplay between stimulatory and inhibitory modulation of the various components that have either a defined role or undefined role in the healing of chronic, diabetic ulcers. The ISP Ratio is defined as the ratio between PI3K and IGF-1R.
Figure 2 is a diagram showing a ratio of PI3K to IGF1R in normal, healed diabetic foot ulcers (DFU) and non-healing DFU. In normal and healing DFU the ratio of PI3K to IGF1R ranges from 0.7 to 1.1 while the ratio for non-healing DFU subjects was equal to or greater than 1.1, ranging from 1.1 to 1.7.
Figure 3 is a set of bar charts showing mean, STDev and non-parametric Whitney-Mann
U-Test results for 21 proteins levels measured in normal and DFU keratinocytes. Analytes:
Receptor Kinases: IGF-IR - insulin growth factor-1 receptor beta, p-IGF-lR Yl 135-1150 - insulin growth factor-1 receptor beta (phosphor-tyrosine 1135-1150), VEGFR1 - vascular endothelial growth factor receptor-1, and c-MET - hepatocyte growth factor receptor (HGFR); the PI3Kinase/AKT Pathway, p-PTEN S380 - phosphatase tensin homolog (phospho-serine
380), PI3 Kinase - phosphoinosityl-3-kinase (PI3K), Akt - Aktl/protein kinase B, GSK-3 - glycogen synthase kinase-3 ; mTOR - mammalian target of rapamycin, and p-mTOR - mammalian target of rapamycin S2448 (phosphor-serine 2448); Pro-inflammatory proteins: COX-2- cyclooxygenase-2, and iNOS - inducible nitric oxide synthase; Survival Pathways: NFKB/p65 - Nuclear Factor Kappa B/p65, ΙκΒ-α - NFKB inhibitor alpha, HIF-la - hypoxia inducible factor-1 alpha, p53 - tumor suppressor transcription factor, pl6INK4a - cyclin- dependent kinase inhibitor/regulator of senescence, and β-Catenin - Catenin beta-1; and
Apoptosis Pathways: Bak - BCL2-antagonist/killer 1, Caspase 3 - cysteine-aspartic protease 3, and Caspase 9 - cysteine-aspartic protease 9.
Figure 4 is a set of box-plots showing significantly increased levels of downstream proteins compared to levels of IGF-1R in Healed and Unhealed DFU keratinocytes. Boxplots showing the calculated ratios for the Level of Each Analyte / Level of IGF-1R demonstrate that the Unhealed patients have significantly (p < 0.05) elevated ratios of POKinase, mTOR, Cox2, p53, Bak and Caspase 9 than Healed patients. Not only is the center higher for unhealed patients, but the quantitative independent two-sample t-test analysis suggests that the 2 population means differ beyond random variation.
Figure 5 is a scheme showing the dynamic Akt switch between DFU and Normal tissues and the ratios calculated for significantly modulated analytes (box-plots). Increased levels of PI3 kinase-induced activation of Akt promote angiogenesis and apoptosis through various downstream effectors.
Figure 6 is a diagram showing the ratio of PI3K to IGF-1R can distinguish Normal, Healing, and Nonhealing DFU. This distinction can be used in order to predict healing or not in DFU Subjects.
Figure 7 is a diagram showing ratios of various analytes to Akt in normal and DFU keratinocytes. For example, using the ratios of PI3K/Akt in individual subjects can determine if the subjects DFU would heal or not. Some Subject's ratios are higher in Normal so an antagonist to the analyte would be expected to reduce the ratio and promote healing, and in those Subjects where the ratio is lower, then an agonist would be expected to increase the ratio and promote healing.
Figure 8 shows a computer system 801 that is programmed or configured to implement or regulate a communication with results related to a prognosis of a wound.
Detailed Description
In some aspects, the biomarkers disclosed herein can serve as diagnostic markers that predict healing versus nonhealing DFU. In some embodiments, the signaling pathways in which these proteins reside and function are points of therapeutic intervention, wherein combinations of
therapies targeting these interrelated pathway signaling proteins is identified. In some embodiments, the patterns of protein expression and activation are useful in guiding treatment decisions on an individual, per-patient basis. In some aspects, the present disclosure provides a comprehensive assessment of protein signaling cascades related to proliferation, migration, inflammation, and apoptosis/senescence in diabetic wounds.
A protein disclosed herein can mean the entire protein or a fragment thereof.
An agonist disclosed herein can include a partial agonist. An antagonist disclosed herein can include a partial antagonist. An agonist or an antagonist can be purified or isolated.
A ratio (e.g., a ratio of a first protein to a second protein) is calculated with normalized values or quantitated values in weight (e.g., ng, μg, mg), moles (e.g, nmol, μιτιοΐ, mmol).
The term "subject" as used herein can refer to a mammal (e.g. , a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee or baboon). In some cases, the subject is a human subject, male or female. In some cases, the subject is an adult, a senior, or a child. A subject disclosed herein may have one or more of the following conditions: HTN, Lymphedema Rt. Leg, Chronic hyperkalemia and Kidney disease, Hyperlipidemai, PVD-Venous, Chronic Kidney Disease, osteoarthritis, Hyperlipidemia, Degenerative and Rheumatoid Arthritis, CAD, AFIB, PVD-Venous, Sleep Apnea, Hypothyroid, Spinal Sten, Hx Pancreatitis, Gastroparesis, AFIB, PVD-arterial, Prostate Cancer, DJD-bilat knee repl, Arterial w Revascularization, Depression, Smoker, Pulmonary HTN, CHF, PVD- Arterial, or Chronic renal disease.
The term "treatment" or 'treating" can refer to cure or ameliorate a condition or disorder including a disease. For example, an effectiveness of a cancer treatment, such as administration of an anti-cancer drug, may be an assessment of the anti-cancer drug to reduce tumor or cancer cell invasiveness, to kill cancer or tumor cells, to eliminate a cancer or tumor in a subject, to reduce a size of a tumor, to weaken or make more susceptible to apoptosis a cancer cell or tumor cell, to reduce or prevent metastasis, or others, or combinations thereof.
The term "effective" as defined herein related to a drug, generally refers to an assessment or determination about whether a drug has achieved the results it is intended to achieve. For example, an effectiveness of an anti-cancer drug or an anti-tumor drug may be an assessment of the anti-cancer drug or the anti-tumor drug to reduce tumor or cancer cell invasiveness, to kill cancer or tumor cells, or to eliminate a cancer or tumor in a subject. An effectiveness of a drug may also include an assessment of the severity and number of side effects or conditions brought on by consuming the drug. The assessment or determination may be performed using methods as described herein.
An "effective amount" when used in connection with a pharmaceutical composition disclosed herein can be an amount sufficient to produce a therapeutic result in a subject in need thereof.
The term "about" can mean the referenced numeric indication plus or minus 15% of that referenced numeric indication.
The term "prognosis," as used herein, generally refers to a prediction of the likely outcome of a subject's current standing or a predication of a future outcome. A prognosis may include a judgment or an opinion of a medical professional of a subject's current standing or future standing. Diagnostic methods or assays may be utilized to make a prognosis. In some cases, a diagnostic method may include performing a tissue biopsy, a cell cytology, an endoscopy, a diagnostic imaging, a blood test, a genetic screening or analysis or any combination thereof.
Wound: a breakdown in the protective function of the skin; the loss of continuity of epithelium, with or without loss of underlying connective tissue (i.e. muscle, bone, nerves) following injury to the skin or underlying tissues/ organs caused by surgery, a blow, a cut, chemicals, heat/ cold, friction/ shear force, pressure or as a result of disease, such as leg ulcers or carcinomas.
Nonhealing Wound: a non-healing or chronic wound is defined as a wound that does not improve after four weeks or does not heal in eight weeks. These include: diabetic foot ulcers, venous-related ulcerations, non-healing surgical wounds, pressure ulcers, wounds related to metabolic disease, wounds that repeatedly break down.
Healing Wound: the process of returning to health; the restoration of structure and function of injured or diseased tissues. The healing processes include blood clotting, tissue mending, scarring, and bone healing. Wound healing is a complex and dynamic process of replacing devitalized and missing cellular structures and tissue layers. The human adult wound healing process can be divided into 4-phases: the hemostasis phase, the inflammatory phase, the proliferation phase, and the remodeling phase.
DFU - Diabetic Foot Ulcer is a serious complication of diabetes which aggravates the patient's condition whilst also having significant socioeconomic impact. The aim of the present review is to summarize the causes and pathogenetic mechanisms leading to diabetic foot, and to focus on the management of this important health issue. Increasing physicians' awareness and hence their ability to identify the "foot at risk," along with guidance on how to treat each individual's DFU with proper foot care and therapeutics, may prevent diabetic foot ulceration and thus reduce the risk of amputation.
Wound Healing Diagnostic (WHD)- a diagnostic test that can be administered to a subject with a wound that measures certain biological parameters and can distinguish between wounds that will heal and those that will not heal.
Wound Therapy Diagnostic (WTD)- a diagnostic test that can be administered to a subject with a wound that measures certain biological parameters and can determine the most appropriate course of treatment that modulates biological processes that are preventing wound healing and which results in wounds that will heal.
Phosphorylation- the addition of phosphate to an organic compound, such as a protein, through the action of a phosphotransferase (phosphorylase) or kinase, that results in increased or decreased functions, such as signal transduction, of the protein.
Signal Transduction: occurs when an extracellular signaling molecule, or ligand, activates a specific receptor located on the cell surface, such as a receptor kinase, or inside the cell. Phosphorylation, or other post-translational modifications like methylation or acetylation,), receptor triggers a biochemical chain of events inside the cell, eventually eliciting a response. Depending on the cell, the response may alter the cell's metabolism, shape, gene expression, or ability to divide. The signal can be amplified at any step, as signaling involves the interaction of multiple proteins in a step-wise fashion of activation. Thus, one signaling molecule can generate a response involving hundreds to millions of molecules.
IGF1R: The insulin-like growth factor (IGF-1) and its signaling through insulin receptor (IR) or mainly through IGF-1 receptor (IGF-IR) is highly implicated in tumor transformation and survival of malignant cell, but is only partially involved in normal cell growth. This is in part due to the interactions with oncogenes. IGF-IR is mainly involved in regulation of cell proliferation, anti-apoptosis, differentiation and cell motility, whereas IR is mostly of impact for control of glucose uptake and metabolism. Ligand-receptor binding results in phosphorylation of tyrosine residues in the IGF-IR tyrosine kinase domain. In the unstimulated state, the activation loop of IGF-IR activation loop (a-loop) is not phosphorylated and several tyrosine residues (1131, 1135 and 1136) block the active site. Upon ligand binding, the three tyrosines of the activation loop are trans-phosphorylated by IGF-lR's dimeric subunit partner. There are a number of proteins associated with and participate in the functional signaling of IGF-IR, any of which may have altered structure or function and, and have the potential to reduce signaling through IGF-IR. These include ARHGEF12, C-src tyrosine kinase, Cbl gene, EHD1, GRB10, IRS1, Mdm2, NEDD4, PIK3R3, PTPN11, RAS p21 protein activator 1, SHC1, SOCS2, SOCS3, YWHAE. The activation of the tyrosine kinase activity of IGF-IR leads to the phosphorylation of several of the above substrates, including the insulin receptor substrate family of proteins [such as Insulin receptor substrate 1 (IRS-1 ), She (Src homology 2 domain containing)
transforming protein 1 ] and some others. Once phosphorylated, these docking proteins activate downstream intracellular signaling through the PI3K/Akt pathway, by way of GRB2/Shc activation of the Ras/MAPK pathways that ultimately leads to increased cellular proliferation. IGF-1R is ubiquitously expressed in tissues, playing a role in tissue growth stimulated by insulin, which liberates IGF-1 to activate the IGF-1R. IGF -I and bFGF regulate transcriptional activity of the IGF-IR gene negatively and positively, respectively. In some embodiments, bFGF increases IGF-IR gene promoter activity by 2-fold and IGF-I decreases transcriptional activity by 50%. In some embodiments, IGF-IR is not an absolute requirement for normal growth. In some embodiments, IGF-IR is crucial for anchorage independent growth, a property of malignant cells, where anchorage dependency can be acquired when the number of IGF-IRs at the cell surface is increased. In some embodiments, IGF- IR has a critical role in anchorage independent growth in prostate cancer and anchorage independent growth in wounds.
p-IGF-lR Yl 135-1150 or phospho-tyrosine 1135-1150 Insulin-like growth factor 1- beta) - a protein found on the surface of human cells. It is a transmembrane receptor that is activated by a hormone called insulin-like growth factor 1 (IGF-1) and by a related hormone called IGF-2. It belongs to the large class of tyrosine kinase receptors and it mediates the effects of IGF-1, which is a polypeptide protein hormone similar in molecular structure to insulin. IGF- IR activation by phosphorylation, for example on tyrosines 1135-1150, the earliest major autophosphorylation sites necessary for kinase activation) plays an important role in growth and continues to have anabolic effects in adults - meaning that it can induce hypertrophy of skeletal muscle and other target tissues.
c-MET- a protein that in humans is encoded by the MET gene (MET proto-oncogene, receptor tyrosine kinase), which earlier in the discovery process had also been called MNNG HOS transforming gene. The protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. MET is a single pass tyrosine kinase receptor essential for embryonic development, organogenesis and wound healing. Hepatocyte growth factor/Scatter Factor (HGF/SF) and its splicing isoforms (NK1 and NK2) are the only known ligand of the MET receptor. MET is normally expressed by cells of epithelial origin, while expression of HGF/SF is restricted to cells of mesenchymal origin. When HGF/SF binds its cognate receptor MET it induces its dimerization through a not yet completely understood mechanism leading to its activation (phosphorylation).
p-PTEN S380 (phospho-serine 380)- the phosphorylated species of a protein that, in humans, is encoded by the PTEN gene. Mutations of this gene are a step in the development of
many cancers and PTEN orthologs have been identified in most mammals for which complete genome data are available. This gene is considered a tumor suppressor that is mutated in a large number of cancers at high frequency. The protein encoded by this gene is a phosphatidylinositol- 3,4,5-trisphosphate 3 -phosphatase. It contains a tensin-like domain as well as a catalytic domain similar to that of the dual specificity protein tyrosine phosphatases. Unlike most of the protein tyrosine phosphatases, this protein preferentially dephosphorylates phosphoinositide substrates. It negatively regulates intracellular levels of phosphatidylinositol-3,4,5-trisphosphate in cells and functions as a tumor suppressor by negatively regulating Akt/PKB signaling pathway by inhibiting the signaling activity of the POKinase protein complex. Phosphorylation at serine 380 inactivates PTEN function, thereby releasing the inhibition of the PI3 Kinase complex.
PI3 Kinase-[also known as phosphatidylinositide 3-kinases, phosphatidylinositol-3- kinases, PI 3-kinases, PI(3)Ks, PI-3Ks or by the HUGO official stem symbol for the gene family, PI3K(s)] are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. PI3Ks are a family of related intracellular signal transducer enzymes capable of phosphorylating the 3 position hydroxyl group of the inositol ring of phosphatidylinositol (Ptdlns). The pathway, with oncogene PIK3CA and tumor suppressor PTEN, is implicated in insensitivity of cancer tumors to insulin and IGF1, and in calorie restriction. Activation of the PI3 Kinases results in phosphorylation, or activation, of the AKT/PKB proteins, which is a central signaling hub located in human cells. Examples of PI 3 kinase signaling pathway proteins include PDK1, PKB, AKT, TSC2, Rheb, mTOR, Ribosomal Protein S6, S6, SEBP1, eiF4E, eiF4F, eiF4G, KI67, FOXO, GSK3 A/B, MDM2, TIAM-1, VAV-1, P-Rex-1, ARAP3, Rac, and Rho.
Aktl/protein kinase B- is a serine/threonine-specific protein kinase that plays a key role in multiple cellular processes such as glucose metabolism, apoptosis, cell proliferation, transcription and cell migration. Aktl is involved in cellular survival pathways, by inhibiting apoptotic processes. Aktl is also able to induce protein synthesis pathways, and is therefore a key signaling protein in the cellular pathways that lead to skeletal muscle hypertrophy, and general tissue growth. Complete deletion of Aktl manifests growth retardation and increased spontaneous apoptosis in tissues such as testes and thymus and since it can block apoptosis, Aktl promotes cell survival and has been implicated as a major factor in many types of cancer. Aktl is also known as Akt.
GSK-3 - also known as GSK3B, is an enzyme that in humans is encoded by the GSK3B gene. Abnormal regulation and expression of GSK3 is a proline-directed serine-threonine kinase that was initially identified as a phosphorylating and an inactivating agent of glycogen
synthase. GSK3A is involved in energy metabolism, neuronal cell development, and body pattern formation.
mTOR- Mammalian Target of Rapamycin [also known as FK506-binding protein 12- rapamycin-associated protein 1 (FRAP1)], is a protein that in humans is encoded by the MTOR gene. The protein complex containing mTOR is a serine/threonine protein kinase that regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis, autophagy, transcription, and fibrosis. Also, mTOR belongs to the phosphatidylinositol 3-kinase-related kinase protein family. There are two complexes containing mTOR: mTORcl and mTORC2. The activity of mTORCl is stimulated by insulin, growth factors, serum, phosphatidic acid, amino acids (particularly leucine), and oxidative stress and mTORC2 phosphorylates the serine/threonine protein kinase Akt/PKB at the serine residue S473, thus affecting metabolism and survival. Phosphorylation of the serine stimulates Akt phosphorylation at a threonine T308 residue by PDK1 and leads to full Akt activation MTOR integrates the input from upstream pathways, including insulin, growth factors (such as IGF-1 and IGF-2), and amino acids. mTOR also senses cellular nutrient, oxygen, and energy levels. The mTOR pathway is dysregulated in human diseases, such as diabetes, obesity, depression, and certain cancers. Rapamycin inhibits mTOR by associating with its intracellular receptor FKBP12 The FKBP12-rapamycin complex binds directly to the FKBP12-Rapamycin Binding (FRB) domain of mTOR, inhibiting its activity.
p-mTOR S2448 (phospho-serine 2448)- mTOR phosphorylated at S2448 binds to both, raptor and rictor. Experiments with chemical inhibitors of the mTOR kinase and of the phosphatidylinositol-3-kinase revealed that downregulation of mTOR S2448 phosphorylation correlates with decreased mTORCl activity.
COX-2 - Cyclooxygenase-2, is an enzyme that acts to speed up the production of certain chemical messengers, called prostaglandins that play a key role in in promoting inflammation. When cox-2 activity is blocked, inflammation is reduced. Unlike Cox-1, Cox-2 is active only at the site of inflammation, and not limited to activity in the stomach.
iNOS - inducible nitric oxide synthase (iNOS), is a small molecule that has various roles in cellular functions and acts via a cGMP -mediated signal transduction pathway. iNOS is both tumouricidal and bactericidal, has nitrosylase activity, and mediates cysteine S-nitrosylation of cytoplasmic target proteins such COX-2. It is regulated by calcium/calmodulin, induced by endotoxins and cytokines, including IFN-gamma, in synergy with bacterial lipopolysaccharides (LPS, TNF or ILlB/IL-1 beta and its expression and function are inhibited by aspirin.
NFKB - nuclear factor kappa-light-chain-enhancer of activated B cells) is a protein complex comprising a subfamily of NFKB proteins, including RelA (NfKB/p65), RelB, and c-
Rel. For example, NfKB/p65 controls transcription of DNA, cytokine production and cell survival. NFKB is found in almost all animal cell types and is involved in cellular responses to stimuli such as stress, cytokines, free radicals, ultraviolet irradiation, oxidized LDL, and bacterial or viral antigens. NFKB plays a key role in regulating the immune response to infection (κ light chains are critical components of immunoglobulins). Incorrect regulation of NFKB has been linked to cancer, inflammatory and autoimmune diseases, septic shock, viral infection, and improper immune development.
ΙκΒ-α - the I-kappa-B proteins inhibit the multimeric NFKB complex by trapping it in the cytoplasm. Kinases ΙκΒ-α or ΙκΒ-β phosphorylates NFKB'S serine residues, marking them for destruction via the ubiquination pathway, allowing activation of the NFKB complex which, once activated, translocates to the nucleus, binds DNA and activates transcription.
HIF-1 (hypoxia-inducible factor 1) is a key transcription factor that is responsive to hypoxic conditions and is known to be involved in coordinating cellular responses to hypoxia. The HIF-1 complex, composed of heterodimer pairs containing an alpha and beta subunit, binds to the promoter of hypoxia-responsive genes. The active transcription complex interacts with several transcription factors, such as p300, signal and transducer of transcription 3 (STAT3), and Redox effector factorl/apurinic/apyrimidinic endonuclease. There are six different HIFs that can form heterodimers: HIF-l a; HIF-1 β (ARNT, aryl hydrocarbon receptor nuclear translocator); HIF-2a (EPAS1, endothelial PAS domain protein 1); ΗΙΡ-2β (ARNT2, aryl-hydrocarbon receptor nuclear translocator 2); HIF-3a; and ΗΙΡ-3β (ARNTL, aryl- hydrocarbon receptor nuclear translocator 3).
HIF-l a- hypoxia-inducible factor 1 -alpha, is a subunit of a heterodimeric transcription factor hypoxia-inducible factor 1 (HIF-1) that is encoded by the HIF-la gene and is considered as the master transcriptional regulator of cellular and developmental response to hypoxia. The dysregulation and overexpression of HIF-la by either hypoxia or genetic alternations have been heavily implicated in cancer biology, as well as a number of other pathophysiologies, specifically in areas of vascularization and angiogenesis, energy metabolism, cell survival, and tumor invasion.
p53 - a specific protein with a mass of 53 kilo Daltons that is produced by a tumor- suppressor gene. Like other tumor-suppressor genes, the p53 gene normally controls cell growth. If p53 is physically lost or functionally inactivated, cells can grow without restraint. Many human tumors have mutations in the gene coding for the p53 protein
pl6INK4a - also known as cyclin-dependent kinase inhibitor 2A, multiple tumor suppressor 1 and as several other synonyms, is a tumor suppressor protein, that in humans is encoded by the CDKN2A gene, pi 6 plays an important role in cell cycle regulation by
decelerating cells progression from Gl phase to S phase, and therefore acts as a tumor suppressor that is implicated in the prevention of cancers, notably melanoma, oropharyngeal squamous cell carcinoma, cervical cancer, and esophageal cancer. pl6 can be used to improve the histological diagnostic accuracy of CIN3. The CDK 2A gene is frequently mutated or deleted in a wide variety of tumors. pl6 is an inhibitor of cyclin dependent kinases such as CDK4 and CDK6. These latter kinases phosphorylate retinoblastoma protein (pRB) which eventually results in progression from Gl phase to S phase, pi 6 was originally found in an "open reading frame" of 148 amino acids encoding a protein of molecular weight 15,845 comprising four ankyrin repeats. pl6Ink4a is named after its molecular weight and its role in inhibiting CDK4.
β-Catenin - a dual function protein, regulating the coordination of cell-cell adhesion and gene transcription. In humans, the CTNNBl protein is encoded by the CTNNBl gene, β-catenin is a subunit of the cadherin protein complex and acts as an intracellular signal transducer in the Wnt signaling pathway. It is a member of the catenin protein family and homologous to γ- catenin, also known as plakoglobin. Beta-catenin is widely expressed in many tissues. In cardiac muscle, beta-catenin localizes to adherens junctions in intercalated disc structures, which are critical for electrical and mechanical coupling between adjacent cardiomyocyte. Mutations and overexpression of β-catenin are associated with many cancers, including hepatocellular carcinoma, colorectal carcinoma, lung cancer, malignant breast tumors, ovarian and endometrial cancer. Alterations in the localization and expression levels of beta-catenin have been associated with various forms of heart disease, including dilated cardiomyopathy, β-catenin is regulated and destroyed by the beta-catenin destruction complex, and in particular by the adenomatous polyposis coli (APC) protein, encoded by the tumor-suppressing APC gene.
BAK - this protein functions as a pro-apoptotic regulator involved in a wide variety of cellular activities. In healthy mammalian cells, BAK localizes primarily to the MOM
(mitochondrial outer membrane), but remains in an inactive form until stimulated by apoptotic signaling. The inactive form of BAK is maintained by the protein's interactions with VDAC2, Mtx2, and other anti-apoptotic members of the BCL2 protein family. Nonetheless, VDAC2 functions to recruit newly synthesized BAK to the mitochondria to carry out apoptosis.
Moreover, BAK is believed to induce the opening of the mitochondrial voltage-dependent anion channel, leading to release of cytochrome c from the mitochondria. Alternatively, BAK itself forms an oligomeric pore, MAC, in the MOM, through which pro-apoptotic factors leak in a process called MOM permeabilization.
Caspase 3 - is a caspase protein that interacts with caspase-8 and caspase-9. It is encoded by the CASP3 gene. CASP3 orthologs have been identified in numerous mammals for which
complete genome data are available. Unique orthologs are also present in birds, lizards, lissamphibians, and teleosts. The CASP3 protein is a member of the cysteine-aspartic acid protease (caspase) family. Sequential activation of caspases plays a central role in the execution- phase of cell apoptosis. Caspases exist as inactive proenzymes that undergo proteolytic processing at conserved aspartic residues to produce two subunits, large and small, that dimerize to form the active enzyme. This protein cleaves and activates caspases 6 and 7; and the protein itself is processed and activated by caspases 8, 9, and 10. It is the predominant caspase involved in the cleavage of amyloid-beta 4A precursor protein, which is associated with neuronal death in Alzheimer's disease. Alternative splicing of this gene results in two transcript variants that encode the same protein
Caspase 9 - is an initiator caspase, encoded by the CASP9 gene. CASP9 orthologs have been identified in all mammals for which complete genome data are available. The aspartic acid specific protease caspase-9 has been linked to the mitochondrial death pathway. It is activated during programmed cell death (apoptosis). Induction of stress signaling pathways JNK/SAPK causes release of cytochrome c from mitochondria and activation of apaf-1 (apoptosome), which in turn cleaves the pro-enzyme of caspase-9 into the active form. Once initiated caspase-9 goes on to cleave procaspase-3 & procaspase-7, which cleave several cellular targets, including poly ADP ribose polymerase.
A "subject," as used herein, includes any animal, e.g. , an animal that has diabetes, an Alzheimer's disease, or a cancer. Suitable subjects include laboratory animals (such as mouse, rat, rabbit, or guinea pig), farm animals, and domestic animals or pets (such as a cat or dog). Non-human primates and, preferably, humans (e.g., human patients), are included.
A "phosphorylation state" of a protein refers to the degree of (total amount of) phosphorylation of the protein. This includes both the number of sites (e.g. suitable Ser, Thr or Tyr amino acid residues) of the protein that are phosphorylated, and the le vel of phosphorylation at any given acceptor site on the amino acid chain.
A "baseline value" or "threshold level" as used herein, refers to the level of expression or acti vation (e.g., phosphorylation) of the same protein in a normal subject (e.g., non-diabetic, non-cancerous, or unstimulated subject). For example, a baseline value includes reference standards, where a predetermined threshold value (or range of values) determines whether an expression level of measured protein, or a level of activated state (e.g., phosphorylation state) of the protein, is above the "normal" value. For each protein whose level is determined, the value can be normalized to the total protem m the cell; or to the amount of a constitutively expressed protein (from a housekeeping gene), such as actin; or the amount of a phosphoprotein may be compared to the amount of its non-phosphoryiated counterpart.
A "significant" increase, as used herein, means a statists call)' significant change, using statistical methods that are appropriate and well-known in the art, generally with a probability value of less than five percent chance of the change being due to random variation. As used herein, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. For example, "a" member of the tested pathway, as used above, includes 2, 3, 4, 5 or more members of the pathway. Similarly, "an" inhibitor of the pathway includes multiple inhibitors.
Receptor Kinases
Protein kinases are a group of enzymes that possess a catalytic subunit that transfers terminal phosphates from nucleotide triphosphates (often ATP) to one or more amino acid residues in a protein (phosphorylation). Modification of these side-chains results in
conformational changes that can alter protein function (i.e., activate its kinase activity). The protein kinase enzymes fall into two broad classes, characterized with respect to substrate specificity: serine/threonine-specific and tyrosine-specific kinases. Phosphorylation of proteins is an important mechanism for communicating signals within a cell (signal transduction) to modulate cellular activity. Tyrosine kinases are divided into two main families: the
transmembrane receptor-linked kinases; and those that are cytoplasmic proteins. Receptor tyrosine kinases (RTKs) play pivotal roles in diverse cellular activities including control of cell growth, differentiation, metabolism, adhesion, motility, and apoptosis. (In general, RTKs are composed of: an extracellular domain, some of which may have a specific ligand binding domain; a transmembrane domain that spans the plasma membrane; and an intracellular kinase domain, which binds proteins based on recognition domains on their protein substrates. Ligand binding results in a series of structural rearrangements to the RTK, including activation of the kinase and substrate phosphorylation. These activated substrate proteins, and then initiate a series of subsequent kinase mediated events that transmits a signal from the receptor to multiple downstream effectors. In cancer, many of these signaling pathways result in the alteration in gene expression patterns, as evident by the number of therapies used in cancer that seek to inhibit the RTKs or inhibit the pathways that RTKs modulate downstream.
An increase in kinase-mediated signal transduction may occur in the absence of ligand binding. There are a number of mutations that result in conformational or catalytic changes in RTK signaling. Chromosomal rearrangements, point mutations, deletions, etc. may result in the constitutive activation or hyper-activation in these critical signaling pathways.
Additionally the modulation of RTK signaling in the absence of ligand may be modulated by spatial deregulation, controlled by receptor internalization or alterations to the lipid and actin
filament composition of cellular membranes. Such aberrant, ligand-independent, non-regulated RTK signaling in cancer cells results in the hyper-activation of downstream signaling cascades leading to cancerous processes and such processes may occur in the keratinocytes in the epithelia of healing wounds. Ligand- dependent activation is also implicated as an aberrant cancer signaling processes wherein compensatory autocrine- or paracrine-based over expression of ligands can activate RTK signaling, especially as a resistance mechanism.
Regardless of the underpinning mechanisms of activation, the common output is increased phosphorylation of the RTK and downstream signaling.
There are a number of therapeutically relevant RTKs (growth factor receptors, for example) that may become aberrantly activated and inappropriately turn on key regulatory processes including cell growth, proliferation, apoptosis, angiogenesis, and cell survival.
Receptors become activated, and dysregulation of receptor signaling has been correlated to the development and progression of wound healing and cancers in a wide range of tissues. Many of these receptors become phosphorylated at specific amino acid residues: tyrosine, threonine, and serine. Phosphorylation either activates the receptors intrinsic kinase activity or enhances binding of adaptor proteins that mediate downstream signaling. As tyrosine is a major phosphorylation, many of these receptors are known as Receptor Tyrosine Kinases (RTK). There are several ways that pharmaceuticals can inhibit RTK signaling, including: blocking ligand binding (the antibody trastuzumab, for example), inhibiting dimer formation where dimer formation is required for activation of signaling (the antibody pertuzumab, for example), or by inhibiting the kinase activity of the RTK with small molecular weight inhibitors (lapatinib, for example) that can cross the cell membrane. Some of these receptors are activated by mutations/translocations/amplifi cations directly to the receptor itself, such as HER2, EGFR, c-MET, fibroblast growth factor receptor (FGFR), or insulin-like growth factor- 1 receptor (IGF- IR). Other mutations in genes coding for proteins that are members of signaling pathways may activate signaling distant and downstream from the receptor, such as in certain mutations/loss of heterozygosity to the tumor suppressor PTEN (phosphatase and tensin homolog) whose loss of function can activate the PBKinase (phosphoinositide-3
kinase)/ Akt (also known as PKB, Protein Kinase B) signaling pathway. Also, signaling may be mediated by the spatial effects of monomer concentration or the sequestering of homo- or heterodimers due to alterations in lipid and actin filaments. Thus, the advent of molecularly targeted drugs has generated a number of therapies that specifically target RTKs or proteins in downstream pathways that the RTKs modulate and these therapies have found clinical utility in treating proliferative diseases like cancer.
Diabetes-related atherosclerosis
Overall, people with diabetes mellitus (DM) have an increased incidence of
atherosclerosis, thickening of capillary basement membranes, arteriolar hyalinosis, and endothelial proliferation. Calcification and thickening of the arterial media are also noted with higher frequency in the diabetic population, although whether these factors have any impact on the circulatory status is unclear. Diabetics may develop atherosclerotic disease of large-sized and medium-sized arteries, and a common atherosclerotic disease of the infrapopliteal segments is particularly common and significant in the diabetic population. Underlying digital arterial disease, when compounded by an infected ulcer in close proximity, can result in complete loss of digital collaterals and precipitate gangrene. The prevalence of this form of arterial disease in diabetic persons is thought to result from a number of metabolic abnormalities, including high low-density lipoprotein (LDL) and very-low-density lipoprotein (VLDL) levels, elevated plasma von Willebrand factor, inhibition of prostacyclin synthesis, elevated plasma fibrinogen levels, and increased platelet adhesiveness.
The pathophysiology of peripheral neuropathy in diabetics is multifactorial and some of the contributing factors include: vascular disease occluding the vasa nervorum; endothelial dysfunction; deficiency of myoinositol-altering myelin synthesis; diminishing sodium-potassium adenine triphosphatase (ATPase) activity; chronic hyperosmolarity, causing edema of nerve trunks; and effects of increased sorbitol and fructose. The resultant loss of sensation in the foot is repetitive stress; unnoticed injuries and fractures; structural foot deformity (such as
hammertoes, bunions, metatarsal deformities, or Charcot foot). These contributing factors lead to the eventual breakdown of tissue. Blistering and ulceration, the DFU, may develop due to complications resulting from unnoticed excessive heat or cold, pressure from poorly fitting shoes, or physical damage from bumping the tissue sufficiently to produce a bruise or wound. These factors, combined with poor arterial inflow, confer a high risk of developing DFU and can contribute significantly to the loss of limbs in diabetic patients.
In some embodiments, the management of diabetic foot ulcers requires offloading the wound by using appropriate therapeutic footwear, daily saline or similar dressings to provide a moist wound environment, debridement when necessary, antibiotic therapy if osteomyelitis or cellulitis is present, optimal control of blood glucose, or evaluation and correction of peripheral arterial insufficiency. In some embodiments, wound coverage by cultured human cells or heterogeneic dressings/grafts, application of recombinant growth factors and hyperbaric oxygen treatments may also be beneficial. In some embodiments, topical wound management is to provide a moist, but not wet, wound bed. After debridement, application of moist sodium chloride dressings or isotonic sodium chloride gels (e.g., Normlgel®, IntraSite® gel) or a hydroactive paste (e.g., DuoDERM®) is typically utilized to manage the ulcer. Optimal wound
coverage requires wet-to-damp dressings, to support autolytic debridement, absorb exudate, and to protect the surrounding healthy tissues. A polyvinyl film dressing (e.g., OpSite, Tegaderm) that is semipermeable to oxygen and moisture and impermeable to bacteria is also used by physicians to treat wounds that are neither very dry nor highly exudative.
Wound coverage may also be based upon other approaches:
Dry wounds: Hydrocolloid dressings, such as DuoDERM® or IntraSite® Hydrocolloid, are impermeable to oxygen, moisture, and bacteria; maintain a moist environment; and support autolytic debridement. They are a good choice for relatively desiccated wounds;
Exudative wounds: Absorptive dressings, such as calcium alginates (e.g., Kaltostat®,
Curasorb®), are highly absorptive and are appropriate for exudative wounds. Alginates are available in a rope form, which is useful for packing deep wounds;
Very exudative wounds: Impregnated gauze dressings (e.g., Mesalt®) or hydrofiber dressings (e.g., Aquacel®, Aquacel-Ag®) are useful for extremely exudative wounds. In these cases, twice-daily dressing changes may be needed;
Infected wounds: For infected superficial wounds, use Silvadene® (silver sulfadiazine) if the patient is not allergic to sulfa drugs; if a sulfa allergy exists, either bacitracin-zinc or Neosporin ointment is a good alternative. Where heavy bacterial contamination of deeper wounds exists, irrigation using one-fourth strength Dakin solution and 0.25% acetic acid may be useful for a brief period of time; a hydrofiber-silver dressing (Aquacel-Ag®) can help control wounds that are both exudative and potentially colonized;
Wounds covered by dry eschar: In this case, simply protecting the wound until the eschar dries and separates may be the best management. Occasionally, painting the eschar with povidone iodine (Betadine) is beneficial to maintain sterility while eschar separation occurs; an uninfected dry heel ulcer in a well-perfused foot is perhaps best managed in this fashion;
Areas that are difficult to bandage: Bandaging a challenging anatomical area, such as around a heel ulcer, requires a highly conformable dressing, such as an extra thin hydrocolloid; securing a dressing in a highly moist challenging site, such as around a sacrococcygeal ulcer, requires a conformable and highly adherent dressing, such as a wafer hydrocolloid;
Fragile periwound skin: Hydrogel sheets and nonadhesive forms are useful for securing a wound dressing when the surrounding skin is fragile.
In some embodiments, topical preparations useful in the management of diabetic foot ulcers are as follows:
Platelet-derived growth factors (PDGF): Topically applied PDGF has a modestly beneficial effect in promoting wound healing. Becaplermin gel 0.01% (Regranex®), a recombinant human
PDGF that is produced through genetic engineering is approved by the US Food and Drug
Administration (FDA) to promote healing of diabetic foot ulcers. Regranex® is meant for a healthy, granulating wound, not one with a necrotic wound base, and is contraindicated with known skin cancers at the site of application;
Enzymatic debridement: Collagen comprises a significant fraction of the necrotic soft tissues in chronic wounds; the enzyme collagenase, derived from fermentation of C. histolyticum, helps remove nonviable tissue from the surface of wounds. In some cases, it is not a substitute for an initial surgical excision of a grossly necrotic wound;
Miscellaneous topical agents: Various other topical agents that have been used for wound management include sugar, antacids, and vitamin A and D ointment;
Cytotoxic agents, such as hydrogen peroxide, povidone iodine, acetic acid, and Dakin solution (sodium hypochlorite), should be avoided, except as noted above under infected wounds.
In some embodiments, mechanical methods are employed to effect healing, including: Vacuum-assisted closure: Clean but nonhealing deep cavity wounds may respond to repeated treatments by application of negative pressure under an occlusive wound dressing (vacuum- assisted closure [VAC]);
Hydrotherapy: Intractable, infected, cavity wounds sometimes improve with hydrotherapy using saline pulse lavage under pressure (PulsEvac®);
Debridement: Surgical management is indicated for debridement of nonviable and infected tissue from the ulceration, removal of excess callus, curettage of underlying osteomyelitic bone, skin grafting, and revascularization. The wound usually requires an initial surgical debridement and probing to determine the depth and involvement of bone or joint structures. Visible or palpable bone implies an 85% chance of osteomyelitis.
In some aspects, once a wound has reached a steady clean state, a decision has to be made about allowing healing by natural processes or expediting healing by a surgical procedure. In some embodiments, surgical options include skin grafting, application of bioengineered skin substitutes, and flap closures. Methods used may include skin grafts, including autologous skin grafts or cadaveric skin to cover relatively deep wounds following surgical excision when the wound bed does not appear appropriate for application of an autologous skin graft.
In some embodiments, appropriate skin substitutes include:
Dermagraft® is a cryopreserved human fibroblast-derived dermal substitute produced by seeding neonatal foreskin fibroblasts onto a bioabsorbable polyglactin mesh scaffold;
Dermagraft® is useful for managing full-thickness chronic diabetic foot ulcers. It is not appropriate for infected ulcers, those that involve bone or tendon, or those that have sinus tracts. A multi center study of 314 patients demonstrated significantly better 12-week healing rates with
Dermagraft® (30%) versus controls (17%). Allergic reactions to its bovine protein component have been reported;
Apligraf® is a living, bilayered human skin substitute. It is not appropriate for infected ulcers, those that involve tendon or bone, or those that have sinus tracts. Allergic reactions to the agarose shipping medium or its bovine collagen component have been reported;
Xenograft: Oasis® is a xenogeneic, acellular collagen matrix derived from porcine small intestinal submucosa in a way that allows an extracellular matrix and natural growth factors to remain intact. This provides a scaffold for inducing wound healing. The use of Oasis® is not recommended for patients with allergies to porcine materials.
In some embodiments, Hyperbaric Oxygen Therapy can also be used in promoting DFU healing. In the presence of an intractable wound and associated non-correctible ischemic arterial disease, hyperbaric oxygen therapy may be beneficial (in selected cases), e.g., 40 hyperbaric oxygen treatments (85 min daily, 5 d/wk for 8 wk)
Therapeutic Approaches
Diabetes herein include Type 1, Type 2, or gestational diabetes. Many medications may have a role in the treatment of diabetes, the complications of diabetes, and the etiologies of diabetic ulcer. For example, hemorheologic agents and antiplatelet agents are used in the management of underlying atherosclerotic disease.
Hemorheologic agents such as pentoxifylline (Trental®) improve intermittent claudication in approximately 60% of patients after 3 months. Cilostazol (Pletal®) is an alternative hemorheologic agent for patients who cannot tolerate pentoxifylline. Cilostazol is contraindicated in patients with congestive heart failure.
Antiplatelet therapy with aspirin or clopidogrel (Plavix®) may be warranted in some cases for the prevention of the complications of atherosclerosis. Antiplatelet agents inhibit platelet function by blocking cyclooxygenase and subsequent platelet aggregation.
Therapies used with varying levels of success in treating DFU include:
1) Clopidogrel (Plavix) selectively inhibits ADP binding to platelet receptor and subsequent ADP-mediated activation of glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation. It is indicated as antiplatelet therapy in some patients with atherosclerotic disease.
2) Aspirin inhibits prostaglandin synthesis, preventing formation of platelet-aggregating thromboxane A2 and may be used in low dose to inhibit platelet aggregation and to improve complications of venous stases and thrombosis. The recommended dose varies with indication, and, often, the literature is unclear on the optimal dosing.
3) Topically applied platelet-derived growth factors (PDGF) such as becaplermin gel (Regranex®) have a modestly beneficial effect in promoting wound healing.
4) Becaplermin (Regranex®), a recombinant human PDGF that is produced through genetic engineering, is approved by the US Food and Drug Administration (FDA) to promote healing of diabetic foot ulcers. Regranex® is meant for a healthy, granulating wound, not one with a necrotic wound base, and it is contraindicated with known skin cancers at the site of application.
In some aspects, the present disclosure provides for a method of predicting a diabetic foot ulcer subject's wound healing by a wound healing diagnostic (WHD) provided by the invention.
In some aspects, the present disclosure provides for a method for providing a specific, or individualized, wound therapy diagnostic (WTD) through the development of signaling protein- pathway guided pharmaceutical strategies.
The present disclosure describes the WHD as a panel of ratios of protein expression between IGF-1R and PI3K (PI3K/IGF-1R) and/or mTOR (mTOR/IGF-lR) and/or COX-2 (COX-2/IGF-1R) and/or p53 (p53/IGF-lR) and/or Bak (Bak/IGF-IR) and/or Caspase-9
(Caspase-9/IGF-lR) obtained from tissue analysis of DFU patients. Each WHD ratio determination value would be used to associate the subject's cellular signaling protein expression ratios to those for healed or unhealed DFUs obtained from the clinical studies that established the likely outcome for wound healing. In some embodiments, a WTD as a panel of signaling protein expression ratios that characterize the mediating processes of normal or impaired wound healing that would be used to identify pharmaceutical therapies to optimize signaling protein expression relationships associated with DFU wound closure or normal tissue signaling.
In some aspects, the present disclosure provides several important cellular processes associated with normal healing for the DFU subjects which include angiogenesis (HIF-Ια, iNOS and VEGFR) and intrinsic cell death/apoptosis (Bak and Caspase-9) signaling proteins.
Consequently, the cellular processes associated with impaired DFU subject healing include survival (NFkB, GSK-3P and β-Catenin) and senescence (p53 and pl6INK4a) signaling proteins.
WTD values are obtained from the ratio of Akt protein expression and the protein expression of
Bak (Bak/Akt) and/or Caspase-9 (Caspase-9/Akt) and/or VEGFR1 (VEGFR 1 /Akt) and/or iNOS
(iNOS/Akt) and/or HIF-Ια (HIF-la/Akt) and/or GSK-3P (GSK-3p/Akt) and/or β-Catenin (β-
Catenin/Akt) and/or NFkB (NFkB/Akt) and/or p53 (p53/Akt) and/or pl6INK4a (P16INK4a/Akt).
Signaling protein ratio signatures of tested subjects would be profiled against these four categories of values obtained from the clinical study to provide corrective pharmaceutical strategies for wound treatment that would promote wound healing. These therapies would be designed for, but not limited to, topical applications of appropriately compounded
pharmaceutical agents selected using signaling protein-pathway guided strategies that would alter the WTD protein expression ratio signature values of nonhealing DFU subjects to those values associated with normal or healing DFU subjects. In some embodiments, the use of signaling protein specific pathway therapies would promote the use of specific nodal targeting for corrective wound treatment.
In some aspects, the present disclosure provides information for the development of pharmaceutical wound healing therapies based on the abnormal signaling protein ratios obtained from the unhealed subject's wound being evaluated. The example is given of a non-healing DFU subject demonstrating WTD ratio values below normal subject values for iNOS/Akt, HIF- Ια/Akt and VEGFR/Akt (angiogenesis panel) and with WTD ratio values abnormally elevated for NFkB/Akt (survival panel). Therapeutic evaluations and considerations for these groupings of abnormal values would prioritize the signaling protein pathway relationships for therapy to achieve the broadest impact for protein expression modulation through supplementation, or inhibition, of pharmaceuticals selected for topical therapy. In this case, a candidate topical pharmaceutical for wound healing therapy would include the combination of an iNOS donor pharmaceutical with a pharmaceutical inhibitor of NFkB expression. Clinical testing of these compounds would be performed from additional RPPA tissue analysis and observations of outcomes for validation and/or assessment of additional cellular processes that may contribute to impaired wound healing. The following factors would be used from the information obtained from the WTD panel analysis to support the selection of the pharmaceuticals suggested for the treatment of this unhealed wound.
For the correction of deficient iNOS protein ratio expression nitric oxide (NO) pharmaceutical wound supplementation by the use of an NO donor compound for wound healing would provide direct enhancement of wound NO bioactivity - and iNOS protein expression - that enhances wound epithelialization (keratinocyte migration), angiogenesis (keratinocyte VEGF activation), collagen deposition and wound remodeling ). NO plays a primary role in the control of VEGF-synthesis and in cell adaptations with upregulated activity. HIF-1 a
accumulation is achieved by attenuated prolyl hydroxylase (PHD) activity with NO production and PHD activity is subject to regulation by NO. NO not only modulates the HIF-1 response but also functions as a HIF-1 inducer during sustained formation. Levels of wound fluid NO metabolites (wound fluid nitrates/NOx) have also been determined to accurately predict the wound healing trajectory of chronic wounds and may individually provide diagnostic information for wound healing to support the need for iNOS supplementation. In some embodiments, iNOS supplementation of the example wound would not only improve the protein
expression of iNOS but also the protein expression of VEGF and HIF-Ια, possibly promoting the necessary corrective influence of the angiogenesis signaling proteins to optimize wound recovery.
Altered regulation of inflammation in wound repair with diabetes is suggested to be a byproduct of dysfunction of the transcription factor nuclear factor-kappa B (NF-kB). During normal wound repair, local inflammation and immune responses are facilitated by tumor necrosis factor-a (TNF-a) regulated activation and upregulation of NF-kB-dependent gene expression for host defense proteins, cytokines, growth factors, proteases and inflammatory enzymes. Several important moderators of impaired wound healing are identified as target genes or byproducts of NFkB activation in the diabetic foot model. These include early phase NF-kB-dependent genes activated by TNF-a for metalloproteases MMP9 and MMP10, that are observed in higher concentrations in chronic diabetic wounds and the anti-apoptosis factor c-FLIP that has been demonstrated to significantly inhibit cellular apoptosis through TNF-a regulated NFkB activation. Additional NFkB-mediated processes associated with suppressive factors associated with DFU wound healing include the inhibition of insulin signaling through enhanced serine phosphorylation of IRS 1 and the upregulation of cytokine, chemokine and inflammatory factors from the senescence associated secretory phenotype (SASP) during the establishment of cellular senescence. In some embodiments, NFkB is a mediator of induced p53-directed programmed cell death/apoptosis by a RAF/MAPK pathway, bypassing TNF-a regulated NFkB activation, signaling the repression of p53-mediated cell death following NFkB inhibition. In some embodiments, the reduction of NFkB protein expression promotes improved recovery of wound healing, reduces dysregulated inflammatory cytokine and chemokine production (SASP), facilitates improved insulin pathway signaling, and/or modulate excessive p53-mediated cell death.
In some embodiments, the topical application (or other use) of a pharmaceutical combination of an acceptable NO (iNOS) donor with an acceptable inhibitor of NFkB protein expression can provide appropriate therapy for the correction of impaired healing of the example wound based on protein expression profiles provided from RPPA tissue analysis. In some embodiments, the WTD may provide clinical information useful in the selection of currently available therapies to improve wound healing as well as for the development of unique or novel pharmaceutical therapies for impaired DFU wound subjects who are evaluated by the use of RPPA tissue analysis.
Diabetic Wound Healing Research
The paradigm for wound healing is divided into four overlapping stages: hemostasis, inflammation, proliferation and remodeling. This process requires a complex coordination of key molecular, cellular and physiologic events by facilitative signaling between hematopoietic,
immunologic, and resident skin cells. Depending upon which diabetic wound healing models are evaluated, increased expression of the tumor suppressor transcription factor p53 and ischemia-induced apoptosis may result in senescence and the inhibition of signaling pathways driving inflammation or cell survival. Other proteins identified in healing models, like the hypoxia-inducible factor-1 (HIF-1) and HIF-1 a proteins (which modulate angiogenesis, cell proliferation, and wound healing, as well as cancer invasion/metastasis) may be altered in the diabetic environment, contributing to impaired wound healing.
RPPA
Understanding the pathogenesis of disease states has traditionally focused on the application of genomic techniques to assess alterations at the DNA level that ultimately results in altered gene expression, aberrations in intercellular location, or the production of proteins that harbor mutations affecting function. The regulation of protein expression and function can occur at many levels but ultimately the modulation of activity can be assessed by measuring the levels of activating or inhibiting posttranslational modifications across multiple proteins in the disease state. While the functional consequences of DNA alterations cannot be ascertained by measuring genomic events directly, an assessment of each protein's posttranslational modifications can provided valuable data that allows for the identification of activated signaling cascades that are aberrantly regulated and contributing to the disease state.
Gene expression arrays, which measure the cellular levels of mRNA are routine and informative for some of these alterations but from such arrays it is difficult to determine the actual level of protein expression, and are unable to detect the posttranslational modifications of proteins. The development of reliable proteomic characterizations that allow for multiple proteins and their posttranslational modifications can provide the necessary global
understanding of a disease state, allowing for the identification of therapeutic points of intervention or the development of diagnostic tests that can identify the best therapy for each molecularly unique sub-classification of a disease.
Proteomics is defined as the large-scale study of proteins, including their structure, function, and, for those in signal transduction pathways, their activation status. Comparative analyses are made difficult because the proteome differs from cell to cell, the patterns change dynamically over time, and there are many proteins that contain polymorphisms, splice variants, and different levels and types of posttranslational modifications. Attempts at the proteomic characterization of diseased tissues have for the most part relied on technologies that assess a single protein (immunohistochemistry, ELISA, Western Blot analysis, for example) and the newer technologies related to Mass Spectroscopy following an initial parsing based upon two-dimensional gel electrophoresis.
The Reverse Phase Protein micro- Array (RPPA) is a highly sensitive, high- throughput, functional proteomic technology that offers many of the advantages needed. It extends beyond the power of immunoblotting by providing a quantitative measure on the differential expression of total proteins and their activation, which is usually the phosphorylated species. Total proteins and their corresponding phosphoproteins, across multiple proteins that are involved in signaling cascades, can be assessed across multiple patient samples, simultaneously, providing a 'snap- shot' of the activation state/functionality of entire pathways. With RPPA, all samples are spotted at the same time, making this method ideally suited for the retrospective analysis of a large number of specimens, in a manner that is analogous to genomic-dot blots. Compared with a conventional Western blot, RPPA analysis uses 20,000 cells to generate quantitative data across multiple. From a lysate of 20,000 cells, multiple, identical nitrocellulose slides are printed and each slide is interrogated with a single highly specific antibody that recognizes either the total protein or a modified protein in the multiplexed samples (over 300 individual samples per array). Thus, samples prepared from 20,000 cells are sufficient to analyze many different protein targets. This enables the simultaneous analysis of a much larger number of proteins from each sample and makes this technique suitable for the analysis of cell populations present in low numbers. Although newer Western blot, signal detection reagents, such as SuperSignal West Femto (Pierce, Rockford, IL), have signal sensitivities comparable to RPPA, they cannot compete with the high-throughput nature or miniscule cell numbers and volume requirements achievable with RPPA. This broad assessment of protein modifications and the determination of a disease tissue's pathway signaling architecture have the potential to recognize meaningful protein and pathway interactions of known proteins, which can lead to the discovery of new protein interactions and the formation of novel signaling pathways.
In some aspects, the present disclosure is related to the area of wound healing in diabetes. In some embodiments, it is related to the novel use of RPPA proteomic analysis of chronic wound tissues from subjects with diabetes for the documentation of the prediction and mechanisms of healing using the ratios of selected sites of proteomic phosphorylation and cellular signaling from prepared chronic wound specimens.
In some aspects, impaired neuropathic-diabetic foot ulcer (DFU) wound healing may be predicted by determination of keratinocyte PI3K (phosphatidyl inositol -3- kinase)/IGF-lR
(insulin-like growth factor- 1 -receptor) proteomic ratios. In Example 1,. comparative, quantitative proteomic assessments of selected signaling pathways of marginal DFU
keratinocytes (n=19) and non-diabetic (control), plantar foot skin keratinocytes (n=3), were performed using reverse phase microarray (RPPA) and laser-capture microdissection (LCM)
technology. When compared with non- diabetic control subj ects, DFU wound keratinocyte signaling activity was significantly (p<0.05) elevated for: 1) the proinflammatory transcription factor, NF- kB; 2) the tumor suppressor transcription factor, P53; 3) the senescence biomarker, P16INK4a; 4) the cellular survival and growth transduction pathway proteins: PI3K, AKT (protein kinase B), β-catenin, glycogen synthase kinase-3 (GSK-3 ), and C- Met; and 5) the P53-directed apoptosis cleavage protein Caspase-3. During a 12- week post-debridement observation period all DFU subjects received standard of care wound treatment and wound off-loading. During this time three (n=3) of the nineteen DFU subjects (16 percent) demonstrated complete healing of the study ulcer.
Following study completion DFU study subject wound status (healed vs. un- healed) correlated with proteomic activity ratios for PI3K/IGF-1R ("P/I-ratio"). PI3K- AKT/mTOR (mammalian target of rapamycin) is the maj or signaling pathway activated by insulin and insulin-like growth factors- 1 and 2 (IGF-1 and IGF-2) through IGF-IR. IGF-IR stimulation activates AKT signaling transduction pathways leading to hypoxia-inducible factor-1 (HIF- 1) expression. Increased HIF-1 expression promotes cell proliferation/survival and is documented as a critical factor for diabetic wound healing. Conversely, phosphatase tensilon homolog (PTEN), a p53-directed PI3K antagonist documented with diabetes, inhibits AKT/mTOR signal pathway activation and induction of HIF-1 mediated gene expression. Our data documents P/I-ratio values (±SEM) of: 0.7 (±0.01) for control study subjects, 1.0 (±0.06) for healed-DFU study subj ects, and 1.3 (±0.03) for unhealed- DFU study subjects. Unpaired t-test analysis for healed and unhealed DFU group P/I-ratios and ANOVA analysis of all study group P/I-ratios documented significant mean differences. In some embodiments, a P/I-ratio provides a novel quantitative gauge of IGF-IR initiated AKT/mTOR signal transduction activity predictive for DFU healing and/or HIF-1 -mediated cellular processes. In some embodiments, increasing P/I- ratio values is inversely proportional to decreasing AKT/mTOR signal transduction activity associated with impaired DFU wound repair. In some embodiments, P53-directed dysfunctional regulation of IGF-IR, PI3K, and AKT/mTOR are important factors associated with impaired DFU wound healing.
In some aspects, the present disclosure provides a method for predicting whether or not a wound in a diabetic patient will heal, comprising the steps of:
A. measuring the levels of protein expression and/or activation in tissue excised from the wound (e.g., a leading edge), wherein one or more of the measured proteins are selected from the insulin signaling pathway or in the POKinase signaling pathway,
B. comparing the levels of the proteins in (A) to positive and/or negative reference standards to determine the level of expression and/or the level of activation of the one or more proteins,
C. determining the ratio of POKinase signaling activity to insulin signaling activity, wherein, a ratio level determined for PBKinase/Insulin signaling that is greater than 1 signifies that the wound will not heal and a ratio of 1 or less signifies that the wound will heal, and
D. providing a report of expression and/or activation levels of the proteins in (A), in which the levels are compared to the levels in a control population and a non-healing wound population, to physicians that characterizes whether a wound will heal or not.
In some aspects, the present disclosure also provides a method of treating a wound in a diabetic patient identified by the method described above as having a wound that will not heal, comprising the steps of:
A. administering to the patient a therapeutic agent that inhibits the PI3 Kinase signaling pathway, and/or
B. administering to the patient a therapeutic agent that increases signaling in the insulin signaling pathway.
In some embodiments, the antagonist is an antagonist of PBKinase complex, Akt, mTOR, 4E.BP1, Ribosomal Protein S6 Kinase, HIF-Ια, PTEN, POKinase, IGFRPB3, Src, GSK3 , β-catenin, or any protein that is a member of the insulin signaling or PBKinase signaling pathways of proteins, or any combination thereof.
In some embodiments, the agonist is an agonist of insulin, insulin-like growth factor 1 (IGF-1), IGF-2, PTEN, PBKinase, mTOR, 4E.BP1, Ribosomal Protein S6 Kinase, HIF-la, PTEN, IGFRPB3, Src, GSK3 , β-catenin, any protein that is a member of the insulin signaling or PBKinase signaling pathways of proteins, or any combination thereof.
In some aspects, disclosed herein are novel biomarkers of diabetic foot ulcer (DFU) wound healing identified by proteomic RPPA methodology used to quantify the level of signaling proteins and the activation states (e.g., phosphorylation sites) in the insulin signaling pathway (ISP), which is exemplified in a comparative clinical study of chronic DFU
keratinocytes and non-diabetic (control) plantar skin specimens (See Figure 1). Patterns of proteomic pathway and nodal analysis for this study were selected to investigate the following as factors correlating to wound outcomes in DFU study subjects: 1) Senescence- related pl6INK4a antagonism of NF-kB expression and apoptosis (Bak, Caspase-3, and Caspase-9); 2) Expression of insulin signaling pathway (ISP) nodes: IGF-1R, PI3K, GSK-3 , β-Catenin, AKT and mTOR; 3) NF-kB-regulated angiogenesis factors - TNF-a, NF-kB,
VEGF, NOS2 and COX2; and 3) Correlations of P53, NF-kB, P16INK4a and ISP nodal expression and signal transduction to DFU subject wound study outcomes (Figure 1). During the data analysis of the clinical study it was determined that the clinical status of DFU subject wound healing demonstrated a significant (p<0.05) correlation with the ratio of
phosphatidylinositol 3-kinase (PI3K) and insulin-like growth factor-1 receptor (IGF-1R) expression from wound keratinocytes (PI3K/IGF-1R). Using linear regression analysis a significant (p<0.05) correlation between P/I ratio values and mTOR expression was also demonstrated for the control and DFU study subject population. This suggests that P/I ratio values may contribute to the expression of mTOR, a downstream insulin-signaling pathway, influencing HIF-1 expression and, perhaps, patterns of wound repair signaling in DFU subjects.
This proteomic expression ratio determination may function as a quantitative measure of ISP signal transduction for AKT/mTOR pathways predictive for DFU wound healing and, perhaps, increased production of the hypoxia-inducible factor-1 (HIF-1) protein as part of the cellular injury response for wound keratinocytes (Figure 1). These expression ratio determinations obtained from wound keratinocytes have not previously been identified as candidate biomarkers for DFU wound-healing nor have they provided valuable personalized clinical information useful for the clinical evaluation and management of DFU subjects.
Briefly, following a cellular injury response within non-diabetic tissue IGF-1R mediates a cellular signaling response to PI3K where, in turn, phosphatidylinositol (3,4)- bisphosphate (PIP2) is converted to phosphatidylinositol (3,4,5)-trisphosphate (PIP3). At this point, once PIP3 activity is sufficient, activation of the AKT/mTOR pathways is initiated to downstream pathways and transcription factors. To engage the cellular injury response, critical levels of IGF-1/PI3K mediate signaling of the AKT/mTOR pathways for the increased expression of the hypoxia-inducible factor-1 (HIF-1) protein. The production of the HIF-1 protein activates the transcription of numerous genes for proteins required for normal wound healing processes such as angiogenesis, glucose metabolism, cell proliferation and survival (Figure 1).
Alternatively, in the cancer cell increased HIF-1 protein production stimulates tumor cell invasion and metastasis. It is suggested that the effect of growth factor (IGF-1) signaling initiation and increased ISP signal transduction (via AKT/mTOR) is an increase in the rate at which the HIF-1 protein is produced. This would suggest that below a threshold of ISP signal transduction, required by AKT/mTOR pathways, that HIF-1 protein production would be insufficient to elevate HIF-1 stimulated gene expression to the levels required for unimpaired wound healing to proceed or for effective promotion of the cellular injury response.
Impaired diabetes wound healing is associated with attenuation of HIF-1 production.
An important assumption is that attenuation of ISP signal transduction, decreased HIF-1 protein
production and diabetes-related impaired wound healing, is in great part related to the presence of P53-regulated genes inhibiting ISP signal propagation. Two of these genes, insulin-like growth factor binding protein-3 (IGFBP-3) and phosphatase and tensilon homolog (PTEN) function to decrease IGF-1R signal initiation and inhibit activation of AKT/mTOR pathways by decreasing pathway signal transduction, respectively. This is achieved by: 1) IGFBP-3 binding to the IGF- 1 ligand blocking its receptor initiation, and 2) by PTEN inhibition of PI3K-produced PIP required for signal transduction and activation of
AKT/mTOR and downstream signaling pathways. With increased P53-directed inhibition of the cellular injury response in diabetes AKT/mTOR cellular signal transduction following PTEN- mediated inhibition of PI3K is variably affected. This results in wound recovery and healing in a small fraction of DFU subjects (those with sufficient ISP signal transduction) and irreversible inhibition of recovery processes and complete healing failure in the remaining chronic wound subjects (those with insufficient ISP signal transduction).
In some aspects, in the non-diabetic environment, PI3K signaling routinely directs phosphorylation of PIP2->PIP3 where PIP3 is required for binding and signal initiation for the AKT/mTOR pathways. In some embodiments, increased PI3K expression that is documented by RPPA reflects the transmission of signal propagation from the growth factor receptor in transit to the AKT/mTOR pathway.
In some embodiments, with diabetes, and the presence of the P53-directed PI3K inhibitor PTEN, PIP3 produced at PI3K is diverted back to PIP2 preventing signal pathway transduction and adding this "recycled" PIP2 into position for re-phosphorylation by PI3K.
In some embodiments, with diabetes, an overall increased level of PIP2 phosphorylation and increased site activation for PI3K now reflects the presence of "inhibited" PIP3 redirected by
PTEN. Increased PI3K expression in diabetes, as documented in our clinical DFU study, now provided a quantitative gauge of the impact of PTEN inhibition on insulin signaling pathway transduction. In the DFU environment, increasing PTEN inhibition as related to the diversion of PIP3 signal initiation at PI3K was determined by comparison of DFU study subject
PI3K/IGF-1 ratio values with control samples. In the DFU study data PI3K/IGF-1 ratio values (±S.E.M.) were lowest for the study control subjects (n=3/0.7 ±0.01). [Control subject ratio values: 0.71 -0.73] DFU subj ects experiencing wound healing within 12- weeks were documented with ratio values that were statistically elevated as compared to control subj ects
(n=3/1.0 ±0.06). [Healed DFU subject ratio values: 0.9-1.1] The remaining DFU study subjects that did not experience wound healing were documented with ratio levels that were significantly higher that control subjects or the healed DFU subjects (n=16/l .3 ±0.03).
[Unhealed DFU subject ratio values: 1.1-1.6]. See Figure 2.
By quantifying cellular signaling relationships describing a correlation between DFU subjects that experience complete wound healing (healed DFU subjects) as compared to DFU subjects not experiencing complete wound healing (unhealed DFU subjects), the PI3K/IGF-1 ratio defines a "threshold" value for DFU healing based on ISP signal transduction. As illustrated in Figure 2, this threshold is defined by the change in correlation of ratio values to clinical wound status and is observed at the ratio value of 1.1. Control subjects and healed DFU subjects are identified with ratio values < 1.1 (range 0.7-1.1) while unhealed DFU subject are identified with ratio values > 1.1 (range 1.1-1.6). As the ratio determinations have been designed, subjects with values below the threshold should experience higher levels of ISP signal transduction at the AKT/mTOR pathway than those subjects with ratio values above the threshold. The identification of a "threshold" for healing for DFU subjects based on proteomic measures of ISP signal transduction is a significant clinical tool for the management of the DFU subject. This information may be clinically applied immediately and will provide for the design of novel platforms for research of the relationships between the ISP cellular injury responses, reparative processes of wound biology and HIF-1 -coordinated gene expressions supporting tissue repair.
The value afforded by the invention of the PI3K/IGF-1 ratio determination as a clinical tool for the evaluation and management of DFU subjects is meaningful and reflects a unique combination of significance and novelty that is underscored by the priority of its potential impact on the treatment of wound healing complications of diabetes.
Active Agents
In some aspects, the present disclosure provides for a pharmaceutical composition that comprises an antagonist and/or an antagonist of one or more proteins (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 proteins). In some embodiments, the pharmaceutical composition comprises an antagonist a first protein, an agonist of a second protein, or a combination thereof. For example, the first protein or the second protein are individually selected from the group consisting of: IGF-IR, PI3 Kinase, Akt, insulin, mTOR, HIF, PTEN, IGFRBP-3, c-MET, GSK-3 , COX-2, iNOS,
NFKB/p65, ΙκΒ-α, p53, pl6INK4a, β-Catenin, Bak, Caspase 3, Caspase 9, and any combination thereof.
In some embodiments, antagonists (e.g., of GSK-3beta) include Beryllium, Lithium,
Anilino maleimides (SB216763, SB415286), Arylpyrazolopyridazines (e.g., 6-aryl pyrazole
[3,4-b] pyridine 4), Bisindole maleimides (e.g., Ro 31-8220, GF 109203x), Indirubins (6- bromoindirubin-3'-oxime, aka BIO), Paullones (alsterpaullone), Psuedosubstrate peptide,
Dibromocantherelline, Meridianine A, CHIR908014, CHIR908023, CHIR908021, SB216763,
AR-A014418, Kenpaullone, Alsterpaullone, Cazpaullone, SB415286, TWS119, Aloisine A,
TDZD-8, NP00111, HMK-32, Manzamine A, Palinurin, Tricantin, L803-mts. Additional examples of antagnoists (e.g., of PI3K/AKT/mTOR) include Everolimus (Novartis),
Temsirolimus (Pfizer), BEZ235 (Novartis), GDC-0980 (Genentech), PF-05212384 (Pfizer), SAR245409 (XL-765; Sanofi/Exelixis), BAY80-6946 (Bayer), Buparlisib (BKM120; Novartis), Pictilisib (GDC-0941; Genentech), PX-866 (Oncothyreon), SAR245408 (XL- 147;
Sanofi/Exelixis), ZSTK474 (Zenyaku Kogyo), BYL719 (Novartis), GDC-0032 (Genentech), MLN01117 (INK1117; Intellikine), GSK2636771 (GSK), SAR260301 (Sanofi), Idelalisib (CAL-101; GS-1101 ; Gilead/Calistoga), AMG319 (Amgen), Perifosine (KRX-0401 ; Keryx), MK2206 (Merck), GDC-0068 (Genentech), GSK2110183 (GSK), GSK2141795 (GSK), ARQ 092 (ArQule/Daiichi Sankyo), AZD5363 (AstraZeneca), AZD2014 (AstraZeneca), MLN0128 (INK128; Intellikine), or CC-223 (Celgene). Additional antagonists (e.g., of β-catenin signaling) include PKF118-310, CGP049090, PKF115-584, PKF222-815, PKF118-744, ICGOOl,
CCT036477, XAV939, Acyl hydrazones, HQBA, Molecules with 2,3,6-trisubstituted pyrido[2,3,-b] pyrazine core skeletons, Carnosic acid, CCT031374, iCRT-3,5,14, NC043, Ibuprofin, or Aspirin. Additional antagonists (e.g., of p53) include Nutlins RG7112
(RO5045337), Benzodiazepinediones (TDP665759), Spiro-oxindoles (MI-219), RITA, JNJ- 26854165 (Serdemetan), Tenovin 1 and 6, SJ-172550, RO-2443/RO-5693, XI -Oi l, Re-activate mutant p53, CP-31398, PRIMA-1 (APR-246), MIRA-1, Phikan083, or NSC319726. Examples of agonists (e.g., of GSK-3beta) include Celecoxib, Staurosporine, Trichostatin A, Curcumin, AKt/protein kinase B signaling inhibitor-2(API-2), Wortmannin, LY294002, Rapamycin, Differentiation-inducing factors (DIFs), and Retinoids. Advexin may inhibit p53; a number of flavonoids are being evaluated for inhibiting GSK3B along with Tidoglusib and indirubin; there are several HDAC inhibitors (PCI-24781) which would inhibit NFkBp65 expression, and CX4945 which is an inhibitor of CK2 which would reduce NFkBp65.
Another approach may be to modulate the PTEN/Akt signaling by shifting p-PTEN to non-phosphorylated version by inhibiting the kinase or activating the phosphatase activity on PTEN. One embodiment increases p-AKT levels (at one or more sites of phosphorylation, i.e. SC79: a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation) or seek to increase signaling downstream of Akt, such as through the mTOR pathway (MHY1485: a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy) which is related to cell survival and may control senescence through p53.
Excipients/Carriers/ Additives
In some instances, a pharmaceutical composition disclosed herein comprises one or more excipients, carriers, or additives. Exemplary excipients, carriers, or additives can include
antioxidant agents, binders, coating materials, colorant agents, diluents, disintegrants, dispersants, emulsifying agents, flavoring agents, glidants, lubricants, pH modifying agents (e.g. , buffering agents), plasticizers, preservative agents, solubilizing agents, stabilizers or stabilizing agents, surfactants, sweetening agents, thickening agents, or pharmaceutically inert materials. In some instances, excipients can comprise nontoxic auxiliary substances.
Exemplary antioxidants can include flavonoids, anthocyanidins, anthocyanins, proanthocyanidins, or combinations thereof. In some instances, one or more antioxidants can be included in the liquid dosage form. In some instances, antioxidants help provide long term stability to liquid compositions, e.g. , at ambient conditions for at least about one month, at least about 3 months, at least about 24 months, or longer, depending on the type and concentration of antioxidant used and depending on other components of the storage microenvironment, such as pH, buffering agent, etc.
Exemplary binders include celluloses such as hydroxypropylcellulose, methylcellulose, and hydroxypropyl methylcellulose; starches such as com starch, pregelatinized starch, and hydroxpropyl starch; sugars such as glucose, dextrose, sucrose, lactose and sorbitol; alcohols such as polyvinyl alcohol and polyethylene glycol; waxes and natural and synthetic gums such as acacia, tragacanth, sodium alginate; synthetic polymers such as polymethacrylates and polyvinylpyrrolidone; and povidone, dextrin, pullulane, agar, gelatin, tragacanth, macrogol, or combinations thereof. Binders can impact cohesive qualities to a tablet formulation, or a particle formulation in a capsule. Tablets can remain intact after compression by including a binder in the pharmaceutical composition.
Exemplary coating materials include hydroxypropyl methyl cellulose 2910, aminoalkyl methacrylate copolymer E, polyvinylacetal diethylaminoacetate, macrogol 6000, titanium oxide, or combinations thereof. Exemplary plasticizers include triethyl citrate, triacetin, macrogol 6000, or combinations thereof.
Exemplary colorant agents include one or more synthetic organic food additives (e.g. , food dyes such as food red dye Nos. 2 and 3, food yellow dye Nos. 4 and 5 and food blue dye Nos. 1 and 2), water-insoluble lake dyes (e.g. , aluminum salts of the above synthetic organic food additives, etc.), natural pigments (e.g. , beta-carotene, chlorophyll, iron oxide red, etc.), or combinations thereof. Other suitable colorant agents can include D&C Red No. 33, FD&C Red No. 3, FD&C Red No. 40, D&C Yellow No. 10, and C Yellow No. 6, or any combination of these or the above colorants. A colorant agent, when included in the liquid dosage form, can be provided in an amount sufficient to provide the pharmaceutical compositions with a more aesthetic and/or distinctive appearance.
Exemplary diluents include cellulose and cellulose derivatives such as microcrystalline cellulose; starches such as dry starch, hydrolyzed starch, and starch derivatives such as corn starch; cyclodextrin; sugars such as powdered sugar and sugar alcohols such as lactose; D- mannitol; inorganic diluents such as aluminum hydroxide gel, precipitated calcium carbonate, carbonate, magnesium aluminometasilicate, dibasic calcium phosphate; and sodium chloride, silicon dioxide, titanium dioxide, titanium oxide, dicalcium phosphate dihydrate, calcium sulfate, alumina, kaolin, talc, or combinations thereof. Diluents, also terms "fillers", can increase the bulk of a tablet so that a practical size is provided for compression.
Exemplary disintegrants include starches, alginic acid, crosslinked polymers such as, e.g. , crosslinked polyvinylpyrrolidone, croscarmellose sodium, potassium or sodium starch glycolate, clays, celluloses, starches, gums, or combinations thereof. Disintegrants can facilitate tablet disintegration after administration, or following contact with dissolution fluid, or as measured in an in vitro dissolution study.
Exemplary emulsifying agents include gelatin, egg yolk, casein, cholesterol, acacia, tragacanth, chondrus, pectin, methyl cellulose, carbomer, cetostearyl alcohol, cetyl alcohol, or combinations thereof. Emulsifying agents can be included in the liquid dosage form in an amount sufficient to facilitate more uniform dispersion of one or more active ingredients or other pharmaceutically acceptable excipient that is not generally soluble in the liquid.
Exemplary glidants include silicon dioxide, talc, dried aluminum hydroxide gel, magnesium silicate, or combinations thereof. Exemplary lubricants include magnesium stearate, calcium stearate, stearic acid, glyceryl behenate, polyethylene glycol, talc, or combinations thereof. Lubricants can also facilitate tablet manufacture.
Exemplary buffering agents include gluconate, lactate, citrate, acetate, phosphate, benzoate, carbonate salts, or combinations thereof. The buffering agent can be present in an amount sufficient to buffer the pH of the solution and minimize degradation of the active ingredients. Some buffering agents can also modulate active ingredient solubility in the liquid dosage form. The pH can be adjusted with a combination of two or more of these buffering agents, e.g. citric acid and sodium benzoate. The buffering agent can be present as a buffer solution. In some instances, the buffering agent can include a phosphate, such as a potassium phosphate or sodium phosphate, or any combination thereof.
Exemplary preservative agents include sodium benzoate, paraoxybenzoic acid esters, methyl, ethyl, butyl, and propyl parabens, chlorobutanol, benzyl alcohol, phenylethylalcohol, dehydroacetic acid, sorbic acid, benzalkonium chloride (BKC), benzethonium chloride, phenol, phenylmercuric nitrate, thimerosal, or combinations thereof. Preservative agents can
be included in the liquid dosage form. The preservative agents can be in an amount sufficient to extend the shelf-life or storage stability, or both, of the liquid dosage form.
Exemplary solubilizing agents include an alcohol, e.g. , 95% ethyl alcohol, a glycol, glycerin, D-mannitol, trehalose, benzyl benzoate, trisaminomethane, cholesterol,
triethanolamine, sodium carbonate, sodium citrate, sodium salicylate, sodium acetate, or combinations thereof. Exemplary alcohols can include ethanol, isopropanol, t-butanol, phenol, cresol, a benzyl alcohol, or any combination thereof. Exemplary glycols include C2-20 alkenes functionalized with a glycol, including propylene glycol, polypropylene glycol, polyethylene glycol, etc., or any combination thereof. Solubilizing agents can be included in the liquid dosage form, e.g. , in an amount sufficient to facilitate greater or more rapid dissolution of one or more active ingredients or other excipients. A solubilizing agent can be included in an amount of about 1 volume percent to 20 volume percent (v/v), or about 4 volume percent to 15 volume percent (v/v), based on the total volume of the solution.
Exemplary amounts of solubilizing agent include about 7 volume percent to 12 volume percent (v/v) based on the total volume of the solution.
Exemplary stabilizing agents include one or more liquid excipients such as ethanol or glycerin; one or more glycols, such as polyethylene glycol, e.g. , PEG-400, propylene glycol, or polypropylene glycol; a cellulose-based component, such as hydroxypropyl
methylcellulose (HPMC) or hydroxymethylcellulose (HMC); or combinations thereof.
Stabilizers can inhibit or retard drug decompositions reactions including oxidative reactions. A stabilizing agent can include any suitable monohydroxy phenol component or polyhydroxy phenol component, or any combination thereof. Such stabilizing agents can also function as antioxidant agents, or antimicrobial agents. Stabilizing agent(s) can be included in the liquid dosage form. Thus, it should be understood that certain solubilizing agents can function effectively as a stabilizing agent. For example, propylene glycol can function as both a solubilizing agent and as a stabilizing agent.
Exemplary surfactants include sucrose esters of fatty acids, polyoxyl stearate, polyoxyethylene hydrogenated castor oil, polyoxyethylene polyoxypropylene glycol, sorbitan sesquioleate, sorbitan trioleate, sorbitan monostearate, sorbitan monopalmitate, sorbitan monolaurate, polysorbate, glyceryl monostearate, sodium lauryl sulfate, lauromacrogol, or combinations thereof. Surfactants can also be anionic, cationic, amphoteric, or nonionic.
Exemplary sweetening agents include sorbitol, saccharin, acesulfame, e.g. , acesulfame potassium, sucralose, xylitol, maltitol, sucrose, aspartame, fructose, neotame, glycerin, sodium saccharate, glycyrrhizin dipotassium, acesulfame K, mannitol, invert sugar, or combinations thereof. In some instances, a sweetening agent, such as one or more sucralose-containing
components or saccharin-containing components, can be added to the pharmaceutical composition to modify the taste of the pharmaceutical composition. In some instances, a viscous sweetener such as one or more of a sorbitol solution, a syrup (sucrose solution), or high-fructose corn syrup can increase viscosity and retard sedimentation. In some instances, the sweetening agent can include an acesulfame-containing, sucralose-containing, or saccharin- containing component. The sweetening agent can include glycerin, saccharin, liquid sugar (sucrose solution), or any combination thereof. In some instances, a sweetening agent can be present in an amount sufficient to minimize or mask any off-flavors in the taste of the active agents (e.g. , opioid analgesic, non-opioid analgesic, antiemetic, laxative, barbiturate, etc), and also to minimize or mask any other off-flavor components included in the pharmaceutical composition.
In some instances, a sweetening agent is present in an amount of about 0.1 volume percent to 85 volume percent (v/v), based on the total volume of the solution. In one example, the sweetening agent is present in an amount of about 5 volume percent to 70 volume percent (v/v), based on the total volume of the solution. Exemplary amounts of glycerin can include about 2 volume percent to 18 volume percent (v/v), or about 5 volume percent to 10 volume percent (v/v). Exemplary amounts of liquid sugar can include about 40 volume percent to 75 volume percent (v/v), or about 60 volume percent to 70 volume percent (v/v), based on the total volume of the solution. Certain types of thickening agent or sweetening agent can also act as a solubilizing agent or a stabilizing agent, or both, or have other properties, when included as a component of a pharmaceutically acceptable carrier. For example, a sweetening agent such as glycerin can also act as a thickening agent. An oral liquid dosage form can also contain, in addition to a sweetening agent, a flavoring agent, for example, one or more of natural and artificial fruit, artificial banana, strawberry, and pineapple.
Exemplary thickening agents include acacia, alginic acid bentonite, carbomer, carboxymethylcellulose calcium or sodium, cetostearyl alcohol, methyl cellulose, ethylcellulose, glycerin, gelatin guar gum, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose ("HPMC"), any other suitable cellulose-based component, maltodextrin, polyvinyl alcohol, povidone, propylene carbonate, propylene glycol alginate, sodium alginate, sodium starch glycolate, starch tragacanth, and xanthan gum, or combinations thereof. A thickening agent or viscosity-enhancing agent can improve the mouth- feel of the liquid oral dosage form and/or to help coat the lining of the gastrointestinal tract.
In some instances, a thickening agent is present in an amount of about 0.1 volume percent to 20 volume percent (v/v), based on the total volume of the solution. In one example, glycerin can be present in an amount of about 1 volume percent to 10 volume percent (v/v), based on the
total volume of the solution. Exemplary amounts of thickening agent can include from about 1 volume percent to 12 volume percent (v/v), or at an amount of about 4 volume percent to 10 volume percent (v/v), based on the total volume of the solution. An exemplary amount can include about 6 to 10 volume percent (v/v).
In some instances, an excipient includes cellulose ethers such as hydroxypropyl methylcellulose (e.g., Methocel K4M) or silicified microcrystalline cellulose; polyvinylacetate- based excipients such as, e.g. , Kollidon SR, and polymers and copolymers based on
methacrylates and methacrylic acid such as, e.g. , Eudragit NE 30D; microcrystalline cellulose, sodium carboxymethyl cellulose, sodium starch glycolate, com starch, colloidal silica, sodium laurel sulphate, magnesium stearate, Prosolve SMCC (HD90), croscarmellose sodium,
Crospovidone NF, Avicel PH200 or combinations thereof.
In some instances, an excipient includes acesulfame potassium, glacial acetic acid, acetone, acetyltributyl citrate, acetyltriethyl citrate, adipic acid, albumin, aliphatic polyester, alitame, almond oil, alpha tocopherol, aluminum monostearate, aluminum oxide, aluminum phosphate adjuvant, ammonia, ammonium alginate, ammonium chloride, anthocyanidin, anthocyanin, ascorbic acid, ascorbyl palmitate, aspartame, attapulgite, bentonite, benzalkonium chloride, benzethonium chloride, benzoic acid, benzyl alcohol, benzyl benzoate, boric acid, bronopol, butylated hydroxyanisole, butylated hydroxytoluene, butylene glycol, butylparaben, calcium acetate, calcium alginate, calcium chloride, calcium hydroxide, calcium lactate, calcium phosphate (tribasic), calcium silicate, canola oil, carbomer, carbon dioxide,
carboxymethylcellulose calcium, carboxymethylcellulose sodium, carrageenan, casein, castor oil, podere cellulose, cellulose acetate, cellulose acetate phthalate, ceratonia, ceresin, cetostearyl alcohol, cetrimide, cetyl alcohol, cetylpyridinium chloride, chitosan, chlorhexidine,
chlorobutanol, chlorocresol, chlorodifluoroethane, chlorofluorocarbon, chloroxylenol, cholesterol, chondrus, citric acid monohydrate, coconut oil, copovidone, com oil, cottonseed oil, cresol, cyclomethicone, denatonium benzoate, dextrate, dibutyl phthalate, dibutyl sebacate, diethanolamine, diethyl phthalate, difluoroethane, dimethicone, dimethyl ether, dimethyl phthalate, dimethyl sulfoxide, dimethylacetamide, disodium edetate, docusate sodium, edetic acid, egg yolk, erythorbic acid, erythritol, ethyl acetate, ethyl lactate, ethyl maltol, ethyl oleate, ethyl vanillin, ethylene glycol stearate, ethylene vinyl acetate, ethylparaben, flavonoid, fructose, fumaric acid, glycerin, glyceryl monooleate, glyceryl palmitostearate, glycine, glycofurol, guar gum, hectorite, heptafluoropropane, hexetidine, hydrocarbon, hydrochloric acid, hydrophobic colloidal silica, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl betadex, hydroxpropyl starch, hypromellose acetate succinate, imidurea, inulin, iron oxide, isomalt, isopropyl alcohol, isopropyl myristate, isopropyl palmitate, lactic acid, lactitol, lanolin, lanolin
(hydrous), lanolin alcohol, lauric acid, lecithin, leucine, linoleic acid, magnesium aluminum silicate, magnesium carbonate, magnesium oxide, magnesium trisilicate, maleic acid, malic acid, maltitol, maltitol solution, maltodextrin, maltol, maltose, medium-chain triglyceride, meglumine, menthol, methionine, methylparaben, mineral oil, lanolin alcohol, monoethanolamine, monosodium glutamate, monothioglycerol, myristic acid, myristyl alcohol, neohesperidin dihydrochalcone, neotame, nitrogen, nitrous oxide, octyldodecanol, oleic acid, oleyl alcohol, olive oil, palmitic acid, paraffin, peanut oil, pectin, pentetic acid, petrolatum, petrolatum alcohol, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric acetate, phenylmercuric borate, phenylmercuric nitrate, phospholipid, phosphoric acid, polacrilin potassium, poloxamer, polycarbophil, polydextrose, poly (dl-lactic acid), polyethylene oxide, poly(methyl
vinylether/maleic anhydride), polyoxyethylene alkyl ether, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene stearate, polyoxylglyceride, polyvinyl acetate phthalate, potassium alginate, potassium alum, potassium benzoate, potassium bicarbonate, potassium chloride, potassium citrate, potassium hydroxide, potassium metabisulfite, potassium sorbate,
proanthocyanidin, propionic acid, propyl gallate, propylene carbonate, propylene glycol, propylene glycol alginate, propylparaben, propylparaben sodium, pyrrolidone, raffinose, saccharin, saccharin sodium, safflower oil, saponite, sesame oil, shellac, simethicone, sodium acetate, sodium ascorbate, sodium benzoate, sodium bicarbonate, sodium borate, sodium carbonate, sodium citrate dihydrate, sodium cyclamate, sodium formaldehyde sulfoxylate, sodium hyaluronate, sodium lactate, sodium metabisulfite, sodium phosphate (dibasic), sodium phosphate (monobasic), sodium propionate, sodium sulfite, sodium thiosulfate, sorbic acid, sorbitan fatty acid ester, soybean oil, stearyl alcohol, sucralose, sucrose octaacetate,
sulfobutylether b-cyclodextrin, sulfur dioxide, sulfuric acid, sunflower oil, suppository bases
(hard fat), tagatose, tartaric acid, tetrafluoroethane, thaumatin, thimerosal, thymol, trehalose, tributyl citrate, tricaprylin, triethanolamine, triolein, vanillin, hydrogenated vegetable oil, vitamin e polyethylene glycol succinate, water, wax (anionic emulsifying), wax (cetyl esters), wax
(microcristalline), wax (nonionic emulsifying), wax (white), wax (yellow), xanthan gum, xylitol, zein, zinc acetate, zinc stearate, food red dye No. 2, food red dye No. 3, food yellow dye No. 4, food yellow dye No. 5, food blue dye No. 1, food blue dye No. 2, beta-carotene, chlorophyll, iron oxide red, titanium dioxide, gluconate, lactate, paraoxybenzoic acid ester,
phenylethylalcohol, dehydroacetic acid, ethyl alcohol, trisaminomethane, sodium salicylate, ethanol, isopropanol, t-butanol, polypropylene glycol, hydroxymethylcellulose, acesulfame, sodium saccharate, glycyrrhizin dipotassium, acesulfame K, or ethylcellulose.
Examples of excipients include acacia, acesulfame potassium, acetic acid (glacial), acetone, acetyltributyl citrate, acetyltriethyl citrate, adipic acid, agar, albumin, alcohol, alginic
acid, aliphatic polyesters, alitame, almond oil, alpha tocopherol, aluminum hydroxide adjuvant, aluminum monostearate, aluminum oxide, aluminum phosphate adjuvant, ammonia solution, ammonium alginate, ammonium chloride, ascorbic acid, ascorbyl palmitate, aspartame, attapulgite, bentonite, benzalkonium chloride, benzethonium chloride, benzoic acid, benzyl alcohol, benzyl benzoate, boric acid, bronopol, butylated hydroxyanisole, butylated
hydroxytoluene, butylene glycol, butylparaben, calcium acetate, calcium alginate, calcium carbonate, calcium chloride, calcium hydroxide, calcium lactate, calcium phosphate (dibasic anhydrous), calcium phosphate (dibasic dihydrate), calcium phosphate (tribasic), calcium silicate, calcium stearate, calcium sulfate, canola oil, carbomer, carbon dioxide, carboxymethylcellulose calcium, carboxymethylcellulose sodium, carrageenan, castor oil, castor oil (hydrogenated), cellulose (microcristalline), cellulose (microcrystalline and carboxymethylcellulose sodium), cellulose (podere), cellulose (silicified microcristalline), cellulose acetate, cellulose acetate phthalate, ceratonia, ceresin, cetostearyl alcohol, cetrimide, cetyl alcohol, cetylpyridinium chloride, chitosan, chlorhexidine, chlorobutanol, chlorocresol, chlorodifluoroethane (HCFC), chlorofluorocarbons (CFC), chloroxylenol, cholesterol, citric acid monohydrate, coconut oil, colloidal silicon dioxide, colorant agents, copovidone, corn oil, com starch and pregelatinized starch, cottonseed oil, cresol, croscarmellose sodium (AC-Di-Sol), crospovidone, cyclodextrins, cyclomethicone, denatonium benzoate, dextrates, dextrin, dextrose, dibutyl phthalate, dibutyl sebacate, diethanolamine, diethyl phthalate, difluoroethane (HFC), dimethicone, dimethyl ether, dimethyl phthalate, dimethyl sulfoxide, dimethylacetamide, disodium edetate, docusate sodium, edetic acid, erythorbic acid, erythritol, ethyl acetate, ethyl lactate, ethyl maltol, ethyl oleate, ethyl vanillin, ethylcellulose, ethylene glycol stearates, ethylene vinyl acetate, ethylparaben, fructose, fumaric acid, gelatin, glucose (liquid), glycerin, glyceryl behenate, glyceryl monooleate, glyceryl monostearate, glyceryl palmitostearate, glycine, glycofurol, guar gum, hectorite,
heptafluoropropane (HFC), hexetidine, hydrocarbons (HC), hydrochloric acid, hydrophobic colloidal silica, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl betadex, hydroxypropyl cellulose, hydroxypropyl cellulose (low-substituted), hydroxypropyl starch, hypromellose, hypromellose acetate succinate, hypromellose phthalate, imidurea, inulin, iron oxides, isomalt, isopropyl alcohol, isopropyl myristate, isopropyl palmitate, kaolin, lactic acid, lactitol, lactose (anhydrous), lactose (inhalation), lactose (monohydrate), lactose (monohydrate and corn starch), lactose (monohydrate and microcrystalline cellulose), lactose (monohydrate and povidone), lactose (monohydrate and powdered cellulose), lactose (spray-dried), lanolin, lanolin (hydrous), lanolin alcohols, lauric acid, lecithin, leucine, linoleic acid, macrogol 15 hydroxystearate, magnesium aluminum silicate, magnesium carbonate, magnesium oxide, magnesium silicate, magnesium stearate, magnesium trisilicate, maleic acid, malic acid, maltitol,
maltitol solution, maltodextrin, maltol, maltose, mannitol, medium-chain triglycerides, meglumine, menthol, methionine, methylcellulose, methylparaben, mineral oil, mineral oil (light), mineral oil and lanolin alcohols, monoethanolamine, monosodium glutamate,
monothioglycerol, myristic acid, myristyl alcohol, neohesperidin dihydrochalcone, neotame, nitrogen, nitrous oxide, octyldodecanol, oleic acid, oleyl alcohol, olive oil, palmitic acid, paraffin, peanut oil, pectin, pentetic acid, petrolatum, petrolatum and lanolin alcohols, phenol,
phenoxyethanol, phenylethyl alcohol, phenylmercuric acetate, phenylmercuric borate, phenylmercuric nitrate, phospholipids, phosphoric acid, polacrilin potassium, poloxamer, polycarbophil, polydextrose, poly (dl-lactic acid), polyethylene glycol, polyethylene oxide, polymethacrylates, poly(methyl vinylether/maleic anhydride), polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters,
polyoxyethylene stearates, polyoxylglycerides, polyvinyl acetate phthalate, polyvinyl alcohol, potassium alginate, potassium alum, potassium benzoate, potassium bicarbonate, potassium chloride, potassium citrate, potassium hydroxide, potassium metabi sulfite, potassium sorbate, povidone, propionic acid, propyl gallate, propylene carbonate, propylene glycol, propylene glycol alginate, propylparaben, propylparaben sodium, pyrrolidone, raffinose, saccharin, saccharin sodium, safflower oil, saponite, sesame oil, shellac, simethicone, sodium acetate, sodium alginate, sodium ascorbate, sodium benzoate, sodium bicarbonate, sodium borate, sodium carbonate, sodium chloride, sodium citrate dihydrate, sodium cyclamate, sodium formaldehyde sulfoxylate, sodium hyaluronate, sodium hydroxide, sodium lactate, sodium lauryl sulfate, sodium metabisulfite, sodium phosphate - dibasic, sodium phosphate (monobasic), sodium propionate, sodium starch glycolate, sodium stearyl fumarate, sodium sulfite, sodium thiosulfate, sorbic acid, sorbitan esters (sorbitan fatty acid esters), sorbitol, soybean oil, starch, starch (pregelatinized), starch (sterilizable maize), stearic acid, stearyl alcohol, sucralose, sucrose, sucrose octaacetate, sugar (compressibile), sugar (confectioner's), sugar spheres, sulfobutylether b-cyclodextrin, sulfur dioxide, sulfuric acid, sunflower oil, suppository bases (hard fat), tagatose, talc, tartaric acid, tetrafluoroethane (HFC), thaumatin, thimerosal, thymol, titanium dioxide, tragacanth, trehalose, triacetin, tributyl citrate, tricaprylin, triethanolamine, triethyl citrate, triolein, vanillin, vegetable oil (hydrogenated), vitamin e polyethylene glycol succinate, water, wax (anionic emulsifying), wax (camauba), wax (cetyl esters), wax (microcristalline), wax (nonionic emulsifying), wax (white), wax (yellow), xanthan gum, xylitol, zein, zinc acetate, zinc stearate, or combinations thereof. Furthermore, dosage forms herein can comprise acceptable carriers or salts known in the art, such as those described in the Handbook of Pharmaceutical Excipients, American Pharmaceutical Association (1986), incorporated by reference herein in its entirety.
Salts
In some instances, a pharmaceutical composition disclosed herein comprises a
pharmaceutically active agent that can be in the form of its free base, its pharmaceutically acceptable salt, prodrug, analog, or complex. Exemplary pharmaceutically acceptable salts include metal salts, such as sodium salts, potassium salts, lithium salts; alkaline earth metals, such as calcium salts, magnesium salts; organic amine salts, such as triethylamine salts, pyridine salts, picoline salts, ethanolamine salts, triethanolamine salts, dicyclohexylamine salts, Ν,Ν'-dibenzylethylenediamine salts; inorganic acid salts such as hydrochloride salts, hydrobromide salts, sulfate salts, phosphate salts; organic acid salts such as formate salts, acetate salts, trifluoroacetate salts, maleate salts, tartrate salts; sulfonate salts such as methanesulfonate salts, benzenesulfonate salts, p-toluenesulfonate salts; and amino acid salts, such as arginate salts, asparginate salts, glutamate salts, or combinations thereof.
In some instances, a pharmaceutically acceptable salt includes bitartrate, bitartrate hydrate, hydrochloride, p-toluenesulfonate, phosphate, sulfate, trifluoroacetate, bitartrato hemipentahydrate, pentafluoropropionate, hydrobromide, mucate, oleate, phosphate dibasic, phosphate monobasic, acetate trihydrate, bis(heptafuorobutyrate), bis(pentafluoropropionate), bis(pyridine carboxylate), bis(trifluoroacetate), chlorhydrate, sulfate pentahydrate, or combinations thereof. In some instances, exemplary pharmaceutically acceptable salts include, e.g. , water-soluble and water-insoluble salts, such as the acetate, amsonate(4,4- diaminostilbene-2,2-disulfonate), benzenesulfonate, benzonate, bicarbonate, bisulfate, bitartrate, borate, butyrate, calcium edetate, camphorsulfonate, camsylate, carbonate, citrate, clavulariate, dihydrochloride, edetate, edisylate, estolate, esylate, flunarate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexafluorophosphate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, 3-hydroxy-2- naphthoate, oleate, oxalate, palmitate, pamoate (l, l-methene-bis-2-hydroxy-3-naphthoate, einbonate), pantothenate, phosphate/di phosphate, picrate, polygalacturonate, propionate, p- toluenesulfonate, salicylate, stearate, subacetate, succinate, sulfate, or combinations thereof. In some instances, a pharmaceutically acceptable salt includes bitartrate, bitartrate hydrate, hydrochloride, p-toluenesulfonate, phosphate, sulfate, trifluoroacetate or bitartrato
hemipentahydrate.
Administration
In some instances, a pharmaceutical composition disclosed herein is administered to a subject in need thereof at about every 4 to about 8 hours. In some instances, a pharmaceutical composition disclosed herein is administered to a subject in need thereof at about every 4 to about 6 hours as needed. In some instances, a pharmaceutical composition disclosed herein is administered to a subject in need thereof at about every 4 to about 8 hours. In some instances, a pharmaceutical composition disclosed herein is administered to a subject in need thereof at about every 6 to about 8 hours as needed. In some instances, a pharmaceutical composition disclosed herein is administered to a subject in need thereof at about every 4 hours, about every 5 hours, about every 6 hours, about every 7 hours, or about every 8 hours. In some instances, a pharmaceutical composition disclosed herein is administered once daily. In some instances, a pharmaceutical composition disclosed herein is administered not more than 2-6 times daily. In another instance, a pharmaceutical composition disclosed herein is administered not more than 4 times daily. In another instance, a pharmaceutical composition disclosed herein is administered 1, 2, 3, 4, 5, 6, 7, or 8 times daily.
In some instances, active agents disclosed herein are formulated to be administered through oral dosage forms (e.g. , tablets, capsules, gels, lollipops), inhalations, nasal sprays, patches, absorbing gels, liquids, liquid tannates, suppositories, injections, I.V. drips, other delivery methods, or any combination thereof to treat subjects in need thereof. Administration can be performed in a variety of ways, including, but not limited to orally, subcutaneously, intravenously, intranasally, intraoptically, trans dermally, topically (e.g. , gels, salves, lotions, creams, etc.), intraperitoneally, intramuscularly, intrapulmonary (e.g. , AERx.RTM. inhalable technology commercially available from Aradigm, or Inhance, pulmonary delivery system commercially available from Inhale Therapeutics), vaginally, parenterally, rectally, or intraocularly.
To prepare a pharmaceutical composition disclosed herein, an effective amount of active agents can be mixed with a suitable pharmaceutically acceptable carrier. Upon mixing of the compounds, the resulting pharmaceutical composition can be a solid, a half-solid, a semi-solid, a solution, suspension, or an emulsion. Such pharmaceutical compositions can be prepared according to methods known to those skilled in the art. The forms of the resulting pharmaceutical compositions can depend upon a variety of factors, including the intended mode of administration and the solubility of the compounds in the selected carrier or vehicle.
The effective concentration of analgesics is sufficient for lessening or alleviating pain. In some instances, the components of the present pharmaceutical compositions are at least one opioid analgesic agent (e.g. , hydrocodone/oxycodone), one non-opioid analgesic agent (e.g. , acetaminophen), and one antiemetic agent (e.g. , promethazine). In other instances,
administration comprises administration of an antiemetic (e.g. , promethazine) separately, prior to, or during administration of the analgesic formulations described herein (e.g. , which comprises hydrocodone and acetaminophen). In another instance, the components of the present pharmaceutical compositions are at least one opioid analgesic agent, a non-opioid analgesic agent, an agent that reduces side effects of the opioid analgesic agent and a stimulant agent. In another instance, the components of the present pharmaceutical compositions are at least one opioid analgesic agent, a non-opioid analgesic agent, a barbiturate agent, an agent that reduces side effects of the opioid analgesic agent and a stimulant agent. In another instance, the components of the present pharmaceutical compositions are at least one opioid analgesic agent, a non-opioid analgesic agent, a barbiturate agent, an agent that reduces side effects of the opioid analgesic agent. In another instance, the components of the present pharmaceutical compositions are at least one opioid analgesic agent, a barbiturate agent, an agent that reduces side effects of the opioid analgesic agent and a stimulant agent. In another instance, the components of the present
pharmaceutical compositions are at least one opioid analgesic agent, a barbiturate agent, an agent that reduces side effects of the opioid analgesic agent. In another instance, the components of the present pharmaceutical compositions are at least one non-opioid analgesic agent, a barbiturate agent, an agent that reduces side effects of the opioid analgesic agent and a stimulant agent. In another instance, the components of the present pharmaceutical compositions are at least one non-opioid analgesic agent, a barbiturate agent, an agent that reduces side effects of the opioid analgesic agent. In another instance, components of the present pharmaceutical compositions are at least one opioid analgesic agent, an agent that reduces side effects of the opioid analgesic agent and a stimulant agent. In another instance, components of the present pharmaceutical compositions are at least one opioid analgesic agent, an agent that reduces side effects of the opioid analgesic agent.
In some instances, an agent described herein is administered by the nasal inhalation route using conventional nebulizers or by oxygen aerosolization to provide convenient pain relief with reduced adverse effects. The agents can be suspended or dissolved in a pharmacologically acceptable inhalation carrier. Examples of such carriers are distilled water, water/ethanol mixtures, and physiological saline solution. Conventional additives including sodium chloride, glucose, citric acid and the like can be employed in these dosage forms to stabilize or to provide isotonic media. In some instances, the pharmaceutical compositions suitable for nasal inhalation by oxygen aerosolization administration comprise hydrocodone or oxycodone, acetaminophen, and promethazine. In another instance, the pharmaceutical compositions suitable for nasal inhalation by oxygen aerosolization administration comprise hydrocodone or oxycodone, and
promethazine. In other instances, an antiemetic (e.g. , promethazine) can be administered separately, prior to, or during administration of the pharmaceutical compositions described herein (e.g. , those comprising hydrocodone and acetaminophen).
In some instances, an agent described herein can also be administered as a self- propelled dosage unit in an aerosol form suitable for inhalation therapy. Suitable means for employing the aerosol inhalation therapy technique are described, for example, in U. S. Pat. No. 6,913,768 to Couch et al., a reference which is incorporated herein by reference in its entirety. The agent can be suspended in an inert propellant such as a mixture of
dichlorodifluoromethane and dichlorotetrafluoroethane, together with a co-solvent such as ethanol, together with flavoring materials and stabilizers. In some instances, the agents useful for a self-propelled dosage unit in aerosol form administration are hydrocodone or oxycodone, acetaminophen, and promethazine. In another instance, the agents useful for a self-propelled dosage unit in aerosol form administration are hydrocodone or oxycodone, and promethazine. In a further instance, the dosage unit can further comprise an agent such as a bronchodilator (e.g. , albuterol).
In some instances, an agent described herein can also be administered as nasal spray/drop pharmaceutical compositions, which can conveniently and safely be applied to subjects in need thereof to effectively treat pain with reduced adverse effects. The
pharmaceutical compositions can further comprise a water soluble polymer such as
polyvinylpyrrolidone, together with other medications and together with bioadhesive material. In some instances, the components of a pharmaceutical composition for nasal spray or drop administration are hydrocodone or oxycodone agent, acetaminophen, and promethazine, or a pharmaceutically acceptable salt of any one of the foregoing, or any combination thereof. In another instance, the components of a pharmaceutical composition for nasal spray or drop administration are hydrocodone or oxycodone agent, and promethazine, or a pharmaceutically acceptable salt of any one of the foregoing, or any combination thereof.
In some instances, a pharmaceutical composition described herein can also be administered topically to the skin of a subject in need thereof. The agents can be mixed with a pharmaceutically acceptable carrier or a base which is suitable for topical application to skin to form a dermatological pharmaceutical composition. Suitable examples of carriers or bases include but not limited to: water, glycols, alcohols, lotions, creams, gels, emulsions, and sprays. A dermatological pharmaceutical composition comprising an analgesic agent can be integrated into a topical dressing, medicated tape, dermal patch absorbing gel and cleansing tissues. In some instances, the dermatological pharmaceutical composition comprises hydrocodone or oxycodone, acetaminophen, and promethazine. In another instance, the
dermatological pharmaceutical composition comprises hydrocodone or oxycodone, and promethazine.
The pharmaceutical compositions described herein can also be in liquid or liquid tannate form. The liquid formulations can comprise, for example, an agent in water-in- solution and/or suspension form; and a vehicle comprising polyethoxylated castor oil, alcohol and/or a polyoxyethylated sorbitan mono-oleate with or without flavoring. Each dosage form comprises an effective amount of an active agent and can comprise pharmaceutically inert agents, such as conventional excipients, vehicles, fillers, binders, disintegrants, pH adjusting substances, buffer, solvents, solubilizing agents, sweeteners, colorant agents and any other inactive agents that can be included in pharmaceutical dosage forms for oral administration. Examples of such vehicles and additives can be found in Remington's Pharmaceutical
Sciences, 17th edition (1985).
In some cases, the pharmaceutical compositions described herein are administered in a suppository form, comprising an outer layer containing the pharmaceutical composition in a suppository base. The suppository base can, for example, be any conventional suppository base material such as glycogelatin, polyethylene glycol, fractionated palm kernel oil, or one or more natural, synthetic or semi synthetic hard fats such as cocoa butter. In some cases, the
pharmaceutical compositions described herein are administered in injection-ready stable liquids for injection or I.V. drip.
Dosage
In some instances, concentrations and dosages (e.g., a single unit dosage or multiple unit dosages) of active agents in a pharmaceutical composition can be varied as desired, as further described herein. Depending on the subject and/or condition being treated and on the administration route, the active agent in a pharmaceutical composition can generally be administered in dosages of 0.01 mg to 500 mg per kg body weight per day, e.g. about 20 mg/day for an average person. The dosage can be adjusted based on the mode of administration.
A typical dosage can be one administration daily or multiple administrations daily. In some instances, for a controlled-release dosage form the unit dose can be designed for
administration over a defined period of time. In some instances, dosage for one or a combination of agents can be from about 0.01 to 5mg, 1 to 10 mg, 5 to 20 mg, 10 to 50 mg,
20 to 100 mg, 50 to 150mg, 100 to 250mg, 150 to 300mg, 250 to 500mg, 300 to 600mg or
500 to lOOOmg V/kg body weight. Dose levels can vary as a function of the specific compound, the severity of the symptoms and the susceptibility of the subject to adverse effects. In another instance, a pharmaceutical composition comprises multiple active agents at the same or different dosages, where the pharmaceutical composition comprises an effective
amount of: an opioid analgesic; an antiemetic; and a stimulant. In some instances, the pharmaceutical composition can further comprise a barbiturate or a non-opioid active agent, or both. The dosage can be adjusted according to the particular actives selected.
In some instances, a pharmaceutical composition comprises an effective amount of one or more active agents that are present at about 0.5 mg to about 60 mg, including but not limited to a dose of about: 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg, 2.5 mg, 3.0 mg, 3.5 mg, 4.0 mg, 4.5 mg, 5.0 mg, 5.5 mg, 6.0 mg, 6.5 mg, 7.0 mg, 7.5 mg, 8.0 mg, 8.5 mg, 9,0 mg, 9.5 mg, 10 mg, 10.5 mg, 11.0 mg, 11.5 mg, 12.0 mg, 12.5 mg, 13 mg, 13.5 mg, 14 mg, 14.5 mg, 15 mg, 15.5 mg, 16 mg, 16.5 mg, 17 mg, 17.5 mg, 18 mg, 18.5 mg, 19 mg, 19.5 mg, 20 mg,20.5 mg, 21 mg, 21.5 mg, 22 mg, 22.5 mg, 23 mg, 23.5 mg, 24 mg, 24.5 mg, 25 mg,25.5 mg, 26 mg, 26.5 mg, 27 mg, 27.5 mg, 28 mg, 28.5 mg, 29 mg, 29.5 mg, 30 mg, 31 mg, 32 mg, 33 mg, 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg, 40 mg, 41 mg, 12 mg, 43 mg, 44 mg, 45 mg, 46 mg, 47 mg, 48 mg, 49 mg, 50 mg, 55 mg, or 60 mg, individually or in a total amount.
Communication Media
The present disclosure provides communication media (e.g., computer control systems) that are programmed to implement methods of the disclosure. Figure 8 shows a computer system 801 that is programmed or otherwise configured to implement or regulate a
communication with determining or recording a prognosis of a wound. The computer system
801 can be an electronic device of a user or a computer system that is remotely located with respect to the electronic device. The electronic device can be a mobile electronic device. The computer system 801 includes a central processing unit (CPU, also "processor" and "computer processor" herein) 805, which can be a single core or multi core processor, or a plurality of processors for parallel processing. The computer system 801 also includes memory or memory location 810 (e.g., random-access memory, read-only memory, flash memory), electronic storage unit 815 (e.g., hard disk), communication interface 820 (e.g., network adapter) for
communicating with one or more other systems, and peripheral devices 825, such as cache, other memory, data storage and/or electronic display adapters. The memory 810, storage unit 815, interface 820 and peripheral devices 825 are in communication with the CPU 805 through a communication bus (solid lines), such as a motherboard. The storage unit 815 can be a data storage unit (or data repository) for storing data. The computer system 801 can be operatively coupled to a computer network ("network") 830 with the aid of the communication interface
820. The network 830 can be the Internet, an internet and/or extranet, or an intranet and/or extranet that is in communication with the Internet. The network 830 in some cases is a telecommunication and/or data network. The network 830 can include one or more computer servers, which can enable distributed computing, such as cloud computing. The network 830, in
some cases with the aid of the computer system 801, can implement a peer-to-peer network, which may enable devices coupled to the computer system 801 to behave as a client or a server. The CPU 805 can execute a sequence of machine-readable instructions, which can be embodied in a program or software. The instructions may be stored in a memory location, such as the memory 810. The instructions can be directed to the CPU 805, which can subsequently program or otherwise configure the CPU 805 to implement methods of the present disclosure. Examples of operations performed by the CPU 805 can include fetch, decode, execute, and writeback. The CPU 805 can be part of a circuit, such as an integrated circuit. One or more other components of the system 801 can be included in the circuit. In some cases, the circuit is an application specific integrated circuit (ASIC). The storage unit 815 can store files, such as drivers, libraries and saved programs. The storage unit 815 can store user data, e.g., user preferences and user programs. The computer system 801 in some cases can include one or more additional data storage units that are external to the computer system 801, such as located on a remote server that is in communication with the computer system 801 through an intranet or the Internet. The computer system 801 can communicate with one or more remote computer systems through the network 830. For instance, the computer system 801 can communicate with a remote computer system of a user. Examples of remote computer systems include personal computers (e.g., portable PC), slate or tablet PC's (e.g., Apple® iPad, Samsung® Galaxy Tab), telephones, Smart phones (e.g., Apple® iPhone, Android-enabled device, Blackberry®), or personal digital assistants. The user can access the computer system 801 via the network 830. Methods as described herein can be implemented by way of machine (e.g., computer processor) executable code stored on an electronic storage location of the computer system 801, such as, for example, on the memory 810 or electronic storage unit 815. The machine executable or machine readable code can be provided in the form of software. During use, the code can be executed by the processor 805. In some cases, the code can be retrieved from the storage unit 815 and stored on the memory 810 for ready access by the processor 805. In some situations, the electronic storage unit 815 can be precluded, and machine-executable instructions are stored on memory 810. The code can be pre-compiled and configured for use with a machine having a processer adapted to execute the code, or can be compiled during runtime. The code can be supplied in a
programming language that can be selected to enable the code to execute in a pre-compiled or as-compiled fashion. The computer system 801 can include or be in communication with an electronic display 835 that comprises a user interface (UI) 840. Examples of UI's include, without limitation, a graphical user interface (GUI) and web-based user interface. Methods and systems of the present disclosure can be implemented by way of one or more algorithms. An
algorithm can be implemented by way of software upon execution by the central processing unit 805.
Aspects of the systems and methods provided herein, such as the computer system 801, can be embodied in programming. Various aspects of the technology may be thought of as "products" or "articles of manufacture" typically in the form of machine (or processor) executable code and/or associated data that is carried on or embodied in a type of machine readable medium. Machine-executable code can be stored on an electronic storage unit, such as memory (e.g., read-only memory, random-access memory, flash memory) or a hard
disk. "Storage" type media can include any or all of the tangible memory of the computers, processors or the like, or associated modules thereof, such as various semiconductor memories, tape drives, disk drives and the like, which may provide non-transitory storage at any time for the software programming. All or portions of the software may at times be communicated through the Internet or various other telecommunication networks. Such communications, for example, may enable loading of the software from one computer or processor into another, for example, from a management server or host computer into the computer platform of an application server. Thus, another type of media that may bear the software elements includes optical, electrical and electromagnetic waves, such as used across physical interfaces between local devices, through wired and optical landline networks and over various air-links. The physical elements that carry such waves, such as wired or wireless links, optical links or the like, also may be considered as media bearing the software. As used herein, unless restricted to non- transitory, tangible "storage" media, terms such as computer or machine "readable medium" refer to any medium that participates in providing instructions to a processor for execution.
A machine readable medium, such as computer-executable code, may take many forms, including but not limited to, a tangible storage medium, a carrier wave medium or physical transmission medium. Non-volatile storage media include, for example, optical or magnetic disks, such as any of the storage devices in any computer(s) or the like, such as may be used to implement the databases, etc. shown in the drawings. Volatile storage media include dynamic memory, such as main memory of such a computer platform. Tangible transmission media include coaxial cables; copper wire and fiber optics, including the wires that comprise a bus within a computer system. Carrier-wave transmission media may take the form of electric or electromagnetic signals, or acoustic or light waves such as those generated during radio frequency (RF) and infrared (IR) data communications. Common forms of computer-readable media therefore include for example: a floppy disk, a flexible disk, hard disk, magnetic tape, any other magnetic medium, a CD-ROM, DVD or DVD-ROM, any other optical medium, punch cards paper tape, any other physical storage medium with patterns of holes, a RAM, a ROM, a
PROM and EPROM, a FLASH-EPROM, any other memory chip or cartridge, a carrier wave transporting data or instructions, cables or links transporting such a carrier wave, or any other medium from which a computer may read programming code and/or data. Many of these forms of computer readable media may be involved in carrying one or more sequences of one or more instructions to a processor for execution.
Kits
The present disclosure provides a kit that comprises reagents for measuring a total amount or a phosphorylation level of two or more proteins disclosed herein, e.g., selected from the group consisting of IGF-1R, PI3 Kinase, Akt, insulin, mTOR, HIF, PTEN, IGFRBP-3, c-MET, GSK- 3β, COX-2, iNOS, NFKB/p65, ΙκΒ-α, p53, pl6INK4a, β-Catenin, Bak, Caspase 3, and Caspase 9.
In some embodiments, the reagents may include H202, Amp, PB, Avidin, Biotin, TPER reagent. Use of a kit may involve one or more of the following procedures:
Cells of interest are isolated from a FFPE biopsy using LCM or macro-dissection.
Cells are disrupted by Boiling in a strong denaturing (SDS) buffer to release denatured proteins.
Denatured proteins in the lysate are then arrayed on a nitrocellulose slide using a touch pin spotter (we use Aushon).
Slides are stained with a non-specific total protein dye (Ruby Sypro) to determine the amount of protein in each spot.
Slides are reacted with a primary Ab (i.e., specific for GSK-3b) that is specific for the protein or p-protein (i.e., p-PTEN S380) of interest.
The slide is then reacted with a biotin-labeled secondary antibody that recognizes the primary Ab (can bind to multiple primaries, so each slide is a specific primary Ab).
The Biotin is then reacted with a SA-labeling system (tyramide) to decorate the spot with fluorophores.
The slide is scanned and the fluorescence in each spot is normalized to the amount of protein.
On each array are + and - controls and a series of known dilutions of the target antigen so that you can extrapolate the unknown to the known and generate a score based on semiquantitative assessment (or quantitative if the linear part of the Std. curve is tight).
Then scores (ratio in his application) are calculated, compared to the score for
healers/nonhealers, and a determination is made as to which signals are up and which are down, and does the pattern match nonhealers or healers. Depending on what analytes are up in the inhibition of survival or activation of senescence signaling pathway are then considered targets for a drug.
In some aspects, the present disclosure provides a method for using a protein microarray to identify a combination of therapeutic agents for individualized treatment of a disease in a patient caused by a peculiar, abnormal network of interconnected cell signaling proteins that leads to an aberrant cellular response in the patient, comprising the steps of: a) measuring with the protein microarray activity states for a plurality of different signaling proteins extracted from diseased cells obtained from the patient; b) providing activity states of signaling proteins from reference cells corresponding to the signaling proteins extracted from the diseased cells obtained from the patient; c) detecting differences between the activity states of the individual signaling proteins from the diseased cells and the activity states of the corresponding individual signaling proteins from the reference cells, thereby providing a snapshot of the signaling proteins in the diseased cells that form an abnormal network of interconnected cell signaling proteins that leads to the aberrant cellular response in the patient; and/or d) reporting a combination of at least two different therapeutic agents for administration to the patient for the purpose of correcting the abnormal network by reducing the difference that was detected in the activity states of two or more of the signaling proteins in the abnormal network of interconnected cell signaling proteins identified by steps (a)-(c) in the diseased cells from the activity states of the corresponding signaling proteins in the reference cells.
Microarray and Data Analysis
In some cases, each array is scanned, spot intensity analyzed, data normalized, and a standardized, single data value is generated for each sample on the array (Image Quant v5.2, GE Healthcare, Piscataway, N. J.). Spot intensity is integrated over a fixed area. Local area background intensity is calculated for each spot with the imprinted adjacent slide background. This results in a single data point for each sample, for comparison to every other spot on the array. The Ward method for two-way hierarchical clustering is performed using JMP v5.0 (SAS Institute, Cary N.C.). Wilcoxon two-sample rank sum test is used to compare values between two groups. P values less than 0.05 are considered significant. Kaplan-Meier (log-rank) survival estimates are used for univariate survival analysis.
In some instances, every array has on-board calibrators (with known amounts of each specific analyte) that allow knowing how much of each protein is detected. Each protein signal on the assay is normalized to the amount of protein in each individual spot on the array. A value of Normalized Fluorescence Intensity (NFI) per mg protein is generated and compared to the linear range of the calibrators to calculate the amount of each protein per mg total protein in the test samples. This gives a semi-quantitative value used to calculate a ratio. For example, a value for an analyte HIF-1 alpha is divided by one that does not change (IGF-IR or Akt for example) to
get the ratio. If the ratio is high, e.g., >1, then there is an increased level of the HIF-la that correlates to healing or nonhealing. In some embodiments, total proteins are measured to gauge the effect of transcription factors on gene expression. In some embodiments, phosphoproteins are measured to see if actively signaling or not.
In some cases, expression or activation levels of proteins are first measured and then compared to their reference standards. Each comparison gives a value, which is used in the next step of determining a ratio to another protein. In some embodiments, calibrators are generated, and a large population of patients is run to get a distribution, which allows to bin the patients on a per analyte basis from low to high. Then the unknown is compared to the distribution to place the patient on a per analyte basis somewhere in the population. Multiple analytes are evaluated, for example those in a signaling pathway (HER2 - Akt - mTOR ->4EBP1), to see if a pathway is on or not.
Examples
Example 1: A comparative clinical study of chronic DFU keratinocytes and non- diabetic (control) plantar skin specimens
A panel of biomarkers comprised of proteins or the activated-state (phosphorylation) of proteins was examined in isolated keratinocytes from the margins of healing and nonhealing diabetic foot ulcers (DFU) and compared to the levels or activation of the same proteins in normal plantar tissues. Alterations in the intracellular levels these proteins and/or in the level of activation were observed that identified the dysregulation of multiple signal transduction pathways and from an analysis of these biomarkers, a correlation was found between sets of biomarkers was identified that can predict healing.
Patient information for fourteen patients who presented with Diabetic Foot Ulcers (DFU). Clinical data includes sex, age, whether they were Type 1 or 2 diabetics, their use of insulin, presence or absence of neuropathy or co-morbidities, the age and size of their ulcer, recent infection histories, whether they had recent surgery and if any amputations had been performed is listed. The information on the patients used to establish the P/I ratio are shown in Table 1.
RPPA measurements on 19 analytes were performed on biopsies (formalin preserved) taken from a patient population that included 18 patients who presented with chronic ulcers (DFU) and 3 biopsies from DFU patients whose ulcer healed, and 3 biopsies taken from normal patients (NOR) and the information on these patients are shown in Table 1. For the two cohorts, the sex (DFU 14 male, 10 female; NOR 3 male, 1 female) and age (DFU Mean 59.96 years, Range36-81 years of age ; NOR Mean 29.75, Range21-51) as shown in Table 1.
The 19 analytes measured by RPPA included a number of important signaling markers that have been associated with various processes that may be involved in the healing or nonhealing of diabetic ulcers are:
1. Akt
2. iNOS
3. mTOR
4. NF kappa B p65
5. P16INK4a
6. P53
7. POKinase
8. VEGF Receptor 1
9. Bak
10. Catenin-beta
11. Caspase.3
12. Caspase.9
13. GSK.3.beta
14. IGF. 1R beta
15. IkB alpha
16. Met
17. Cox.2
18. p-mTOR S2448
19. IGF IR Y1 135.1150
From the 30 patient biopsies that were analyzed, shown in Tables 1 and 1 (cont), only 22 of these had sufficient cellularity to allow for RPPA analysis. Those that were suitable for RPPA analysis included 3 normal patient biopsies, 3 diabetic patients whose ulcers healed, and 16 diabetic patients whose ulcers did not heal following standard treatment modalities.
RPPA analysis was performed on lysates made from the tissues obtained for each patient, and the results of this analysis for 19 analytes are shown in Tables 2 and 2 (cont.). Values represent normalized results for the analytes measured in 18 DFU patients and 4 Normal Controls.
When compared with non-diabetic control subjects, DFU wound keratinocyte signaling protein levels were significantly (p<0.05) elevated for:
1) the pro-inflammatory transcription factor, NF-kB;
2) the tumor suppressor transcription factor, P53;
3) the senescence biomarker, P16INK4a;
4) the cellular survival and growth transduction pathway proteins: PI3K, AKT (protein kinase B), β-catenin, glycogen synthase kinase-3 (GSK-3 ), and C-Met; and
5) the P53-directed apoptosis cleavage protein Caspase-3.
During a 12-week post-debri dement observation period all DFU subj ects received standard of care wound treatment and wound off-loading. During this time three (n=3) of the
nineteen DFU subjects (16 percent) demonstrated complete healing of the study ulcer.
Following study completion, DFU study subject wound status (healed vs. un-healed) correlated with proteomic activity ratios for PI3K/IGF-1R (P/I-ratio). PI3K-AKT/mTOR (mammalian target of rapamycin) is the major signaling pathway activated by the hormone insulin and insulin-like growth factor-1 (IGF-1). IGF-1 cellular stimulation of AKT signaling has been demonstrated to induce the expression of hypoxia-inducible factor-1 (HIF-1) that may be critical to the initiation of angiogenesis and the healing of diabetic wounds. Conversely, phosphatase tension homolog (PTEN), a p53-directed PI3K antagonist documented with diabetes, inhibits AKT/mTOR activation and suppresses induction of hypoxia- inducible factor- 1 (HIF-1) mediated gene up-regulation. The data documents P/I- ratio values (±SD) of: 0.7 (±0.02) for control study subjects, 1.0 (±0.1) for healed- DFU study subjects, and 1.3 (±0.1) for unhealed-DFU study subjects. Unpaired t-test analysis for healed and unhealed DFU group P/I-ratios and ANOVA analysis of all study group P/I -ratios documented significant mean differences.
The P/I-ratio may provide a novel quantitative gauge of IGF-1 initiated AKT/mTOR signal transduction. In this case, increasing P/I-ratio values would be inversely proportional to decreasing AKT/mTOR signal transduction associated with impaired DFU wound repair.
Proteomic assessments from this pilot study document the neuropathic DFU as a complex, senescent wound and suggest P53-directed dysfunctional regulation of IGF-1, PI3K, and AKT/mTOR signaling as critical factors responsible for impaired DFU wound healing.
The results indicate that:
1) The unexpected finding that, when the ratio of PBKinase to IGF-1R is greater than about 1, a diabetic ulcer will not heal and alternate therapies should be employed to promote healing.
2) The unexpected finding of novel specific protein drug targets in non-healing diabetic ulcers that should be inhibited to promote healing.
3) The unexpected finding that a therapeutic strategy for treating non-healing wounds would be to inhibit PI3K signaling, opening up the use of such inhibitors as potential therapeutic agents for treating non-healing diabetic ulcers.
4) A cut point for DFU management can be discerned from the data, wherein the ratio of PI3K to IGF-1R is greater than 1.5 can predict non-healing and a therapeutic approach of inhibiting PBKinase signaling in non-healing diabetic ulcers discerned from the data and that this cut point can be used for prospective patient selection.
In summary, the results of the DFU wound healing study report the correlation of keratinocyte insulin pathway PI3K/IGF-1R ratio values to wound healing outcomes in DFU
subjects. These findings provide the basis for the invention described with this report. These novel signal pathway relationships have not been previously reported and describe quantifiable thresholds of ISP signal transduction and P53-directed processes that may be responsible for promoting impaired diabetic wound healing. This invention will have immediate application and impact on the clinical management of wound healing complications with diabetes and will provide a novel platform for future research and development of combined clinical and pharmacological treatment pathways for the devastating morbidity associated with this problem. Study findings reported with this invention also provide irrefutable evidence of the value provided by proteomic analysis technology (RPPA and LCM) in support of investigations of mechanisms of wound healing and impaired tissue repair. The role of P53-mediated dysfunctional insulin signaling pathway transduction and supporting data suggesting a downstream link with HIF-1 expression in diabetes impaired wound healing would not have been achieved without RPPA and LCM technology. Additionally, this study has appropriately underscored the importance of understanding the critical roles played by P53- directed processes as they impact the cellular injury response and the pro- inflammatory cellular dynamics required for wound repair. Wound repair is a productive extrinsic stress response generally unaffected by the intrinsic stresses that threaten unchecked cell division and proliferation. As isolated phenomena P53-directed processes may appear to promote dysfunctional cellular responses following cellular injury. P53 can limit the consequences of extrinsic stress from the cellular injury response and wound repair by inhibiting proinflammatory processes, initiating cell death, senescence, or cell cycle arrest and promoting oxidative cellular metabolism. Ultimately, it is the balance (or imbalance) achieved following the regulation of these intrinsic and extrinsic processes that provides the
environment and outcomes that are achieved in wound repair. The active antagonism demonstrated by P53-directed processes during wound healing can be a constant factor.
Example 2: Comparative, quantitative proteomic assessment of DFUs.
DFU subjects, adults with chronic, full-thickness, neuropathic foot ulcers selected from a hospital patient population, and control study subjects, non-diabetic adults who volunteered to submit plantar foot tissue specimens for control tissue analysis were evaluated using a comparative, quantitative proteomic assessment of twenty-one (n=21) signaling pathway proteins, spanning multiple pathways. The assessment of signaling proteins of DFU (n=18) and non-diabetic (normal) plantar skin (n=3), was performed on keratinocytes isolated from full thickness plantar foot skin samples obtained using a three-millimeter punch biopsy technique.
Punch specimens were obtained from the viable ulcer margin immediately following clinical debridement of the wound and from control subject's plantar foot areas. For tissue biopsies all
study subjects were allowed to receive a suitable volume of injectable local anesthetic for tissue retrieval, if needed. The punch biopsy sites were closed by use of non-absorbable sutures and dressed with occlusive foam or silicon bandages. All subject tissue specimens were immediately placed in formalin to preserve morphology and phosphoprotein levels in tissues.
DFU study participants continued with normally scheduled wound evaluations as routinely coordinated by the medical and nursing staff. A twelve-week post-debridement observation period was scheduled for all DFU study patients to assess wound healing, study subject compliance and for evaluation of off-loading methods assigned for patient care. During a 12-week post-debridement observation period three (n=3) DFU subjects demonstrated complete healing of their study ulcers. RPPA quantitatively measured the expression levels and activation (phosphorylation) status of proteins in signaling pathways relevant to wound healing. RPPA allowed for the simultaneous assessment from all biopsies, providing a high-dimensional 'snapshot' of signaling activity in DFU keratinocytes.
In the DFU study group there were seventeen subjects with Type II diabetes, one with Type I diabetes, fifteen male and three female subj ects. The average age (mean value) of the DFU subjects was 60.3 years (ranging from 48-75; median age = 60). The average age of the DFU study ulcer was nineteen (19) months, ranging from 2-120 months (median ulcer age = 11 months). Comparing the healed and unhealed DFUs wound age in months (± STDev): Mean ulcer age - healed DFUs = 18.0 months (±16.1) vs. unhealed DFUs=19.2 months (±19.2). The mean DFU wound sizes were measured by planometric methods and were: 7.5cm2 (±13.2cm) for unhealed DFUs vs. 1.6cm (± 1.0cm) for healed DFUs. Healed and unhealed DFU wound sizes were not significantly different. The control study group (n=3) was comprised of three healthy adult males with an average age of 23 years.
DFU subject wound care consisted of moist to dry dressings, foams and alginates with and without nanocrystaline silver, collagenase, antibiotic ointments or hydrogels with or without nanocrystaline silver. No study patients received allograft, xenograft, living, single or bi-layered human cell based dressings (e.g., Dermagraft™ or Apligraf™) or adjunctive hyperbaric oxygen therapy (HBOT) during or within six months of this study.
DFU study subj ects had been taking medications for glycemic control prior to tissue specimen retrieval. These medications were not changed during the study observation period and are listed in Table 3- Diabetic Medications Taken During the Study. DFU study subjects listed by number with their pre-study medications for glycemic control. HEALED- indicates subjects with healed study DFU wounds at the completion of the twelve-week observation period. TIDM-indicates study subject with Type I DM; all other study subjects diagnosed with Type II DM.
Significant differences were observed in multiple signaling proteins following non- parametric Whitney-Mann U-Test comparison of normal and DFU keratinocytes (Figure 3). Unexpectedly, many of these elevated proteins that are abnormally expressed in DFUs are known to be dysregulated to some degree in most cancer types, including breast, colon, lung, pancreatic, ovarian, and hepatic tumors. The proteins exhibiting significantly (p < 0.01) increased levels in nonhealing DFU keratinocytes compared to normal tissue included: members of the PI3K/AKT signaling pathway (p-PTEN S380, PI3 Kinase, AKT, GSK-3P and p-mTOR S2448); the NFkB pathway (NFKB/p65 and p53); the β-catenin pathway (GSK-3P, pl6INK4a, and Caspase 3). Total mTOR and COX-2 were also elevated (p < 0.05) in nonhealing DFUs.
When the data cross all analytes was subjected to hierarchical clustering to see if there were patterns of significant dysregulated in the analytes of the signaling pathways between normal and DFU patients. Normal (Subjects 19, 20, and 21) and DFU patients were separated. Based upon the signaling architecture of the two populations, DFU patients significantly exhibit higher levels of multiple proteins across the PI3 Kinase/ Akt pathway, the survival pathways (ΝίκΒ/ρ65 and β-catenin), and the cell surface receptor, c-MET a target of the TCF/ -catenin transcription complex. Thus, RPPA analysis identified an activity-relationship that corresponds to maj or components that have been observed individually in wound healing found in the literature, but the analysis of multiple pathways allows for correlative and combinatorial relationships to be determine, critical to determining the salient biomarker groups that can predict healing versus nonhealing DFU and to identify combinatorial therapeutic approaches to treating DFU.
The level of expression (and activation) of IGF-1 R, a cell surface receptor involved in insulin and IGF-1 signaling, was not significantly different between normal and DFUs (healed or unhealed). To assess correlative alterations in downstream signaling, a ratio of the downstream proteins to IGF-1R was calculated in an attempt to identify perturbations to signaling that may distinguish healing from nonhealing DFUs (Figure 6). There were several proteins whose ratios of expression levels were significantly elevated in nonhealing DFU, including: PI3 Kinase and mTOR, members of the Akt signaling pathway that facilitates cell cycle progression and inhibits apoptotic events; p53, a regulator of cell cycle arrest, apoptosis, and senescence; Caspase 9, indicative of intrinsic apoptosis; Bak, the pro-apoptotic protein that is increased in response to p53 and which is activated by Caspase 9; and COX-2, whose transcription and stabilization may be modulated by Akt and/or NfKB/p65 signaling, indicative of a pro-inflammatory state.
In our analysis, there were no significant differences between normal, healing DFU, or nonhealing DFU levels for total or phosphorylated IGF-1R, suggesting that increased IGF-1R
signaling in DFUs was not inhibiting wound healing. However, there was a significant increase in PI3 Kinase/mTOR signaling in DFUs.
Expression of c-Met was significantly increased in DFUs compared to normal. The observed increased levels of c-Met may be responsible for the observed increased PI3
Kinase/ Akt signaling in DFU. The IGF-1R and IR receptors, are known to form heterodimer pairs with c-Met, mediating transactivation of c-Met in the absence of its ligand, HGF
(hepatocyte growth factor), thereby potentiating un-regulated signaling in multiple pathways (DFU levels compared to normal, Figure 4). Our observed signaling architecture in DFUs suggests patterns of cross-talk between pathways involved in apoptosis (p53, caspases), proliferation and migration (PI3Kinase/Akt/mTOR), inflammation (Cox-2, NFKB), and senescence (p53, pl6INK4a).
RPPA identified active signaling pathways in DFUs which may help identify points of therapeutic intervention to treat nonhealing DFUs (Figure 5). Observed differences between healing and nonhealing DFUs suggest an increased level of pro-apoptotic proteins and a potential role for c-Met/IGF-lR heterodimer signaling through the PI3Kinase/Akt pathway as an important driver in the nonhealing wound. In the absence of altered levels of IGF-1R or its activation by phosphorylation, a significant modulation of pathways related to increased
PI3Kinase/AKT signaling coupled with increased inflammatory and apoptotic signaling occurs, perhaps in response to c-Met activation.
The nonhealing DFU is a disease of dysregulated signal transduction potentially influenced by somatic mutations to many of the same genes as those involved in cancer. Altered signaling due to somatic mutations can interfere with mRNA transcription or protein function. These mutations change signaling efficiency, altering the control of transcription factors that modulate the intercellular levels of key proteins or the regulated patterns of post-translational modifications (PTM). An interesting observation in DFUs is the inactivating phosphorylation of PTEN (p-PTEN S380), resulting in increased PI3Kinase/Akt signaling which can trigger senescence in addition to survival (Figure 7).
A PI3Kinase/Akt imbalance can contribute to the prevention of healing in DFUs and can potentiate certain cancers. Many of the active signaling pathways observed in DFUs are evident in cancers, suggesting that drugs developed for one disease may have utility in treating the other. For example, the diabetes drug metformin, an activator of AMPK-directed inhibition of
Akt/mTOR-mediated proliferation and Cyclin Dl synthesis, reduces the incidence and progression of some cancers. In diabetics, metformin may be associated with larger ulcerations and inhibition of keratinocyte proliferation, but these DFUs do not progress to amputation.
Activation of survival and senescence signaling pathways, like NFKB, p53 and β-catenin, can
contribute to nonhealing DFUs. In some embodiments, nonhealing DFUs can be treated using topical applications of anti-cancer therapies targeting proteins in these pathways or for the development of diagnostic tests to guide therapeutic decisions when treating DFUs.
Example 3
This example illustrates an assessment of the wound healing potential of DFU wound subjects A and B from a comparative analysis of the IGF-1R protein expression ratio of the subject ulcer following RPPA analysis in the Wound Healing Diagnostic (WHD). For their evaluation each subject has completed the steps of having a small (<3mm diameter) punch biopsy of the wound marginal epidermis performed after wound debridement. This is followed by the step of immediately placing the epidermal wound margin biopsy tissue in formalin fixative solution. Following tissue fixation the specimen is dissected using macro-dissection or laser capture microdissection methods to adequately isolate the basal keratinocyte cells from the specimen for RPPA analysis. Protocols are then followed for the completion of RPPA cell lysate analysis against a panel of protein analytes that would include those used in the study performed with the invention. The WHD panel for healing assessment would include values of IGF-1R protein expression ratios with the following signaling proteins: PI3K (PI3K/IGF-1R) and/or mTOR (mTOR/IGF-lR) and/or COX-2(COX-2/IGF-lR) and/or Bak (Bak/IGF-IR) and/or p53 (p53/IGF-lR).
Following the completion of the RPPA WHD ratio analysis on two subjects presenting with DFU at the time of diagnosis, Subject A's tissue specimen PI3K/IGF-1R ratio value was 0.9, while the Subject B tissue specimen PI3K/IGF-1R ratio value was 1.4. After comparing these values with the DFU study WHD ratios for this invention (see Figure 7) it was determined that the values obtained from Subject A's DFU wound demonstrated that the PI3K/IGF-1R value was associated with wounds that experienced healing, while the PI3K/IGF-1R value determine for Subject B's DFU wound value was associated with wounds that did not heal. Subsequent clinical observation was continued with both subjects while optimal wound dressings and offloading methods were continued with Subject A's wound demonstrating complete healing in 12 weeks, or less, while Subject B's wound remained unhealed at the end of a twelve week period of observation. During this time the Subject B DFU wound was prepared for evaluation using the wound therapy diagnostic (WTD) panel assessment to determine topical corrective pharmaceutical therapies for the promotion of wound healing as presented in the following example.
As can be seen from Figure 6, using the ratio of PI3K to IGF-1R as a guide, the
PI3K/IGF-1R, analysis of Subject A's signaling generated a ratio of 0.9 which is within the Box for Healing wounds while the ratio of PI3K to IGF-1R for Subject B was 1.3, which is within the
Box for Healing wounds. Thus based on the ratio of 0.9 for Subject A's DFU, this ulceration was expected to heal, while that of Subject B, ratio of 1.3, was not expected to heal.
As Subject B was expected to have a nonhealing DFU, a subsequent analysis was performed to identify potential points of therapeutic intervention based upon the ratio of a number of analytes to Akt. The analytes included: VEGFR1, iNOS, HIF-la, Bak, GSK-3b, Catenin b, NFkb p65, pl6INK4a, and p53 (Figure 7). As the levels of these protein analytes increased there is a decrease in the ratio, and those with significant differences would be considered points of therapeutic intervention. For example in Subject B the ratio of pl6INK4a / Akt was found to be 1.4 and this ratio in Normal keratinocytes is 0.5. By inhibiting the level of pl6INK4a the ratio would be expected to decrease and by shifting the level of pl6INK4a lower, there would be less contribution to the activation of senescence, which is a terminal event that causes irreversible cell death. So by treating with a pINK3A inhibitor the over activation of senescence would be lessened, keratinocytes would live longer and the wound would heal.
Example 4. Treatment.
One or more subjects are treated with a pharmaceutical composition disclosed herein.
The pharmaceutical composition comprises an antagonist and/or an agonist as described herein. For example, antagonists (e.g., of GSK-3beta) include Beryllium, Lithium, Anilino maleimides (SB216763, SB415286), Arylpyrazolopyridazines (e.g., 6-aryl pyrazole [3,4-b] pyridine 4), Bisindole maleimides (e.g., Ro 31-8220, GF 109203x), Indirubins (6- bromoindirubin-3'-oxime, aka BIO), Paullones (alsterpaullone), Psuedosubstrate peptide,
Dibromocantherelline, Meridianine A, CHIR908014, CHIR908023, CHIR908021, SB216763,
AR-A014418, Kenpaullone, Alsterpaullone, Cazpaullone, SB415286, TWS119, Aloisine A,
TDZD-8, NP00111, HMK-32, Manzamine A, Palinurin, Tricantin, L803-mts. Additional examples of antagnoists (e.g., of PI3K/AKT/mTOR) include Everolimus (Novartis),
Temsirolimus (Pfizer), BEZ235 (Novartis), GDC-0980 (Genentech), PF-05212384 (Pfizer),
SAR245409 (XL-765; Sanofi/Exelixis), BAY80-6946 (Bayer), Bupariisib (BKM120; Novartis),
Pictilisib (GDC-0941; Genentech), PX-866 (Oncothyreon), SAR245408 (XL- 147;
Sanofi/Exelixis), ZSTK474 (Zenyaku Kogyo), BYL719 (Novartis), GDC-0032 (Genentech),
MLN01117 (INK1117; Intellikine), GSK2636771 (GSK), SAR260301 (Sanofi), Idelalisib
(CAL-101; GS-1101 ; Gilead/Calistoga), AMG319 (Amgen), Perifosine (KRX-0401 ; Keryx),
MK2206 (Merck), GDC-0068 (Genentech), GSK2110183 (GSK), GSK2141795 (GSK), ARQ
092 (ArQule/Daiichi Sankyo), AZD5363 (AstraZeneca), AZD2014 (AstraZeneca), MLN0128
(INK128; Intellikine), or CC-223 (Celgene). Additional antagonists (e.g., of β-catenin signaling) include PKF118-310, CGP049090, PKF115-584, PKF222-815, PKF118-744, ICGOOl,
CCT036477, XAV939, Acyl hydrazones, HQBA, Molecules with 2,3,6-trisubstituted
pyrido[2,3,-b] pyrazine core skeletons, Carnosic acid, CCT031374, iCRT-3,5,14, NC043, Ibuprofin, or Aspirin. Additional antagonists (e.g., of p53) include Nutlins RG7112
(RO5045337), Benzodiazepinediones (TDP665759), Spiro-oxindoles (MI-219), RITA, JNJ- 26854165 (Serdemetan), Tenovin 1 and 6, SJ-172550, RO-2443/RO-5693, XI -Oi l, Re-activate mutant p53, CP-31398, PRIMA-1 (APR-246), MIRA-1, Phikan083, or NSC319726. Examples of agonists (e.g., of GSK-3beta) include Celecoxib, Staurosporine, Trichostatin A, Curcumin, AKt/protein kinase B signaling inhibitor-2(API-2), Wortmannin, LY294002, Rapamycin, Differentiation-inducing factors (DIFs), and Retinoids.
The examples and embodiments described herein are for illustrative purposes only and various modifications or changes suggested to persons skilled in the art are to be included within the spirit and purview of this application and scope of the appended claims.
Table 1: Patient Demographics and Clinical Information
Table 2. Normalized expression values from DFU patients that healed, did not heal, and normal controls and from whose biopsy RPPA data was possible.
NT kappa B VEGF
Patient IDs Akt iNOS j mTOR P16INK4a P53 i PI3. Kinase Bak
p65 Receptor 1
DFU
MM #001 0.821 0.995 1.095 0.874 1.035 1.187 1.162 0.957 0.909
EDR #003 1.083 0.697 1.281 0.990 1.044 1.041 1.090 1.080 1.188
NTM #004 0.859 0.929 0.974 1.086 1.350 1.141 1.157 1.044 0.954
JRL #006 1.270 1.017 0.920 1.043 1.293 1.175 1.059 0.810 0.882
NAB #008 1.093 1.091 1.313 1.228 1.568 1.293 1.175 0.884 0.928
WCP #009 1.671 1.192 0.955 1.070 1.536 1.142 1.408 1.096 0.779
DMN #010 1.329 1.132 1.085 1.150 1.691 1.495 1.382 0.959 0.918
TJ #011 1.077 0.928 1.058 1.093 1.493 1.027 1.058 0.910 0.841
BMP #012 1.045 0.964 1.072 1.118 1.116 1.192 1.059 0.936 0.936
GWW #013 0.923 1.104 1.103 1.276 1.083 1.202 1.286 1.234 1.268
patient #014 1.048 1.135 1.163 1.256 1.262 1.159 1.286 1.320 1.000
WLM #015 1.407 1.126 1.105 1.493 1.464 1.080 1.526 1.507 1.098
MRL #017 1.126 1.072 0.874 1.167 1.266 1.232 1.304 0.856 0.857
JAS #018 1.050 0.950 0.961 1.039 1.295 1.118 1.291 0.891 1.022
ATL #019 1.103 1.063 1.394 1.150 1.786 1.367 1.212 1.078 1.283
JCP #021 0.953 1.022 1.197 0.839 0.944 1.458 0.911 0.838 0.937
NEP #023 1.202 1.195 1.224 1.149 1.421 1.396 1.376 1.064 1.057
CHM #025 1.264 1.084 1.087 0.926 1.522 1.550 1.249 0.960 0.984
Normal
MPW #027 0.822 0.893 0.625 0.400 0.400 0.604 0.674 0.879 1.032
BCB #029 0.896 1.345 0.696 0.247 0.436 0.811 0.920 1.305 1.307
PJM #030 0.879 1.402 0.649 0.247 0.395 0.790 0.898 1.362 1.251
Table 2 (Cont.).
Table 3. Diabetic Medications Taken During the Study.
Claims
claimed is:
A method, comprising:
A. measuring an individual level of an expression or activation of a first protein and a second protein in a sample from a wound, wherein the first protein and the second protein are individually selected from the group consisting of: IGF-1R, PI3 Kinase, Akt, insulin, mTOR, HIF, PTEN, IGFRBP-3, c-MET, GSK-3 , COX-2, iNOS, NFKB/p65, ΙκΒ-α, p53, pl6INK4a, β-Catenin, Bak, Caspase 3, Caspase 9, or any combination thereof, and
B. calculating a ratio of the first protein to the second protein.
The method of claim 1, wherein the method is a method of determining a diagnosis of the wound in a subject.
The method of claim 1 or 2, wherein the measurement is repeated for at least 1, 2, 3, 4, or 5 times, and wherein when the method is repeated more than 1 time, the measurement may be conducted at different time points or at the same time point.
The method of any preceding claim, wherein the measurement is repeated during a course of monitoring the wound.
The method of any preceding claim, wherein the calculation is implemented at least in part by a computer.
The method of claim 5, wherein the calculation is implemented at least in part by a computer processor.
The method of claim 6, wherein the computer processor is a computer microprocessor. The method of any preceding claim, further comprising determining a likelihood that a wound will not heal when the ratio is greater than 1, or that the wound will heal when the ratio is 1 or less.
The method of claim 8, wherein the determination is implemented at least in part by a computer.
The method of claim 9 wherein the determination is implemented at least in part by a computer processor.
The method of claim 10, wherein the computer processor is a computer microprocessor. The method of any preceding claim, further comprising evaluating the wound visually. The method of any preceding claim, further comprising communicating a result via a communication medium.
The method of claim 13, wherein the communication medium is a document.
15. The method of claim 14, wherein the communication medium is a computer file, an email, a fax, or a paper document.
16. The method of any preceding claim, wherein the ratio is calculated with values
generated from a comparison of the measured levels and corresponding reference standards.
17. The method of any preceding claim, wherein the sample is a tissue from the wound.
18. The method of any preceding claim, wherein the sample is from a marginal edge of the wound.
19. The method of any preceding claim, wherein the sample comprises a keratinocyte
isolated or purified from the wound.
20. The method of claim 19, wherein the first protein and the second protein are
individually measured from the keratinocyte or a cellular lysate thereof.
21. The method of any preceding claim, comprising measuring the expression of the first protein and the second protein individually.
22. The method of any preceding claim, comprising measuring the activation of the first protein and the second protein individually.
23. The method of any preceding claim, wherein the measured level is determined by
measuring a total amount of the first protein and/or the second protein individually.
24. The method of any preceding claim, wherein the measured level is determined by
measuring an amount of an activated form of the first protein and/or the second protein individually.
25. The method of any preceding claim, wherein the activation is phosphorylation.
26. The method of any preceding claim, wherein the measured levels are normalized
fluorescence intensity (NFI) per mg protein.
27. The method of any preceding claim, wherein the values are normalized expression
values.
28. The method of any preceding claim, wherein the wound will not heal when the ratio is ≥ 1.2, > 1.3, > 1.4, or > 1.5.
29. The method of any preceding claim, further comprising treating the subject.
30. The method of claim 29, wherein the treating comprises administering to the subject a pharmaceutical composition that comprises an antagonist of a first protein, an agonist of a second protein, or a combination thereof, wherein the first protein, the second protein, or the first protein and the second protein are individually selected from the group consisting of: IGF-IR, PI3 Kinase, Akt, insulin, mTOR, HIF, PTEN, IGFRBP-3, c-MET,
GSK-3 , COX-2, iNOS, NFKB/p65, ΙκΒ-α, p53, pl6INK4a, β-Catenin, Bak, Caspase 3, Caspase 9, and any combination thereof.
31. The method of claim 29, wherein the treating comprises administering to the subject a pharmaceutical composition that comprises an inhibitor of POKinase signaling, an activator of insulin signaling through IGF-1R, or any combination thereof.
32. The method of claim 31, wherein the inhibitor of POKinase signaling is an inhibitor of POKinase complex, Akt, mTOR, 4E.BP1, Ribosomal Protein S6 Kinase, HIF-Ια, PTEN, POKinase, IGFRPB3, Src, GSK3 , β-catenin, any protein that is a member of the insulin signaling or POKinase signaling pathways of proteins, or any combination thereof.
33. The method of claim 31 or 32, wherein the activator of insulin signaling through IGF-1R is selected from the group consisting of insulin, insulin-like growth factor 1 (IGF-1), IGF -2, PTEN, POKinase, mTOR, 4E.BP1, Ribosomal Protein S6 Kinase, HIF-la, PTEN, IGFRPB3, Src, GSK3 , β-catenin, any protein that is a member of the insulin signaling or POKinase signaling pathways of proteins, and any combination thereof.
34. A method of treating a wound in a subject in need thereof, comprising treating the
subject with a pharmaceutical composition that comprises an antagonist of a first protein, an agonist of a second protein, or a combination thereof, wherein the first protein, the second protein, or the first protein and the second protein are individually selected from the group consisting of: IGF-1R, PI3 Kinase, Akt, insulin, mTOR, HIF, PTEN, IGFRBP- 3, c-MET, GSK-3 , COX-2, iNOS, NFKB/p65, ΙκΒ-α, p53, pl6INK4a, β-Catenin, Bak, Caspase 3, Caspase 9, and any combination thereof.
35. The method of any one of claims 30-34, wherein the pharmaceutical composition
comprises the agonist and the antagonist, which are administered simultaneously.
36. The method of any one of claims 30-34, wherein the pharmaceutical composition
comprises the agonist and the antagonist, which are administered sequentially.
37. The method of any one of claims 30-36, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
38. The method of claim 37, wherein the pharmaceutically acceptable carrier comprises water.
39. The method of any one of claims 1-38, wherein the second protein is IGF-1R.
40. The method of any one of claims 1-38, wherein the second protein is Akt.
41. The method of any one of claims 1-38, wherein the first protein is PI3 Kinase and the second protein is IGF-1R.
42. The method of any one of claims 1-38, wherein the first protein is PI3 Kinase and the second protein is insulin.
43. The method of any one of claims 1 -38, wherein the first protein is PI3 Kinase and the second protein is Akt.
44. The method of any preceding claim, wherein the first protein or the second protein is Akt that is Aktl .
45. The method of any preceding claim, wherein the first protein or the second protein is IGF- lR that is IGF-lRp.
46. The method of any preceding claim, wherein the first protein or the second protein is IGF- lR that is p-IGF-lR Yl 135-1150 (phospho-t rosine 1 135-1150).
47. The method of any preceding claim, wherein the first protein or the second protein is HIF that is HIF- la.
48. The method of any preceding claim, wherein the first protein or the second protein is mTOR that is p-mTOR S2448 (phospho-serine 2448).
49. The method of any preceding claim, wherein the first protein or the second protein is PTEN that is p-PTEN S380 (phosphor-serine 380).
50. The method of any preceding claim, wherein the subject has or is suspected of having diabetes, Alzheimer's disease, a cancer, or any combination thereof.
51. The method of any preceding claim, wherein the subject is a human.
52. The method of any preceding claim, wherein the wound is a diabetic ulcer, a pressure ulcer, a venous stasis ulcer, a radiation ulcer, a skin injury, an unhealed surgical wound, a wound from a surgical procedure, a wound from a peripheral vascular disease, a wound from a complication of trauma, a wound in a cancer patient, a wound in a patient receiving a steroid therapy, a wound from an inflammatory skin disease, a chronically impaired cutaneous wound, or any combination thereof.
53. The method of any preceding claim, wherein the wound is a diabetic foot ulcer.
54. A pharmaceutical composition that comprises an antagonist of a first protein, an agonist of a second protein, or a combination thereof, wherein the first protein or the second protein are individually selected from the group consisting of: IGF-1R, PI3 Kinase, Akt, insulin, mTOR, HIF, PTEN, IGFRBP-3, c-MET, GSK-3 , COX-2, iNOS, NFKB/p65, ΙκΒ-α, p53, pl6INK4a, β-Catenin, Bak, Caspase 3, Caspase 9, and any combination thereof.
55. The pharmaceutical composition of claim 54, wherein the second protein is IGF-1R.
56. The pharmaceutical composition of claim 54, wherein the second protein is Akt.
57. The pharmaceutical composition of claim 54, wherein the first protein is PI3 Kinase and the second protein is IGF-1R.
58. The pharmaceutical composition of claim 54, wherein the first protein is PI3 Kinase and the second protein is insulin.
59. The pharmaceutical composition of claim 54, wherein the first protein is PI3 Kinase and the second protein is Akt.
60. The pharmaceutical composition of any one of claims 54-59, wherein the first protein or the second protein is Akt that is Aktl.
61. The pharmaceutical composition of any one of claims 54-60, wherein the first protein or the second protein is IGF-1R that is IGF-ΙΡνβ.
62. The pharmaceutical composition of any one of claims 54-61, wherein the first protein or the second protein is IGF-ΙΡνβ that is p-IGF-ΙΡνβ Yl 135-1150 (phospho-tyrosine 1135- 1150).
63. The pharmaceutical composition of any one of claims 54-62, wherein the first protein or the second protein is HIF that is HIF-la.
64. The pharmaceutical composition of any one of claims 54-63, wherein the first protein or the second protein is mTOR that is p-mTOR S2448 (phospho-serine 2448).
65. The pharmaceutical composition of any one of claims 54-64, wherein the first protein or the second protein is PTEN that is p-PTEN S380 (phosphor-serine 380).
66. The pharmaceutical composition of any one of claims 54-65, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
67. The pharmaceutical composition of claim 66, wherein the pharmaceutically acceptable carrier comprises water.
68. A method of making a pharmaceutical composition of any one of claim 54-67.
69. A kit that comprises a reagent for measuring a total amount or a phosphorylation level of two or more proteins selected from the group consisting of: IGF-1R, PI3 Kinase, Akt, insulin, mTOR, HIF, PTEN, IGFRBP-3, c-MET, GSK-3 , COX-2, iNOS, NFKB/p65, ΙκΒ-α, p53, pl6INK4a, β-Catenin, Bak, Caspase 3, and Caspase 9, wherein the kit is employed to predict a likelihood of wound healing in a subject.
70. The kit of claim 69, wherein the kit predicts a prognosis of a wound in a subject.
71. The kit of claim 69 or 70, wherein one of the proteins is PI3 Kinase, IGF-1R, or Akt.
72. The kit of claim 69 or 70, wherein the proteins are PI3 Kinase and IGF-1R.
73. The kit of claim 69 or 70, wherein the proteins are PI3 Kinase and insulin.
74. The kit of claim 69 or 70, wherein the proteins are PI3 Kinase and Akt.
75. The kit of any one of claims 69-74, wherein the first protein or the second protein is Akt that is Aktl.
76. The kit of any one of claims 69-75, wherein the first protein or the second protein is IGF- lR that is IGF-lRp.
77. The kit of any one of claims 69-76, wherein the first protein or the second protein is IGF- lR that is p-IGF-lR Yl 135-1150 (phospho-t rosine 1 135-1150).
78. The kit of any one of claims 69-77, wherein the first protein or the second protein is HIF that is HIF- la.
79. The kit of any one of claims 69-78, wherein the first protein or the second protein is mTOR that is p-mTOR S2448 (phospho-serine 2448).
80. The kit of any one of claims 69-79, wherein the first protein or the second protein is PTEN that is p-PTEN S380 (phosphor-serine 380).
81. The kit of any one of claims 69-80, wherein the subject has or is suspected of having diabetes, Alzheimer's disease, a cancer, or any combination thereof.
82. The kit of any one of claims 69-81, wherein the subject is a human.
83. The kit of any one of claims 69-82, wherein the wound is a diabetic ulcer, a pressure ulcer, a venous stasis ulcer, a radiation ulcer, a skin injury, an unhealed surgical wound, a wound from a surgical procedure, a wound from a peripheral vascular disease, a wound from a complication of trauma, a wound in a cancer patient, a wound in a patient receiving a steroid therapy, a wound from an inflammatory skin disease, a chronically impaired cutaneous wound, or any combination thereof.
84. The kit of any one of claims 69-83, wherein the kit further complies an instruction
manual.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562175394P | 2015-06-14 | 2015-06-14 | |
US62/175,394 | 2015-06-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016205259A1 true WO2016205259A1 (en) | 2016-12-22 |
Family
ID=57546497
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/037455 WO2016205259A1 (en) | 2015-06-14 | 2016-06-14 | Methods of diagnosing and treating wounds |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2016205259A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2761757C1 (en) * | 2021-06-07 | 2021-12-13 | федеральное государственное бюджетное образовательное учреждение высшего образования "Ростовский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РостГМУ Минздрава России) | Method for predicting wound healing by secondary tension in patients with diabetic foot syndrome |
US20210391065A1 (en) * | 2018-12-18 | 2021-12-16 | Mölnlycke Health Care Ab | Method for selecting a wound product for a patient |
CN114617878A (en) * | 2022-05-16 | 2022-06-14 | 深圳大学 | Application of CK2 inhibitor in preparation of anti-aging drugs |
WO2023247792A1 (en) | 2022-06-24 | 2023-12-28 | Trauma Care Consult Traumatologische Forschung Gemeinnützige Gesellschaft Mbh | Method of diagnosing wounds |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130040953A1 (en) * | 2011-08-10 | 2013-02-14 | Amy S. Paller | Promotion of wound healing |
US20130172253A1 (en) * | 2011-12-28 | 2013-07-04 | Kuwait University | Method of diagnosing and treating oxidative stress-impaired wound healing |
WO2013144349A1 (en) * | 2012-03-30 | 2013-10-03 | Societe De Developpement Et De Recherche Industrielle | Method and kit for the classification and prognosis of tissue or organ fibrosis in a reparative or reactive process |
WO2015038474A1 (en) * | 2013-09-12 | 2015-03-19 | Rush University Medical Center | A transcriptomic index for characterizing the cellular repair response after soft tissue injury in diarthrodial joints |
-
2016
- 2016-06-14 WO PCT/US2016/037455 patent/WO2016205259A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130040953A1 (en) * | 2011-08-10 | 2013-02-14 | Amy S. Paller | Promotion of wound healing |
US20130172253A1 (en) * | 2011-12-28 | 2013-07-04 | Kuwait University | Method of diagnosing and treating oxidative stress-impaired wound healing |
WO2013144349A1 (en) * | 2012-03-30 | 2013-10-03 | Societe De Developpement Et De Recherche Industrielle | Method and kit for the classification and prognosis of tissue or organ fibrosis in a reparative or reactive process |
WO2015038474A1 (en) * | 2013-09-12 | 2015-03-19 | Rush University Medical Center | A transcriptomic index for characterizing the cellular repair response after soft tissue injury in diarthrodial joints |
Non-Patent Citations (1)
Title |
---|
SOMANATH ET AL.: "Akt1 is necessary for the vascular maturation and angiogenesis during cutaneous wound healing", ANGIOGENESIS, vol. 11, no. 3, 16 April 2008 (2008-04-16), pages 277 - 288, XP019598623 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210391065A1 (en) * | 2018-12-18 | 2021-12-16 | Mölnlycke Health Care Ab | Method for selecting a wound product for a patient |
RU2761757C1 (en) * | 2021-06-07 | 2021-12-13 | федеральное государственное бюджетное образовательное учреждение высшего образования "Ростовский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РостГМУ Минздрава России) | Method for predicting wound healing by secondary tension in patients with diabetic foot syndrome |
CN114617878A (en) * | 2022-05-16 | 2022-06-14 | 深圳大学 | Application of CK2 inhibitor in preparation of anti-aging drugs |
WO2023247792A1 (en) | 2022-06-24 | 2023-12-28 | Trauma Care Consult Traumatologische Forschung Gemeinnützige Gesellschaft Mbh | Method of diagnosing wounds |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Choueiri et al. | Targeting the HIF2–VEGF axis in renal cell carcinoma | |
Lloyd et al. | Mechanisms of resistance to CDK4/6 blockade in advanced hormone receptor–positive, HER2-negative breast cancer and emerging therapeutic opportunities | |
Chen et al. | Expression and function of the epidermal growth factor receptor in physiology and disease | |
WO2016205259A1 (en) | Methods of diagnosing and treating wounds | |
Romano et al. | Treatment implications of the emerging molecular classification system for melanoma | |
Leroy et al. | Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition | |
Elkabets et al. | mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer | |
Königshoff et al. | Increased expression of 5-hydroxytryptamine2A/B receptors in idiopathic pulmonary fibrosis: a rationale for therapeutic intervention | |
US20210236500A1 (en) | Inhibition of autophagy using phospholipase a2 inhibitors | |
Mohamed et al. | Role of adenosine A2A receptor in cerebral ischemia reperfusion injury: Signaling to phosphorylated extracellular signal-regulated protein kinase (pERK1/2) | |
JP2018515570A (en) | PLX-8394 or PLX-7904 for use in the treatment of BRAF-V600 related diseases | |
JP2014503821A (en) | Drug selection for malignant cancer therapy using antibody-based arrays | |
US20230068698A1 (en) | Combination therapy for cancer | |
WO2013173436A1 (en) | Pre-selection of subjects for therapeutic treatment with an hsp90 inhibitor based on hypoxic status | |
EP2986740A1 (en) | Companion diagnostic for cdk4 inhibitors | |
Whaley-Connell et al. | Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat | |
Widjaja et al. | IL11 stimulates ERK/P90RSK to inhibit LKB1/AMPK and activate mTOR initiating a mesenchymal program in stromal, epithelial, and cancer cells | |
NZ615738A (en) | Methods for predicting and improving the survival of gastric cancer patients | |
Ulu et al. | Epidermal growth factor receptor inhibitor PKI-166 governs cardiovascular protection without beneficial effects on the kidney in hypertensive 5/6 nephrectomized rats | |
Funakoshi et al. | Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line | |
KR20200036879A (en) | Therapeutic combination of 3rd generation EGFR tyrosine kinase inhibitor and cyclin D kinase inhibitor | |
Tanaka et al. | Expression level of sonic hedgehog correlated with the speed of gastric mucosa regeneration in artificial gastric ulcers | |
Field et al. | Amplifying local serotonin signaling prior to dry-off hastens mammary gland involution and redevelopment in dairy cows | |
JP2021504462A (en) | Pyrimidine derivative as a tropomyosin receptor kinase A (TRKA) inhibitor | |
Yuan et al. | Expressions of transforming growth factor β1 signaling cytokines in aortic dissection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16812265 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16812265 Country of ref document: EP Kind code of ref document: A1 |